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Abstract 
One of the most common post-translational modifications is covalent attachment of 
carbohydrates to proteins. At the cell surface, molecular recognition events involved in 
cancer metastasis are mediated by sugar moieties of glycoproteins. Evidence from both 
patient (histochemical analysis) and experimental work (tumour models) show that the 
metastatic tumour phenotype is associated with altered sialylation of tumour cell surfaces. 
Structural domains that recognize and bind specific carbohydrates without altering the 
recognized sugars are usually called lectins. Mistletoe lectin isoform I (MLI), from Viscum 
album, is an example which has strong binding affinity for sialic acids especially α2,6 
sialic acid. 
In the present study, mistletoe lectin isoform I chain B (MLB) was targeted through 
conducting polymerase chain reaction (PCR) for cDNA which was reverse transcribed 
from the extracted V. album RNA. The targeted sequence was successfully amplified, 
cloned and sequenced.  The sequence data showed a clear indication that the insert is our 
desired gene product allowing us to go on to design a fusion protein. Both N- and C- 
terminus fusion strategies were used to assemble constructs of the MLB chain fused to 
GFP in the pGFPuv expression vector which was transformed into BL21 E. coli and the 
expression of the target gene/fusion was successfully carried out. The same mechanism 
was used to generate positive and negative control fusion proteins from elderberry S. nigra 
lectin and snowdrop G. nivalis lectin respectively. The expressed fusions proteins were 
purified through affinity chromatography using CNBR-activated Sepharose 4B column 
coupled with degalactosylated fetuin so as to confirm the sialic acid binding activity of 
MLB. The binding of MLB+GFP fusion proteins to the membrane glycans of human 
cancer cells was also confirmed through the treatment of human metastatic melanoma cells 
with the fusion protein and the fusions were detected to actively attach and cross the cell 
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membrane. Following the confirmation of MLB binding to sialic acid residues on fetuin 
and cancer cell membrane in which a novel attempt, the MLB sequence was further 
analysed by bioinformatics to identify the glycan binding domain and two main putative 
sugar binding sites were identified. Then a range of Lectin-Toxin fusions were designed 
from the whole MLB and the two glycan binding sites linked with wasp venom 
(Mastoparan) and honey bee venom (Melittin) through a cathepsin-B biodegradable 
spacer. 
Finally, the Lectin-Toxin fusions were screened against a range of cancer cell lines 
specifically WM-115 and WM 266-4 melanoma lines and a healthy melanocyte cell line 
(HEMn) in order to confirm the fusions binding and crossing the cell membrane of the 
tissues and also confirm their apoptotic effect. The fusion proteins were confirmed to have 
almost no cytotoxic effect on the healthy human melanocytes (HEMn). However, strong 
cytotoxic effect was observed during the treatment of human primary (WM-115) and 
metastatic (WM 266-4) melanoma cells with the fusion proteins. 
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Chapter 1. Introduction 
1.1 Glycobiology 
Glycosylation is one of the major forms of post-translational modifications in the cells of 
eukaryotes where it has been found to influence biochemically important protein 
properties, including protein dynamics, folding, immune responses, ligand binding, 
solubility and stability (Tsai, Wang & Huang, 2014).  All of the chain structures of sugars 
in a cell or organism are known as the glycome, and the glycosylation machinery is said to 
be coded by 1 to 2 percent of the genome (Elkund & Freeze, 2005). 
Biological information is thought of as a flow from DNA > RNA > Protein, however cells 
require two other major classes of molecules beyond this template, carbohydrates and 
lipids. Carbohydrates and lipids generate energy, serve as intermediates in biosynthetic 
pathways or as structural components or as signalling molecules. Carbohydrate structural 
roles are important in cell-cell interactions and interactions with the surrounding matrix. 
Cells and macromolecules are found with covalently attached oligosaccharides or glycans 
(sugar chains), sometimes these glycans can be found as free standing entities.  
Glycans mediate or modulate a wide range of cell to cell and cell to matrix interactions 
which are crucial in the functioning and development of complex multicellular organisms, 
they also function in the interactions between different organisms, for example between 
parasite and host (Rodrigues, Acosta-Serrano et al. 2015).  Highly dynamic glycans are 
plentiful in the cytoplasm and in the nucleus and bound to proteins where they serve as 
regulatory switches (Varki & Sharon, 2009). 
From glycans, glycoconjugates are formed, this is when polysaccharides, oligosaccharides 
or monosaccharides (known as the glycones) covalently link to proteins or lipids (the 
aglycones), resulting in the formation of glycolipids, glycoproteins or proteoglycans. 
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The study of glycan activities related to cellular life is known as glycobiology (Kresge, 
Simoni et al. 2010). A unique range of biological activities may come from the members 
of this protein and lipid -glycoform pool. Within one species of one organism and under 
defined conditions, a distinct array of glycans is expressed by each cell type and the 
expression patterns tend to be conserved. However, stereotypic species to species changes 
during developmental stages may change these expression patterns, for example T cells 
switch to peanut-agglutinin positive from negative during their thymic development (Lowe 
and Marth 2003). 
1.2 Structure of Glycans 
Glycans are the most abundant organic biomolecules on the earth and have essential roles 
in the life of all living organisms as building blocks and well known compounds for 
energy supply and storage.  The structure of glycan compounds is very varied; they can be 
seen as free mono, oligo and polysaccharides or attached to other biomolecules like 
proteins or lipids to form glycoconjugates such as glycoproteins, glycolipids and 
peptidoglycan which are all extensively observed in the human body. For example, about 
50% of all human proteins are glycosylated. Genome sequencing projects have shown that 
sugar-processing enzymes in living organisms from eubacteria to archaea and eukaryotes 
occupy around 1% of highly conserved regions of each genome (Apweiler, Hermjakob et 
al. 1999, Wong 2005). 
Glycans are molecules made up of a combination of sugar units, mainly the six-carbon 
hexose sugars, which include mannose, galactose and glucose.  These sugars are only 
presented in the D-enantiomer configuration; due to the asymmetric chirality of the groups 
(Varki & Sharon, 2009).  Proteins and nucleotides being linear polymers, have only one 
type of basic linkage, however monosaccharides have the ability to theoretically generate 
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two configurations of the glycosidic linkage α or β (depending on whether the OH group 
of the anomeric carbon extends up or down from the carbon), furthermore the many 
hydroxy groups of the sugar also permit several possible regioisomers, plus a 
monosaccharide can be involved in more than two glycosidic linkages, thus serving as a 
branchpoint which will link in one of several positions on nearby chains of 
monosaccharides or other types of molecules, resulting in the variable structure and 
function of the glycans.   
Glycan structures are thus enormously diverse and the main reason of this diversity is the 
fact that their structures are defined by their functions but not vice versa. In consequence, 
they are very flexible and frequently adjust to physiological needs (Cantor and Schimmel 
1980, Pocanschi, Kozlov et al. 2011). The structural complexity is further complicated 
when it comes to membrane glycans because the fluidity of the outer layer of the lipid 
bilayer makes it almost impossible to study the structure of a specific surface glycolipid.  
Despite exceptions in some types of glycoproteins that are tethered to cytoplasm contents, 
studying cell surface proteins is equally as complex as studying cell surface glycolipids for 
similar reasons (Roseman 2001). 
 
1.3 Biosynthesis 
Different enzymes or transferase complexes are needed for each pathway to initiate 
glycosylation.  The monosaccharide (being the first sugar) which is linked to the lipid or 
protein defines its pathway, analogous with nucleotides for proteins, then either a single 
sugar or a sugar chain may be added (Elkund, Freeze & Patterson, 2012).  For biosynthesis 
of glycans activated monosaccharides (nucleotide sugars) are required, these are delivered 
to specific locations in the Golgi apparatus or the endoplasmic reticulum.  
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There are two main glycoconjugate structures, N-glycans and O-glycans. 
 
1.4 N-glycans 
N-glycans are covalently attached to protein at asparagine (Asn) residues by an N-
glycosidic bond. Five different N-glycan linkages have been reported, of which N-
acetylglucosamine to asparagine (GlcNAcβ1-Asn) is the most common.  The N-glycans 
are primarily processed in the endoplasmic reticulum (ER) (Mitra et al, 2006).  In the first 
instance there needs to be the assembly of an oligosaccharide precursor structure which is 
linked to the lipid dolichylphosphate (Dol-P), this is done by linking, via pyrophosphates, 
to two N-acetylglucosamine residues (GlcNac) in the cytosolic end of the ER.  Studies 
using glucosidase and protease degradation indicate that to the GlcNAc five mannose 
residues are added sequentially, using GPD-Man as a donor, flipping the glycan across the 
ER membrane and orienting it in the ER lumen (Herbert, Follemer & Helenius, 1995).  To 
this, using the Dol-P-Man donor, another four mannose residues are added.  Three 
additional glucose residues are added to the terminal ends of the glycan by the donor Dol-
P-Glc, this completes assembly of the dolichol oligosaccharide precursor (Hanahima et al, 
2014).  An ER membrane enzyme, oligosaccharyltransferase (OST) then transfers the 
precursor to the asparagine residue on a peptide chain (that is being synthesized and 
translocated through the ER membrane) from the dolichol (the amide group of asparagine 
is attached to the reduced terminal of N-acetylglucosamine to form an aspartylglucosamine 
linkage). During the formation of this linkage, C-1 of the N-acetylglucosamine residue 
replaces its original attachment with the hydroxyl group to attachment with the amino 
group. Following attachment, a series of processing reactions, the initial steps of which 
appear to be conserved in eukaryotes, occur and these have a major role in lysosomal 
trafficking and protein folding.  Firstly, glucosidases I and II and mannosidase I act on the 
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oligosaccharide precursor to remove the 3 glucoses and 4 mannoses (Hall et al 2014).  
Post-trimming in the ER, the protein can now be transferred to the Golgi apparatus, here 
the N-glycan (N-acetylglucosamine transferase I) substitutes the mannose residues with 
GlcNAc moieties.  The alterations that have occurred aid in the formation of the substrate 
for the enzyme α-Mannosidase II, which acts on the N-glycan in the medial Golgi and 
removes two further mannose residues (the α1-3 linked and α1-6 linked mannose).  This 
leaves just 5 residues in the original glycan which is now named the trimannosyl core 
(Varki & Sharon, 2009). To this resulting N-glycan product (named 
GlcNAc1Man3GlcNAc2-Asn) the GlcNAcT-II enzyme adds another GlcNAc residue to 
the remaining mannose branch forming an antenna. There are many other enzymes in 
eukaryotes that can form various complex and diverse glycan structures by adding other 
sugar residues, such as fructose, galactose and GlcNAc, in fact deficiencies in these 
enzymes can cause disease, for example, Ehlers-Danlos syndrome (where patients are 
deficient in collagen processing) and congenital disorder of glycosylation (CDG) (Eklund 
and Freeze 2006). 
All N-glycans share a common core sugar sequence, Manα1–6(Manα1–3)Manβ1–
4GlcNAcβ1–4GlcNAcβ1-Asn-X-Ser/Thr, and are classified into three types: (1) 
oligomannose, in which only mannose residues are attached to the core; (2) complex, in 
which “antennae” initiated by N-acetylglucosaminyltransferases (GlcNAcTs) are attached 
to the core; and (3) hybrid, in which only mannose residues are attached to the Manα1–6 
arm of the core and one or two antennae are on the Manα1–3 arm (Figure 1). Two of the 
three groups (high mannose and complex oligosaccharides) are the most abundant types of 
glycosylation found on the majority of glycoproteins (Stanley, Schachter et al. 2009).  
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Figure 1. Types of N-glycans. N-glycans added to protein at Asn-X-Ser/Thr sequons are of three general types in a 
mature glycoprotein: oligomannose, complex, and hybrid. Each N-glycan contains the common core Man3GlcNAc2Asn. 
A: Oligomannose N-glycan which composed of N-acetyleglucosamine (Blue squares) and mannose (Green circles) 
residue; B: Complex N-glycan which composed of N-acetyleglucosamine (Blue squares), mannose (Green circles), 
galactose (Yellow circles), Fucose (Red Triangle) and sialic acid (Burgundy squares) residues; C: Hybrid N-glycan 
which composed of N-acetyleglucosamine (Blue squares), mannose (Green circles), galactose (Yellow circles) and sialic 
acid (Burgundy squares) residues (Stanley, Schachter et al. 2009).  
 
The pattern of glycosylation and the modification of the glycans attached to glycoproteins 
are partially dependent on the structure of the proteins as seen for example in the 
glycosylation of blood group substances and mannose 6-phosphate (Fredriksson, 
Podbielska et al. 2010, Sleat, Sun et al. 2013). 
 
1.4.1 Diversity of N-glycans 
The above description is a general profile of N-glycans. However, a range of differences 
are seen between them especially in those of complex type. In order to comprehend this 
diversity, it is better to look individually at the outer chain and the core portion of N-
glycans. The core portion is composed of two N-acetylglucosamine residues and three 
mannoses. The complex types of oligosaccharides also have side chains elongating from α-
mannose residues and the first residue of this side chain is N-acetylglucosamine. Diversity 
arises from the variation in the number of N-acetylglucosamine residues linked to α-
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mannoses and the positions to which N-acetylglucosamine are linked (Re, Miyashita et al. 
2011) (Figure 2).  
Another reason for N-glycan diversity is the variation in the side chains that contain non-
reducing termini on which majority of the carbohydrate functionalities rely on.  The glycan 
units formed by subultimate and terminal sugars at “outer” positions of a glycan often 
determine the function(s) or recognition properties of a glycoconjugate. 
 
 
 
 
 
 
 
Figure 2. Typical complex N-glycan structures found on mature glycoproteins (Stanley, Schachter et al. 2009). 
 
N-Glycans occur on many secreted and membrane-bound glycoproteins at Asn-X-Ser/Thr 
sequons. Analyses of protein sequence databases have revealed that about two thirds of the 
entries contain this consensus sequence (Jensen, Karlsson et al. 2012). 
 
1.4.2 Functions of N-glycans 
Inhibitors of N-linked glycosylation have been used to determine the function of N-glycans 
for example tunicamycin; also inhibitors of N-glycan processing such as castanospermine, 
deoxynojirimycin, and swainsonine; have been used as a mutants generated in a gene 
coding for a glycosylation activity. This has been done in model organisms such as yeast, 
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cultured mammalian cells, Drosophila, C. elegans, zebrafish, and mouse. Mouse mutants 
in particular have provided enormous insights into the functions of N-glycans. Deletion of 
the Mgat1 gene that encodes GlcNAcT-I prevents the synthesis of complex and hybrid N-
glycans, and Man5GlcNAc2 is found at all complex and hybrid N-glycan sites. Elimination 
of GlcNAcT-I in the mouse results in death during embryonic development. The complex 
N-glycans that fail to be synthesized in mice lacking GlcNAcT-I, GlcNAcT-V, GlcNAcT-
IVb, and FucT-VIII are important in retaining growth factor and cytokine receptors at the 
cell surface, probably through interactions with glycan-binding proteins. Furthermore, 
deletion of genes encoding sialyltransferases, fucosyltransferases, or branching N-
acetylglucosaminyltranferases (other than GlcNAcT-I) have produced viable mice in the 
main with defects in immunity or neuronal cell migration or emphysema or inflammation. 
N-Glycans are known to become more branched when cells become cancerous, and this 
change facilitates cancer progression. Tumors formed in mice lacking GlcNAcT-V or 
GlcNAcT-III may be retarded in their progression. Thus, glycosyltransferases have been 
targets for the design of cancer therapeutics (Hibberd, Trevillian et al. 2012, Stanley, 
Batista et al. 2013, Stanley 2014, Xiao, Smeekens et al. 2016). 
 
1.5 O-glycans 
O-glycosylation is a common covalent modification of serine and threonine residues of 
mammalian glycoproteins. O-glycans and their structures are comprised of four common 
core subtypes, based on differentiating linkage reaction of a monosaccharide to 
unsubstituted GalNAc (GalNacαSer-Thr), so the reduced terminal of N-acetylgalactosamine 
of glycans is attached to the hydroxyl groups of serine and threonine residues of 
polypeptides.  They represent the second most abundant form of carbohydrate-protein 
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binding and are also known as mucin-type glycans since the initial description of this 
conjugate was in a mucus substance called mucin (Corfield 2004).  
Based upon the binding pattern between glycans and amino acids, O-glycans can be 
divided to different subgroups as follows: (a) mucin type carbohydrates, N-
acetylgalactosamine attached to serine or threonine; (b) O-GlcNAc type, N-
acetylglucosamine attached to serine or threonine; and (c) xylose attached to serine or 
threonine in proteoglycans. Animal cells contain these three groups abundantly. Less 
known groups are (d) galactose attached to hydroxylsine in collagen, (e) xylosyl glucose or 
glucose attached to serine or threonine in clotting factors, and (f) fucose attached to plasma 
glycoproteins. In addition, in plants, there are (g) arabinose attached to hydroxyproline and 
galactose attached to serine, and in fungi, mannose attached to serine or threonine (Sadler 
1984, Harris, Leonard et al. 1991, Brockhausen, Schachter et al. 2009, Joshi, Steentoft et 
al. 2015, Stanley 2015). 
 
 
 
 
 
 
 
 
Figure 3. Complex O-GalNAc glycans with different core structures. Representative examples of complex O-GalNAc 
glycans with extended core 1, 2, or 4 structures from human respiratory mucins and an O-GalNAc glycan with an 
extended core 3 structure from human colonic mucins. All four core structures (in boxes) can be extended, branched, and 
terminated by fucose in various linkages, sialic acid in α2-3 linkage, or blood group antigenic determinants. Core 
structures 1 and 3 may also carry sialic acid α2-6-linked to the core N-acetylgalactosamine (Brockhausen, Schachter et 
al. 2009). 
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1.5.1 Biosynthesis  
The transfer of the first sugar from UDP-GalNAc directly to serine or threonine in a 
protein initiates the biosynthesis of all O-GalNAc glycans. Subsequently, with the addition 
of the next sugar, different mucin O-glycan core structures are synthesized. In contrast to 
N-glycosylation and O-mannosylation, no lipid-linked intermediates are involved; no 
glycosidases appear to be involved in the processing of O-GalNAc glycans within the 
Golgi. 
The O-glycans of mucins produced in a specific tissue predict the enzyme activities that 
are present in that tissue. All four core structures (figure 3) can be extended, branched, and 
terminated by fucose in various linkages, sialic acid in α2-3 linkage, or blood group 
antigenic determinants. All of the core structures can be sialylated and biosynthesis of O-
glycans can be modified and then terminated through the addition of a sialic acid residue in 
the early stages of synthesis.  These additions give rise to a series of different structures of 
O-glycans that cause restriction in the biosynthetic pathways leading to the four core types. 
These have been designated tumour associated antigens (T-antigens) and found in 
association with cancer cells (Xia et al, 2012). 
1.5.2 Functions of O-glycans 
All mammalian cells studies to date show O-GalNAc glycosylation. In the secreted mucins 
of the gastrointestinal, genitourinary and respiratory tracts, the O-GalNAc glycans of 
mucous glycoproteins are essential for hydration and protection of the epithelium. 
Furthermore, mucins trap bacteria via specific receptor sites within the O-glycans. Some 
sugar residues or their modifications can mask underlying antigens or receptors. 
O-GalNAc glycans, especially in the mucins, have a significant effect on the conformation 
of the attached protein and dependent on the size and hence bulkiness of the O-glycans. 
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The underlying peptide epitopes are variably recognized by antibodies. In addition, O-
glycosylation of mucins provides almost complete protection from protease degradation. 
 
1.6 Sialic Acids 
Sialic acid is a nine-carbon monosaccharide. Sialic acids (Sias) are typically found to be 
terminating branches of N-glycans, O-glycans, and glycosphingolipids (gangliosides) (and 
occasionally capping side chains of GPI anchors) (Yabu, Korekane et al. 2013, Bate, 
Nolan et al. 2016). They generate biologically significant diversity due to (1) the different 
α linkages that may be formed between the C-2 of Sias and underlying sugars mediated by 
specific sialyltransferases (CMP-Sias is used as high-energy donors). Linkages to the C-3 
or C-6 positions of galactose residues are most common or to the C-6 position of N-
acetylgalactosamine residues. Sialic acids may also occupy internal positions within 
glycans, the most common being one Sia residue attached to another, often at C-8 position 
and (2) a variety of natural modifications, the C-5 position may have an N-acetyl group 
(giving Neu5Ac) or a hydroxyl group (as in Kdn). The 5-N-acetyl group can also be 
hydroxylated, giving N-glycolylneuraminic acid (Neu5Gc). Less common, the 5-amino 
group is not N-acylated, giving neuraminic acid (Neu). These give the four “core” Sia 
molecules (Neu5Ac, Neu5Gc, Kdn, and Neu) to which one or more additional 
substitutions may occur at the hydroxyl groups on C-4, C-7, C-8, and C-9 (O-acetyl, O-
methyl, O-sulfate, O-lactyl, or phosphate groups). The carboxylate group at the C-1 is 
ionized at physiological pH, but can be condensed into a lactone with hydroxyl groups of 
adjacent saccharides or into a lactam with a free amino group at C-5. Combinations of 
different glycosidic linkages with the multitude of possible modifications generate 
hundreds of ways in which Sias can present themselves. 
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1.6.1 Physiological and Pathophysiological Roles of Sialic Acids 
Sialic acid is considered as one of the most important biomolecules of life since its 
derivatives and terminal orientation on cell membranes and macromolecules play a major 
role in many biological and pathological processes (Schauer 2000). They are also 
negatively charged molecules by which they attract/repulse molecules and cells then they 
specifically bind to positively charged molecules and transport them. Moreover, as 
glycoprotein components they protect endothelia through their contribution in giving high 
viscosity to the lining of mucins such as in the intestine and they contribute in shaping cell 
membranes supramolecular structures such as gangliosides and consequently influence 
their functions (Siebert, von der Lieth et al. 1996, Schauer, Ernst et al. 2000). 
Sialic acid is the most abundant type of terminal family on vertebrate carbohydrates and 
their taxonomic distribution is surprising because they are found in both the deuterostome 
lineage animals and some of their pathogens (Moxon, Rainey et al. 1994). 
The nine carbon glycans on erythrocytes are binding sites for parasites and viruses which 
bind differentially to different type of sialic acids and/or their linkages of different species. 
These binding sites can be in the form of either decoy binding sites or pathogen receptors 
(Wybenga, Epand et al. 1996). 
The two main and very common types of sialic acids are N-glycolylneuraminic acid 
(Nau5Gc) and N-acetylneuraminic acid (Nau5Ac) (Figure 4). The former comes from 
Nau5Ac after hydroxylation of its acetyl group by CAMP-Nau5Ac hydroxylase (CMAH). 
While, Nau5Gc exists in the glycosylation pattern of all mammals, CMAH gene is 
deactivated in humans and thus Nau5Gc is absent in their normal glycosylation system. 
However, this form of sialic acid has been detected in human cancer cells and the reason is 
believed to be the interaction between glycosylation pattern of cancer tissues and 
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Neu5Ac                                                                                              Neu5Gc 
exogenous sources of Nau5Gc such as red meat and other milk products (Taylor, Gregg et 
al. 2010). Thus targeting this form of sialic acid may aid in drug delivery. 
Despite the general thought that the biosynthesis of a certain oligosaccharide is mainly 
controlled by a specific cognate glycosyltransferase, the biosynthesis process has remained 
complex and partially understood. A poor correlation between glycosyltransferase 
enzymes and their products suggest the existence other factors with relevant role (Kudo, 
Ikehara et al. 1998, Mehr and Withers 2015). One of the most common glycan structures 
in the antennae of N-linked chains is α2,6-sialylation of lactosamine (Galb1,4GlcNAc) 
which is catalysed only by b-Galactoside α2,6-sialyltransferase (ST6Gal.I) enzyme. 
Attempts to compare glycosylation patterns of cancer cells with their surrounding healthy 
cells have found strong correlations between the elevations of ST6Gal.I activity and 
glycosylation changes in different types of cancer cells specifically colon cancer. They 
have also found that this elevation increases further in metastatic colon tissues (Gessner, 
Riedl et al. 1993, Lise, Belluco et al. 2000). The increase in α2,6-sialylation in membrane 
glycoconjugates of colon cancer cells was confirmed via using sialic acid binding lectin 
from Sambucus nigra (SNA) and Tricosanthes japonica (Dall'Olio and Trere 1992, 
Yamashita, Fukushima et al. 1995).  
Thus lectin mediated binding to sialic acid presents a possible drug targeting mechanisms. 
 
 
 
 
 
Figure 4. N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). 
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1.7 Altered Glycosylation in Cancer Cells 
It is assumed that cell to cell interactions are probably affected by cell-type specific 
carbohydrates. It is thus possible that specific signals are provided by the diversity of 
carbohydrate structures in different cell types and these signals are recognized by counter-
receptor molecules. It is then reasonable to assume that different cell recognition 
molecules are provided to cells according to the alteration of their surface carbohydrates 
and these molecules are essential when cells interact with each other and differentiate. The 
tumour cell interaction with other cells, in order to achieve tumour cell colonization and 
metastasis, is similarly facilitated by alteration of cell surface carbohydrates (Rabinovich 
and Croci 2012, Tsuboi 2015). 
These cell surface carbohydrates have long been a target for drug design (reviewed in 
Toporkiewicz, Meissner et al. (2015)). 
 
1.8 Glycan Binding Proteins 
A wide variety of physical properties of glycans such as shape, mass and charge mediate 
their biological roles and it appears that nature has taken advantage of this diversity 
through interacting proteins known as glycan binding proteins (GBPs) which are binding 
counterparts for glycans. These proteins have the ability to bind different structures of 
glycans and their recognition property has become the key factor in their exploitation 
(Simpson, Sacher et al. 2015). The carbohydrate-protein conjugates can be classified into 
proteoglycans and glycoproteins. In proteoglycans, the carbohydrates are relatively large 
(˃3000dalton) and they are formed by replications of disaccharide units. In glycoproteins, 
structure repetition is usually absent except for poly-N-acetyllactosamines (Fukuda 1994). 
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The GBPs are found in all organisms and they are mainly divided into two different 
classes, glycosamingoglycan-binding proteins and lectins (Simpson, Sacher et al. 2015). 
 
1.8.1 Glycosamingoglycan (GAG)-binding Proteins 
Glycosaminoglycans are highly negatively charged linear polysaccharides found on the 
surface and inside of cells. They are composed of repetitive disaccharide units attached to 
the core proteins through covalent bonds to build proteoglycans. The constituent of the 
units is a combination of amino type of sugars such as N-acetylglucosamine and N-
acetylgalactosamine with variably sulphated (except hyaluronic acid) galactose or uronic 
acid such as glucuronic and iduronic acid (Esko, Kimata et al. 2009). The interaction with 
many proteins like cytokines and growth factors and regulating their functions are the key 
roles in the biological functions of GAGs (Handel, Johnson et al. 2005). 
The most studied type of GAGs is heparin which is a repetitive unit of uronic acid (10% 
glucuronic acid and 90% iduronic acid) attached to glucosamine residues in the form of 
linear copolymer of 1    4 and the existence of carboxylate and sulphate residues in their 
main structure gives them a highly negative charge. While the trisulphated disaccharide is 
the most common unit in heparins, the average amount of sulphate groups contained in 
their disaccharides is 2.7 groups (Figure 5A) (Gallagher, Turnbull et al. 1992, Linhardt, 
Ampofo et al. 1992). 
Heparan sulphate is a derivate of heparin with unique structure composed of the same 
repeated 1  4 linear copolymers but it is predominantly between glucuronic acid and 
glucosamine (Figure 5B). In heparan sulphates the average of sulphate per disaccharide is 
less than 1. While, all the disaccharide sequences found in heparin are in heparan sulphate 
as well, a few extra minor sequences in heparan sulphate have increased its structure and 
sequence complexity. Further complexity in heparan sulphate comes from observing 
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substantial levels of iduronic acid in its structure since the structure is mainly composed of 
glucuronic acid. Also, the average molecular weight of heparan sulphate (29,000Da) is 
higher than heparin (8000Da) because of longer chains (Griffin, Linhardt et al. 1995).  
There are other types of GAGs with the ability to bind proteins such as hyaluronan, 
chondroitin, dermatan and keratan sulphate. Their main structures are composed of similar 
components such as N-acetylgalactosamine and N-acetylglucosamine linked to glucuronic, 
iduronic and glucose in alternating 1      4 or 1     3 linear copolymers (Templeton 1992). 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structure of heparin and heparan sulphate. A: Major repeating disaccharide unit in heparin (iduronicacid-2-
sulphate = glucosamine-2,6-disulphate; 75–90% of disaccharide sequences). B: Major disaccharide repeating unit of 
heparan sulphate (glucuronic acid =N-acetylglucosamine; 10–50% of disaccharide sequences) (Hileman, Fromm et al. 
1998). 
 
 
1.8.2 Lectins 
At the end of 19th century a novel family of proteins were discovered that have ability to 
agglutinate erythrocytes and they were named as phytoagglutinins because the first 
discovery was from a plant (The seed of ricin (Ricinus communis)) or hemagglutinins 
because they can agglutinate red blood cells (Sharon and Lis 2004). 
Lectin terminology which is a Latin word meaning “to select” and its use in terminology 
came about with the development of knowledge about this family and its functions and the 
term soon changed from the individual name to a generic term. At the beginning of their 
discovery there were relatively few studies about lectins and almost all were from plants. 
However, lectin research increased very steadily from 1960s on-ward and lectins became a 
very popular topic for two reasons. Firstly, a wide range of applications of lectin became 
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apparent such as detection and isolation of glycoconjugates, cell and tissue histochemistry, 
and observation and characterization of physiological and pathological changes in the cell 
surface glycans from cell differentiation to cancer. Secondly, simple and quick isolation 
and purification of a variety of lectins through immobilized carbohydrates affinity 
chromatography became possible (Sharon and Lis 2003).   
Lectins are generally defined as non-immune origin proteins with the ability to specifically 
attach to carbohydrates. The purpose behind using the non-immune origin term is to 
differentiate them with carbohydrate specific enzymes such as glycosidase and kinase 
which cannot agglutinate cells. The majority of lectins have the ability to recognize just a 
few of the hundreds of monosaccharide found in nature such as mannose, fucose, glucose, 
galactose, N-acetylneuraminic acid, N-acetylglucosamine, and N-acetylgalactosamine, 
however, majority of oligosaccharides built from these monosaccharides may also be 
bound by lectins (Sharon and Lis 2003).  
Lectins can also agglutinate cells and attach to polysaccharides and glycoproteins because 
of their di- or oligovalent structures which gives each lectin molecule at least two glycan 
binding sites that help cross linking between cells through their cell surface carbohydrates 
or between other molecules that contain carbohydrates. However, some types of lectins do 
not possess glycan binding property because of their monovalent structure. It is also 
important to notice that non-carbohydrate ligands may attach to lectins through one or 
more binding sites, although the main ligands for lectins are carbohydrates (Goldstein, 
Hughes et al. 1980, Barondes 1988, Sharon and Lis 2003). 
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1.8.2.1 Classification of Lectins 
Lectins have been classified according to different principles such as origin, carbohydrate 
specificity, and localization in cells and organisms. The outcome of these classifications 
overlap each other as a result of common properties shared between different lectins as 
shown in table 1 (Lakhtin, Afanas' ev et al. 2008, Lakhtin, Lakhtin et al. 2011). 
 
Table 1. Some known classiﬁcations of lectins (Lakhtin, Lakhtin et al. 2011). 
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Because of the size of lectin classifications, only their taxonomical origin classification is 
explained in this review. 
 
1.8.2.2 Plant Lectins 
The plant kingdom contains many types of carbohydrate-binding domains spread all over 
the kingdom and often the occurrence of a specific domain is not restricted to a specific 
plant family. For instance, hundreds of putative lectin genes were found recently in the full 
genome analysis of Arabidopsis, rice and soybean which belong to all main lectin super 
families (Jiang, Ma et al. 2010).  
While many of the known plant lectins have affinity to specific monosaccharides, results 
from glycan array studies conducted on different plant lectins showed that one glycan 
structure cannot characterize a particular glycan-binding domain (CBD) but a 
carbohydrate-binding proﬁle is required instead (Lannoo, Peumans et al. 2006, Fouquaert, 
Smith et al. 2009, Taylor and Drickamer 2009). The affinity of a typical CBD is also lower 
for simple glycans than for complex glycans such as N-glycans which have a bulky 
structure with a particular glycan complementary to a shallow depression on the surface of 
a particular CBD (Garcia-Pino, Buts et al. 2007, Schouppe, Rougé et al. 2010). Any 
increase of amino acid numbers in the primary binding site of particular CBD extend the 
binding with the sugar residues of complex carbohydrates because of increasing the 
number of hydrogen bonds (H-bonds). Therefore, the affinity of CBDs for simple glycan 
structures are much lower than for complex structures (N-glycans) which are believed to 
be natural binding targets for the majority of plant lectins (Garcia-Pino, Buts et al. 2007, 
Van Damme, Lannoo et al. 2008). 
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According to the expression pattern, the production of lectin in plants can be divided into 
two main types. First, lectins with regulated expression patterns during plant development 
and synthesized by the ER associated ribosomes without any effects of external 
environmental conditions. The cellular positions of this type are inter/extra cellular spaces 
or vacuolar compartment and they mainly accumulate in seeds and different storage tissues 
such as bulbs, tubers and rhizomes. For instance, different isoforms of common bean lectin 
Phaseolus vulgaris agglutinin (PHA) and snowdrop lectin Galanthus nivalis agglutinin 
(GNA) are produced during the development of the plants and accumulate in their seeds 
and bulbs respectively (Van Damme, Peumans et al. 1998a). Second, lectins may be 
synthesized in cytoplasm under certain external abiotic or biotic stress conditions such as 
drought, wounding and insect herbivory. This group of lectins is called inducible plant 
lectins and they are mainly stored in non-storage tissues like root, leaves and flowers. 
Since their cellular positions are nuclear or cytoplasmic compartments, this type is mainly 
characterized by cellular localization and relatively low expression levels (Van Damme, 
Lannoo et al. 2008). 
 
1.8.2.3 Animal Lectins 
Animal lectins are a group of glycan-binding proteins with highly diverse amino acid 
sequences and primary structures. It is believed that the discovery of animal lectin was 
long before the discovery of plant lectins; however, in the first discoveries many of them 
were not known as carbohydrate binding proteins (Kilpatrick 2002).  
The lectins of different animals have different structures and activities which are both 
strongly associated with each other and the latter is entirely dependent on the former. 
Moreover, the primary structure of animal and plant lectins is heterologous even though 
they share similar preferential carbohydrate binding property. Also, animal lectins are 
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different from enzymes and antibodies in terms of origin because animal lectins are neither 
catalyst and nor of immune origin. However, each animal lectin possesses a specific 
carbohydrate recognition domain (CRD) which helps the lectin to recognise and attach to 
complex carbohydrate structures (Lis and Sharon 1998, Ghazarian, Idoni et al. 2011).  
According to their structures and activities, animal lectins are grouped into eight main 
families with similar sequence and structural properties as follow: Calcium-requiring 
lectins (C-type), mannose-6-phosphate binding lectins (P-type), galectins lectins (S-type), 
immunoglobulin-like lectins (I-type), M-type lectins, L-type lectins, chitinase-like lectins 
and F- type lectins (Anderson, Evers et al. 2008). 
 Animal lectins have many important in vivo biological functions such as cell trafﬁcking, 
prevention of autoimmunity, and immune regulation. However, their core function is the 
recognition of pathogen carbohydrates and inaccessible carbohydrates of the host cells. 
Thus, recognition function is a direct defence line against pathogens such as ingesting and 
killing infectious foreign organisms that have mannose on their surface glycans via 
macrophages mannose specific receptors (Kilpatrick 2002, Singh and Sarathi 2012). 
The largest and most diverse family among animal lectins is C-type family. The 
independently folding carbohydrate binding domain (CRD) of this family is calcium (Ca2+) 
dependent because during binding CRDs usually bind to Ca2+. The CRD of C-type lectins 
contains receptors often found in the immune system and their functions change according 
to the form of glycan recognition. For example, if they recognise endogenous mammalian 
glycans, they influence glycoprotein turnover and cell adhesion but their influence changes 
to pathogen recognition in the case of binding to glycans on microorganisms (Kolatkar, 
Leung et al. 1998). 
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1.8.2.4 Viral Lectins 
Viruses have their own lectins like other organisms and their lectins are generally known 
as hemagglutinins (HA). By far the most studied viral lectin is influenza virus 
hemagglutinin which has affinity for terminal sialic acids. The avian and human influenza 
virus infections primarily happen through binding of the virus hemagglutinin to terminal 
α2-3- linked sialic acids of intestinal epithelial cell receptors and terminal α2-6- linked 
sialic acids of respiratory tract cell receptors respectively. In order to adapt to human host 
and infect human population, avian inﬂuenza viruses had to cross species barriers and 
conduct a switch from α2-3 specific to α2-6 speciﬁc (Figure 6) (Stevens, Blixt et al. 2006). 
The influenza virus hemagglutinin has ability to agglutinate human red blood cells through 
binding to cell surface sialic acid-terminated oligosaccharides and the de-sialylation of the 
cells is shown to inhibit this agglutination. However, sialic acid is not the only ligand for 
cell agglutination because in some cases the agglutination is shown to happen because of 
other ligands (Rogers and Paulson 1983). While the type of terminated sialic acid on 
oligosaccharides mainly affects the binding of hemagglutinin to red blood cells, the 
binding is also affected by the inner conﬁguration of the oligosaccharides. For example, 
changing GalNAc to GlcNAc in Siaa2– 3Galß1–3GalNAc oligosaccharide on red blood 
cells would inhibit agglutination property of two out of four viruses (Gambaryan, 
Yamnikova et al. 2005). 
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Figure 6. Interaction between influenza HA and a human receptor analog. Modeled interaction surfaces between the 
binding site of the influenza virus HA (grey) and a ‘human’ Siaa2–6 receptor analogue lactoseries tetrasaccharide c 
(LSTc) shown in blue, pink and green. HA of three different influenza viruses from (a) swine H1, (b) human H3 and (c) 
swine H9 and LSTc, which is terminated by a Sia in an a2–6 configuration. The residues involved in potential hydrogen 
bonds of the LSTc and the HA are shown in red and demonstrate the different amino acid residues of the HA that are 
involved in binding and how different sites are involved for different strains of virus. The H9 conformation is different, 
being folded back on itself. Reproduced, with permission (Lamblin, Degroote et al. 2001). 
 
1.8.2.5 Bacterial Lectins 
Bacterial lectins are known as adhesins because of their main role in adhesion process 
carried out by bacteria during the colonialization of cell surfaces of the host to withstand 
the cells defence mechanism. The main cause of bacterial adhesion is the interaction 
between hosts cell surface carbohydrates and surface filamentous proteins of bacteria 
known as fimbriae which are working as adhesive organelles through their lectin subunits. 
The interaction between cell surface carbohydrates and bacterial adhesion is a serious 
threat on any living cells which are in contact with the external environment because it 
gives access to the colonized bacteria to use the carbohydrate array decorating cell surfaces 
known as glycocalyx (Sharon 1987). 
Many studies have been conducted to investigate the binding affinity of bacterial adhesins 
with glycans. Type 1 fimbriae (FimH) is one the most-studied adhesins that has affinity for 
high-mannose containing glycoproteins with multiple terminal α-D-mannosyl units such as 
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glycoproteins on the surface or urothelial cells which are easy targets for uropathogenic E. 
coli (UPEC) and cause urinary tract infections. About 90% of all known strains of UPEC 
contain Type 1 fimbriae which helps the bacterial infection through binding to 
oligomannoside residues on glycoprotein uroplakin Ia. In order to prevent this infection, 
efforts have been invested to progress an approach called antiadhesion therapy to 
potentially inhibit the binding ability of this adhesion (Martinez, Mulvey et al. 2000, Ofek, 
Hasty et al. 2003, Pieters 2007). 
 
1.9 Structure of Plant and Animal Lectins 
Plant lectins are generally known as soluble multivalent proteins with multiple glycan-
binding sites which allows them to agglutinate cells. On the other hand, animal lectins 
have different structures and physical natures and are generally grouped into three main 
categories which are intrinsic membrane-bound glycoproteins, monovalent proteins and 
glycoproteins, and multivalent proteins and glycoproteins (Lis and Sharon 1986, Gabius 
and Gabius 1997). 
The leguminous plants family is one of the main sources of plant lectins as it contains 
different type of lectins known as the leguminous lectins. These lectins have different 
biological activities but similar primary structures and the most studied examples among 
them are Phaseolus vulgaris agglutinin (PHA) from the red kidney bean, Ricinus 
communis agglutinin (RCA) from the castor bean and Concanavalin A ( Canavalia 
ensiformis) from jack bean. The non-leguminous plants also contain many lectins with 
similar structures and carbohydrate binding specificities but their primary structure is 
completely different from leguminous lectins. The well-studied examples of non-
leguminous lectins are mistletoe lectin (ML) from (Viscum album L.), tomato lectin from 
(Lycoperiscon esculentum) and jimsonweed agglutinin from (Datura stramonium) (Loris, 
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Hamelryck et al. 1998, Villacampa, Almolda et al. 2013, Nishimoto, Tanaka et al. 2014, 
Hagens, Klein et al. 2015). 
Regarding sequence homology, animal lectins can also be classified into different groups. 
For example C-type family has a sequence motif that needs Ca+2 for their binding activity 
in contrast to the sequence motif of another family known as galectins that does not need 
Ca+2 for binding activity (Powell and Varki 1995, Gabius and Gabius 1997).  
The majority of lectins used in research of animal cell glycoconjugates are plant lectins 
because they are commercially available and their preparation is cheaper than a high cost 
preparation of animal lectins (Drickamer and Taylor 1993, Unitt and Hornigold 2011). 
 
1.10 Carbohydrate-Binding Specificities of Lectins 
Plant lectins were historically classified according to their monosaccharide specificity as 
they were first shown to bind glycans through the inhibition of lectin-induced 
agglutination of cells by specific monosaccharides or their derivatives. For example, lectin 
from concanavalin A (Con A) and ricin (RCA) were classified as mannose and galactose-
binding lectins respectively. Animal lectins can accordingly be classified because their 
binding can also be inhibited by monosaccharides. Thus, lectins like bovine heart 
galaectin-1 and asialoglycoprotein receptor from the hepatocyte were classified as 
galactose and N-acetylgalactosamine/galactose binding lectins respectively (Zhou and 
Cummings 1992). 
Lectins bind to carbohydrates through different types of non-covalent bonds such as 
hydrophobic interactions, hydrogen bonds and metal coordination. The existence of a large 
number of hydroxyl groups on the surface of glycans provides lectins appropriate partners 
especially in the complex networks of hydrogen bonds where the hydroxyl groups function 
as both donor and acceptor (Bourne and Cambillau 1993, Weis and Drickamer 1996). 
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There are many factors that affect carbohydrate recognition by lectins; for example, 
cations such as Ca2+ and Mn2+ play a major role in some of these conjugations either 
directly via attaching to glycans or indirectly through building binding spots such as in the 
C-type lectin or legume lectin conjugations respectively. Despite the general hydrophilic 
nature of carbohydrates which can clearly be seen in the interaction of Gal-specific lectins 
with aromatic residues, hydrophobic interaction also strongly affects carbohydrates-lectins 
binding (Shaanan, Lis et al. 1991, Hamelryck, Loris et al. 1999, Cummings and McEver 
2009). 
While the multivalent nature of lectins probably gives them ultimate selectivity, primary 
monosaccharide specificity is also a major factor in the carbohydrate recognition by lectins 
and it is usually an indicator for a particular branched carbohydrate to be recognized by a 
specific lectin. Thus, complex carbohydrates bearing Glc or Man are bound by the 
Glc/Man-specific lectins (e.g. Lathyrus ockrus and Con A) but Gal-specific lectins (e.g. 
Erythrina corallodendron, EcorL) need the presence of Gal (or its amino-acetylated 
derivative) to perform binding (Drickamer 1992).  
The cell-cell interactions critically need carbohydrates to be specifically recognized by 
lectins such as those required throughout lymphocyte-homing, embryogenesis, host-
pathogen interactions, fertilization, and tissue development. Investigating lectin-
carbohydrate interactions at the molecular level is thus important to broadly understand 
their intervention in biology and medicine (Sastry and Ezekowitz 1993, Beuth and 
Pulverer 1994, Bookbinder, Cheng et al. 1995). 
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1.11 Mistletoe Lectin (ML) 
European mistletoe (Viscum album L.) grows as a semiparasite plant on deciduous and 
coniferous trees. Mistletoe extract has been focused upon by many researchers for a long 
time as a traditional remedy to treat patients with diabetes, cancer, hypertension, arthrosis 
and/or arthritis, and atherosclerosis (Hajto, Hostanska et al. 1989, Büssing, Suzart et al. 
1996). 
The immunomodulatory activities like induction of cytokine secretion and increasing the 
activity of natural killer (NK) cells alongside with cytotoxic effects of mistletoe extracts 
have also been suggested in the previous studies. Interestingly, the studies showed that 
these activities mainly come from the active lectins (MLs) in mistletoe extract. The lectins 
of mistletoe are classified and grouped into three isoforms: MLI (viscumin), MLII and 
MLIII (Eifler, Pfüller et al. 1994, Gamerith, Amann et al. 2014). 
The main and major lectin isoform is ML-I which gives immunomodulatory potency to 
mistletoe lectin and it is a type II ribosome-inactivating proteins (RIPII). It also consists of 
two different subunits A (MLA) and B (MLB) which are bound together by a disulphide 
bond and both of them are N-glycosylated (Figure 7). The A-subunit (MLA) is a toxic part 
of MLI which contains a highly specific N-glycosidase which gives the subunit the ability 
to effectively halt protein synthesis in cells via modifying 28S rRNA of eukaryotic 
ribosome 60S subunit. On the other hand, the B-subunit of the lectin is responsible for the 
binding function and also increases the cytotoxicity of the toxic subunit through causing 
cell agglutination in vitro and facilitates cell internalization (Eck, Langer et al. 1999, Niwa, 
Tonevitsky et al. 2003). Critically, Hajto, Hostanska et al. (1989) showed that using A-
subunit alone at the same concentration is completely inactive because it cannot bind to the 
cellular receptor glycoproteins and perform cell internalization by itself. 
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Despite similarity between the primary sequences of these three isoforms of mistletoe 
lectin, they have different carbohydrate binding specificities. The first and main isoform 
(MLI) was originally shown to have main affinity to D-galactose and 120 folds stronger 
than its affinity to N-acetylgalactosamine (GalNAc) (Wu, Chin et al. 1992). However, 
Müthing, Meisen et al. (2004) state that ML-I should be considered as sialic acid specific 
(not galactose-specific) because ML-I has higher affinity to sialylated residues than to 
galactosylated residues in glycoproteins. The second isoform (MLII) has equivalent 
affinity to both D-galactose and GalNAc whereas the third (MLIII) isoforms shows 
affinity only to GalNAc. The molecular weights of these isoforms are also different from 
each other as follow: both toxic and binding chains of MLI (A: 29kDA, B: 34kDA) are 
greater than the chains of MLII and MLIII (A: 27kDA, B: 32kDA) (A: 25kDA, B: 30kDA) 
respectively (Lee, Gabius et al. 1992, Wu, Chin et al. 1992, Tonevitsky, Agapov et al. 
2004). 
In order to evaluate the antineoplastic activity of mistletoe lectin, human lung carcinoma 
cells were treated with chemotherapeutic drugs such as doxorubicin and cisplatin alone and 
in combination with Viscum album agglutinin-1 (VAA-1). Stronger synergistic effects 
were observed in all drugs tested with mistletoe agglutinin (VAA-1) and it is believed that 
the inhibition of tumour protein synthesis through ribosomes inactivation by MLA is the 
source of antineoplastic activity of mistletoe lectin (Li 2002) 
It has also been suggested to precisely study the anticancer activity of both MLI and MLIII 
isoforms especially after the observation of strong apoptotic activity from both isoforms in 
the treatment of leukemic B- and T- cells. Despite the fact that MLIII was less effective 
than MLI in the treatment of B-cells, both isoforms shown potential apoptotic effects in the 
treatment of T-cells (Büssing, Wagner et al. 1999). 
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In order to separately examine the therapeutic effects of these isoforms, designing 
recombinant protein from each isoform has been suggested. Eck, Langer et al. (1999) 
reported that the biochemical and biological activity of recombinant rMLIA proteins 
designed from the toxic MLA chain of MLI remained the same in comparison to the 
activity of the wild chains. Pevzner, Agapov et al. (2004) also tested the antigenicity of 
recombinant MLB chains designed from MLI and MLIII and they found that there is an 
antigenic epitope in the B-chain of MLI which is absent in the B-chain of MLIII. However, 
the same antigenic epitope was detected even in the recombinant B-chain of MLIII. The 
proper folding of carbohydrate-binding sites was also observed in recombinant MLIIIB via 
ELISA tests (Pevzner, Agapov et al. 2004). 
Thus the binding chain of mistletoe lectin is an interesting candidate as a therapeutic 
targeting peptide. 
 
 
 
 
 
 
 
 
Figure 7. Cartoon plot showing the three domains for the A chain labeled I, II, and III; colored yellow, turquoise and violet. For the B 
chain domain I and II are colored according to their subdomains: The linker regions l1 and l2 are shown in orange, the homologous 
subdomains a, b, g are colored yellow, blue, and green. The disulfide bond connecting the two chains is shown as a blue bold dashed 
line and labeled. Dashed circles indicate the nucleotide binding site (“NUC”) for the A chain, the low (“G1”) and high affinity (“G2”) 
galactose binding sites in chain B and the three glycosylation sites clearly identified in the electron density (Krauspenhaar, Eschenburg 
et al. 1999). 
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1.12 Elderberry Lectin (SNA) 
Elderberry lectin (SNA) is a member of carbohydrate-binding proteins which has been 
extensively studied in the last few decades. The SNA lectin like other type of lectins 
contains different isoforms with different activities but the main and well-studied isoform 
is isoform I (SNA-I). The discovery of SNA-I and its carbohydrate affinity has made the 
lectin to become an important tool in the molecular biology, biochemical and physiological 
studies. SNA-I belongs to type 2 ribosome-inactivating proteins (RIPII) with strong 
cytotoxic activity similar to ricin RIPII (Girbes, Ferreras et al. 2004, Stirpe 2004). It is also 
sold commercially and may be used in cancer detection (Sigma Aldrich, UK).  
The SNA-I lectin is composed of two main parts which are a toxic RIPII chain (A chain) 
and a binding chain (B chain). The binding chain possesses a strong and specific affinity 
toward NeuAc(α2-6)Gal/GalNAc glycoconjugates. Therefore, it has been widely used in 
the study of glycoconjugate especially conjugates contain sialic acid residues (Shibuya, 
Goldstein et al. 1987). 
While many studies have been conducted about elderberry lectins, their biological function 
has remained unclear except in the plant which is believed to be defence against insects 
and viruses. However, a high level of RIPII in SNA-I lectin was shown to have a harmful 
toxic effect on animal physiology through the activation of cellular signal of gut mucosa 
which was detected in the animals fed with a high amount of the elderberry fruit (Tejero, 
Jiménez et al. 2015). 
On the other hand, the cytotoxicity and binding properties of elderberry lectin (SNA-I) 
have been used as a powerful tool in cancer research. The lectin has been suggested to be 
used as an agent to detect of Neu5Ac(α-2,6) terminal residues on cancer cells. For 
example, SNA staining intensity on colorectal cells can be used as an indicator of cancer 
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recurrence because previous studies have proven a relationship between colon cancer and 
the induction of particular sialyltranferase on their cell surfaces (Fernández-Rodríguez, 
Feijoo-Carnero et al. 2000, Dall'Olio, Malagolini et al. 2014).  
 
1.13 Snowdrop Lectin (GNA) 
The bulb of snow drops (Galanthus nivalis) contains a lectin called Galanthus nivalis 
agglutinin (GNA) which has strong binding affinity for mannose. The structural analysis 
has shown that the lectin is formed of similar 12.5kDa subunits that initially come from 
post translationally modified bigger subunits 15kDa synthesized on the rough endoplasmic 
reticulum (ER) (Van Damme, Allen et al. 1988). 
Functionally, GNA is considered as tetrameric protein with strong binding affinity to α-D-
mannose carbohydrates. It is also known as a resistant protein to proteolytic activity in 
which has made the lectin a focus for genetic modification of crops plants with the GNA 
gene for insect protection and as an appropriate carrier to transport other toxic peptides to 
the insect gut (Fitches, Audsley et al. 2002).  
While the GNA mechanism of action to exploit its cytotoxicity against insects is still 
unknown, it is believed that the binding of GNA to the glycoproteins of gut epithelium is 
the key point in GNA activity (Fitches, Woodhouse et al. 2001). In the earlier studies 
different fusion proteins were produced from GNA C-terminally fused to different peptides 
such as GFP and Manduca sexta allatostatin (Manse-AS) which were orally fed to the 
haemolymph of L. oleracea larvae and confirmed that GNA can efficiently deliver 
biological peptides to the gut of larvae  (Raemaekers 2000, Fitches, Audsley et al. 2002). 
Other studies have also been carried out to exploit the activities of GNA lectin in crop 
protection through genetic manipulation since the lectin is not harmful to mammals 
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(Pusztai, Grant et al. 1993, Rao, Rathore et al. 1998, Stoger, Williams et al. 1999, Nakasu, 
Edwards et al. 2014). 
These studies in insect protection demonstrate that a lectin can effectively deliver a toxic 
peptide across biological membranes. Thus could a similar strategy be used to target and 
kill cancer cells. 
 
1.14 Glycosylation and Cancer 
The focus on the cancer relationship with proteins, DNA and RNA has been driven to a 
high level and it has undoubtedly revealed crucial information about this disease. 
However, this lead to glycans (and lipids) being margined for sometimes because it was 
believed that they are not as related as the aforementioned molecules to cancer. However, 
recent modifications in proteomic methodologies and modern technologies help advances 
in glycomic and lipidomic researches and allow extensive studies about the role of these 
two molecules in cancer progression. To date, all the studies carried out about 
glycosylation changes in cancer confirm association between altered glycosylation and 
cancer development and progression (Igl, Polašek et al. 2011).  
Changes in cancer cell glycosylation simply means changes in the structure of glycans 
attached to the cell surface glycoproteins causes by altered expression and function of 
glycosidases and glycosyltransferases which may finally change the type of proteins that 
interact with the cell surface glycoproteins and modulate cell signalling and adhesion (Zou 
2005).  
Abnormal glycosylation is in fact a universal characteristic of cancer cells because it 
frequently happens in almost all the types of cancer cells and has vital roles in the cell-cell 
interaction, cancer progression and metastasis (Chen, Jan et al. 2013, Li, Xu et al. 2014). 
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This aberration was first observed when abnormal glycan structures were detected by 
antibodies used against cancer cells (Chen, LaRoche et al. 2007). While the mechanism of 
producing these abnormal glycans is still not clear and the direct relationship between 
cancer initiation and altered glycosylation has not yet been discovered, the contribution of 
these alterations in cancer development from the early stage to metastasis has been well 
established (Fuster and Esko 2005).  
The aberrant glycosylation of glycoproteins on cancer cells has been specifically focused 
on by researchers especially the mucins which are highly glycosylated by GalNAc on 
serine or threonine (O-glycosylation) and contains majority of oncogenic related glycan 
structures. Despite the variety of changes in glycan structures, two changes are well 
documented through biomarker studies which are the formation of truncated version of 
oligosaccharides and the formation of abnormal terminal structures such as sialylation of 
normal counterparts.It appeared that most of these changes come from glycosyltransferases 
up or down regulation; therefore, a study was carried out to see the consequences of the 
absence of a functional enzyme such as Cosmc chaperone protein through performing 
mutation in its sequence. The mutation was shown to cause the accumulation of cancer-
associated precursors (Ju, Lanneau et al. 2008). Thus, it is sensible to consider that non-
clonal signature of cell surface glycans is unstable because of a wide range of genetic 
origin clonal alteration associated with cancer and their expression mosaicism in tissue 
sections reflect differentiation and variation during cancer development (Nakasaki, Mitomi 
et al. 1989). Although, cancer cell glycosylation goes through a wide range of variations 
during cancer progression because of their non-clonal nature, it finally stabilizes through 
achieving positive properties of the invaded cell populations. Therefore, these glycan 
alterations can be considered as cancer biomarkers and to be detected via using lectins and 
antibodies as they are visible on the cell surfaces (Hollingsworth and Swanson 2004). 
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1.15 Altered Glycosylation in Melanoma Cancer 
One of the most fatal malignancies which has broadly increased in the last few decades is 
melanoma cancer. Melanoma is well known for being unnoticeable during the early stages 
of progression and becomes metastatic in a very short period of time. To progress and 
reach metastasis, melanoma is associated with the alterations in the enzymatic activity of 
some specific glycosyltransferases responsible for the glycosylation of cell surface 
glycoproteins. These alterations may include changes in the structure of N-glycans of the 
glycoproteins and consequently changes the functionality of the proteins especially those 
responsible for metastasis (Hakomori 2002). Sialic acid is one of major terminal residues 
in the cell surface glycans with its properties related to the invasion and malignancy of 
melanoma tumours, by helping the malignant melanocytes escape from the attachment to 
the matrix components (Due to changed properties) and thus helps them to easily migrate 
and interact with platelets and leukocytes through association with selectins and finally 
facilitate metastasis (Rambaruth and Dwek 2011). Despite the increased amount of sialic 
acid linkages in melanoma which is often with N-acetyllactosamine, many modifications 
were also detected in their linkages. Increased sialylation of 9-O-acetylation is also 
detected in melanoma and has become a biomarker for human melanoma cells (Cheresh, 
Reisfeld et al. 1984, Kohla, Stockfleth et al. 2002). 
To screen the changes in glycosylation profile of melanoma cells during the stages of 
cancer development, N-glycans of L1CAM oligosaccharides were precisely studied at 
different stages of progression. The oligosaccharides were found highly sialilated and alter 
their glycosylation profile during progression stages form vertical growth phase (VGP) to 
metastasis. The L1CAM oligosaccharides of melanoma cells at primary stage were found 
to have both α2-3- and α2-6-linked sialic acids whereas the oligosaccharides of metastatic 
cells loss α2-3-linked sialic acids and only keep α2-6-linked sialic acids. Therefore, it is 
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suggested to target specific N-glycans of melanoma cells and recognise them as new 
biomarkers to specifically target the cancer cells (Hoja-Łukowicz, Link-Lenczowski et al. 
2013). 
 
1.16 Cancer Therapy 
The major drawback of conventional anticancer therapeutics (Those used in conventional 
chemotherapy) is a lack of specificity that leads to a poor therapeutic index and causes 
substantial toxicity not just for cancerous tissues but also for the healthy tissues. On the 
other hand, a high level of specificity may be achieved by using monoclonal antibodies an 
interest in which has considerably increased recently as well as their applications in cancer 
medicine. Although, the therapeutic potential of monoclonal antibody may be limited by 
production time and cost, the antibody-drug conjugation is considered as a potential 
approach for cancer therapy as the systemic cytotoxicity of the drug is reduced and cancer 
patients can achieve higher therapeutic benefits from targeted anticancer therapies (Alley, 
Okeley et al. 2010, Casi and Neri 2012). Table 2 shows different strategies which have 
been employed for drug targeting.  
Table 2. A variety of strategies, previously employed for drug targeting. 
Ligand Target molecule (cell) 
MR kDa 
size (nM) 
Immunogeni
city 
Clinical status 
Costs of 
productio
n 
 
       
Antibody 
fragments 
Fab 
 
 
eg, NCA-90 (granulocyte), CEA 
(apical surface of 
gastrointestinal epithelium, 
lung tissues, breast, and 
colorectal cancer), VEGF 
(breast, colon, lung, gastric, 
renal, and oropharyngeal 
cancers), HER2 (breast, 
ovarian, stomach cancer) 
 
 
50 (5) 
 
 
Lower 
than mAb 
 
 
 
 
Approved by 
FDA: 
certolizumab 
pegol, CEA-
scan 
 
 
$615/40 
mg 
 
 
 
 
 
 
 
scFv eg, CEA, HER2 30 (3) Lower than Preclinical trial Low  
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Monoclonal 
antibodies 
(mAb) 
Fab 
Rituximab 
 
 
 
 
Trastuzumab 
Bevacizumab 
Alemtuzumab 
 
 
 
 
Panitumumab 
 
 
 
 
 
 
 
 
Proteins and 
peptides 
RGD 
 
 
DARPins 
 
 
DNA or RNA 
oligonucleotid
es 
Aptamers 
 
Other 
targeting 
molecules 
Folates 
 
 
 
 
Lectins 
 
Transferrin 
CD20 (pre-B and B-cell) 
 
 
 
 
HER2 
VEGF 
CD52 (lymphocytes, especially 
T-cells, monocytes, 
macrophages, monocyte-
derived dendritic cells 
[moDCs], and the epithelial 
cells of the distal epididymis) 
EGFR (normal cells and non-
small-cell lung cancer [NSCLC], 
breast, head and neck 
[squamous cell carcinoma of 
head and neck], gastric, 
colorectal, prostate, bladder, 
pancreatic, ovarian, and renal 
cancers) 
 
 
Integrins αVβ3 and αVβ5 
(overexpressed on tumor 
endothelium) 
eg, CD4 (T helper cells, 
monocytes, macrophages, and 
dendritic cells), HER2. 
 
 
 
proteins, surface receptors 
 
 
 
 
folate receptors: RFC (all 
cells), FR (ovarian, brain, head 
and neck, renal, and breast 
cancers) 
 
Lectins receptor: DC-SIGN 
(dendritic cell), CLR (cancer) 
CD71 (present on all cells, but 
overexpressed on cancer cells) 
145 (15) 
 
 
 
 
145 (15) 
145 (15) 
145 (15) 
 
 
 
 
145 (15) 
 
 
 
 
 
 
 
 
 
 
1–5 
(1–2) 
 
14–20 
(5–10) 
 
 
 
 
8–13 
(3–5) 
 
 
 
0.44 
(0.3) 
 
 
 
10–200 
(2–20) 
80 
(5–10) 
* 
 
 
 
 
** 
*** 
**** 
 
 
 
 
® 
 
 
 
 
 
 
 
 
 
 
High 
 
 
High 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
ᴓ 
 
Low 
In clinical use 
 
 
 
 
 
 
 
 
 
 
 
In clinical use 
 
 
 
 
 
 
 
 
 
 
Clinical trials 
 
 
Phase I/II  
clinical trials 
 
 
 
 
FDA approved 
Macugen 
 
 
 
Yes 
 
 
 
 
Not in clinical 
use 
Not in clinical 
use 
High cost of 
final 
product, 
about 
$2,000–
$20,000/g 
 
 
 
 
 
 
 
High cost: 
$2,000–
$20,000/g 
 
 
 
 
 
 
 
 
Low 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
Low 
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Notes: Size–length in the longitudinal section; 
*low: 11% positive in HACA (human anti-chimeric antibody) test; 
**very low: 0.11% positive in HAHA (human anti-human antibody) test (Genentech, Inc., South San 
Francisco, CA, USA); 
***very low: 0.63% tested patients positive for treatment-emergent anti-bevacizumab antibodies; 
****anti-alemtuzumab antibodies were detected in 80.2% of alemtuzumab-treated patients. Titers generally 
increased during first 3 months of each course, declined by month 12. At month 12, 29.3% of patients 
remained positive for anti-alemtuzumab antibodies; ᴓlow: 2% patients developed binding and neutralizing 
antibodies;®some are potent toxins. Costs are in US$. 
Abbreviations: Av, average; CEA, carcino-embryonic antigen; CLR, C-type lectin receptor; DC-SIGN, 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; EGFR, endothelial growth 
factor receptor; FR, folate receptor; Fv, variable fragments; Fab, antigen-binding fragments; KD, equilibrium 
dissociation constant; MR, mannose receptor; RFC, reduced folic carrier; mAbs, monoclonal antibodies; 
scFv, single chain variable fragments; VEGF, vascular endothelial growth factor. 
 
In theory antibody-drug conjugates (ADCs) are simple but practically it may be a 
considerable challenge. The development of an effective ADC needs many properties to be 
achieved and optimized such as retention of immunoreactivity, stability (the drug should 
be protected and attached to the conjugate until it reaches the targeted site in vivo), 
pharmacokinetics (preventing the accumulation of the drug in other non-targeted organs) 
and finally the drug should be successfully released on the targeted site. However, these 
parameters were not considered in developing early ADCs which were mainly relying on 
the existent chemotherapy agents with known cytotoxic profiles and the main target was 
just increasing tumour specificity of the agents. An example of the very first anti-cancer 
ADCs is BR96-doxorubicinis which is a combination of BR96 Lewis-Y specific 
(chimeric) monoclonal antibody attached to doxorubicin chemotherapy through a 
hydrazone linker (Trail, Willner et al. 1993). 
In the development of a new generation of ADCs other requirements have also been taken 
in to consideration such as designing conjugates from tumour specific monoclonal 
antibodies (mAbs) with appropriate formats that help tuning the conjugate uptake by 
tumours and also using appropriate linker to properly manage the drug protection and 
 38 
 
release. Thus, the cross-reactivity of the ADCs and their cytotoxicity to healthy tissues and 
organs have been minimized (Polson, Ho et al. 2011). 
While some successful ADCs have been developed and used in cancer therapy, the 
development of next generation ADCs needs to find more effective drugs to be bound with 
mAbs. The current ADCs have limited capacity because of the limited amount of drugs 
can be realistically administrated to patients. The reasons behind this limitation are the 
high cost of the therapy and the limited amount of drug that can be loaded on the mAbs 
because loading extra amount of drug often results in loss of potency. Moreover, the 
amount of drugs that reach malignancies is just a small amount of the injected does 
(maximum 0.08%/g of tumour) because of the environment of tumours which has a high 
level of interstitial ﬂuid pressure (IFP) plays as a barrier for diffusion and consequently 
results in a poor localization of mAbs (Hamblett, Senter et al. 2004, Heldin, Rubin et al. 
2004). Therefore, it is important to discover more potent bioactive molecules and use them 
as a carrier vehicle like mAbs to develop better tumour targeting conjugates. As seen in 
table 2 lectins are an explored but uncommercialised possibility. 
 
1.17 Drug Targeting 
Delivery of a specific drug to a specific location needs the production of targeted drug 
delivery systems (DDS) and one of the efficient and selective types of DDSs is known as 
prodrug. A prodrug is a drug conjugate in inactive form until it gets to the target site and 
becomes active via a specific condition within the site. It typically works in two different 
manners: first, drug conjugate breaks down within the target site to one or two therapeutic 
agents; second, the conjugate reacts with two or more compounds within the target site so 
as to produce therapeutic agents in a special intracellular condition (Minko 2004, Rek, 
Krenn et al. 2009). 
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The typical selective drug delivery systems (DDSs) contains three main components which 
are targeting moiety, drug and carrier. All the components are bound together by the 
carrier which also increases the solubility of the system. As well as, two crucial features 
should be found in any DDS system: first, the drug should be protected from degradation 
by the delivery moiety until it reaches the target site. Second, separation of the drug from 
the conjugate should be assured within the target site. To achieve these features especially 
the second one, the therapeutic agent should be attached to the delivery conjugate through 
specific type of linkages such as a tetrapeptide Gly-Phe-Leu-Gly biodegradable linker 
which can be cleaved by cathepsin B enzyme and liberate the agent at a specific site 
(Kopeček, Kopečková et al. 2001, Lu, Shiah et al. 2002). It is also possible to make the 
whole DDSs moiety biodegradable and degrades within the target site such as the 
conjugation between indole-3-acetic acid and horseradish peroxidase that changes to a 
cytotoxic agent through the degradation of the conjugate because of the radical cations 
results from the oxidization of indole-3-acetic acid by horseradish peroxidase (Minko 
2004).  
 
1.18 Lectin-mediated Drug Delivery 
The reduced efficacy of drugs delivered through traditional non-targeted therapeutics and 
their numerous side effects on healthy tissues (Which hence reduce drug dosage and delay 
treatments) provide the innovation to develop an alternative way to deliver drugs. 
Therefore, selective drug delivery systems (DDS) became a strong research focus with the 
promise of potential to specifically deliver drugs to target sites and at the same time 
reduces the side effects of the drug on the normal tissues. It also increases the efficacy of 
therapy through increasing exposure between the drug and the target site. In fact lectins 
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were originally one of the candidates suggested by Woodley and Naisbett (1988) to be 
used as a targeting moiety in designing DDS (Bies, Lehr et al. 2004). 
During designing functional DDSs, identification of specific moieties on target site to be 
utilized by the drug is crucial. However, there are extra parameters that should be taken 
into considerations in lectin based drug delivery systems such as the environment of 
transporting path and the target site itself (Minko 2004, Rek, Krenn et al. 2009). The acidic 
environment of the gastrointestinal tract and pancreatic enzymes are good examples that 
cause degradation and early activation of drugs. On the other hand, catabolic assault from 
bacterial origin enzymes such as β-D-galactosidase and β-D-glucosidase can also damage 
drugs delivered through colon. However, advantages can be taken from these bacterial 
enzymes through developing DDSs with ability to utilize the enzymes such as drug-
carbohydrate conjugates (Prodrug) (Guarner and Malagelada 2003, Rek, Krenn et al. 
2009). 
 
1.19 Lectin-based Drug Targeting 
The logic behind using lectins in drug delivery is the simple fact that more than half of cell 
membrane proteins and lipids are heavily glycosylated with glycans which are targeting 
sites for lectins. The expression pattern of glycans change from one cell type to another 
and a range of different glycan array are expressed by different cells. For instance, glycans 
expressed by carcinogenic cells are different than those expressed by their healthy 
counterparts. Thus, lectins with affinity to these glycan arrays can be used to deliver drugs 
to specific cells and tissues (Haltner, Easson et al. 1997). 
There are two main mechanisms to accomplish lectin-based drug targeting: direct and 
reverse lectin targeting. In direct lectin targeting, endogenous cell surface lectins recognize 
carbohydrate moieties of DDS but in reverse targeting endogenous carbohydrate moieties 
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on glycoproteins and glycolipids are recognized by the exogenous lectins of DDS (Bies, 
Lehr et al. 2004, Plattner, Ratzinger et al. 2009). Furthermore, cytotoxicity and apoptosis 
induction are two other features of lectin based DDSs which increase the potential of the 
system for cancer treatments (Thies, Nuge et al. 2005, Plattner, Ratzinger GEngleder et al. 
2009). In order to exploit their cytotoxicity, lectins can be used in two different 
approaches. First, a non-toxic lectin can be attached to a therapy that will activate and 
become toxic within the target site. Second, a toxic lectin can be used to act as both toxic 
agent and homing moiety through apoptosis induction (Minko 2004, Heinrich, Welty et al. 
2005). However, difficulty in finding lectins with selective cytotoxicity towards specific 
sites is a limitation of the second approach (Ghazarian, Idoni et al. 2011).  
Mistletoe lectin (MLI) is one of the potent anticancer candidates with strong cytotoxicity 
that causes protein synthesis inhibition in cells (Mody, antaram Joshi et al. 1995). The total 
extract of mistletoe containing all three lectins (MLI, MLII, MLIII) has been widely used 
in cancer research and many positive results have been achieved especially in breast cancer 
treatments. However, in the treatment of MV3 melanoma cancer cells with MLI, MLII and 
MIII separately, isoform I (MLI) in particular showed more cytotoxicity than other 
isoforms (MLII and MLIII). Therefore, MLI could be a good candidate for the second 
approach of lectin based drug targeting (Thies, Nugel et al. 2005). 
 
1.20 Cathepsin B Protease and Melanoma Cancer 
Cathepsin is a large protease family found in a well-defined organelles of cells and possess 
unique structure and substrate specificity (Guicciardi, Leist et al. 2004). The family has at 
least twelve members of different structures of serine-, cysteine- and aspartyl- which are in 
an inactive proenzyme state inside cells. However, they transform to active state once they 
come out of cells and enhance the degradation of the components of the basement 
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membrane and extracellular matrix (Szpaderska and Frankfater 2001, Vasiljeva, 
Reinheckel et al. 2007, Vasiljeva and Turk 2008). Thus, the metastatic potential of cancer 
cells can be determined via assessing the proteolytic activity of cathepsin family members 
(Podgorski and Sloane 2003).  
The main activities of aspartyl- or cysteinyl- proteases are the degradation of extracellular 
matrix and removing physical barriers that limit cell movement and facilitate cell 
spreading and invasiveness (Jedeszko and Sloane 2004). Different level of cellular 
activities are possessed by different types of cathepsins but cathepsin B, D, K and L are 
shown to be the most active ones and play crucial enzymatic roles (Guzinńska-
Ustymowicz, Zalewski et al. 2004, Lankelma, Voorend et al. 2010).  
In the studies carried out to investigate the relationship between cathepsins expression and 
the progress of metastatic melanoma, direct association was found between the 
overexpression of cathepsins and rapid melanoma distribution (Roshy, Sloane et al. 2003, 
Murata, Yatsuda et al. 2010). This association was later observed at the highest rate 
between cathepsin B and the invasion potential of melanoma cells in a study conducted to 
modulate metastasis of melanoma cells through using inhibitors of cathepsin B, D and L. 
The flow cytometry analysis in the study showed that the level of cathepsin B expressed on 
the cell surfaces was much higher in metastatic melanoma cells than primary melanoma 
cells, while, comparable amount of cathepsin D and variable amount of cathepsin L were 
detected on both cells. Real time quantitative RT-PCR was also performed to confirm 
these results and similar results were achieved as the rate of procathepsin B transcripts was 
found significantly higher in metastatic melanoma cell lines than primary melanoma cell 
lines (Matarrese, Ascione et al. 2010). 
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Thus we can utilise a cathepsin B cleavable linker sequence between a lectin carrier and a 
cytotoxic peptide, releasing the toxin from the carrier specifically at the cancer cell. 
 
1.21 Cytotoxic Peptides 
A wide range of cytotoxic peptides are known and thus this study will focus on only two 
(Melittin and Mastoparan) due to previous studies conducted with these peptides in anti-
cancer research. 
1.21.1 Melittin 
The cytotoxicity of bee (Apis mellifera) venom comes from only 12% of its whole volume 
which consist of 100ng dry venom and 88% is water. Melittin is the most abundant 
haemolytic and cardio-toxic peptide in bee venom occupies 50% of the active part 
(Shaposhnikova, Egorova et al. 1997, Hussein, Nabil et al. 2001). 
Melittin is a 26-amino acid (GIGAVLKVLTTGLPALISWIKRKRQQ) cationic peptide 
with amphipathic features which gives the peptide an ability to interact and damage 
biological membranes (Habermann 1972, Dempsey 1990). The disruption of cell 
membrane phospholipid bilayer is believed to be the main cytotoxic effect of melittin on 
cells that leads to the formation of transmembrane pores (Raghuraman and Chattopadhyay 
2007). 
Promising cytotoxic activities against cancerous cells were observed from bee venom in 
general and melittin in particular. In order to assess these activities both in vitro and in vivo 
experiments were conducted. Their in vivo applications are limited due to the side effects 
and hemolysis (Liu, Yu et al. 2008, Hoshino, Urakami et al. 2009). The in vitro studies 
showed that bee venom significantly inhibits cancer cell proliferation and clonogenicity. 
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For instance, treating mouse melanoma cells (K1735M2) with bee venom was seen to 
positively supress cell growth and migration (Liu, Chen et al. 2002). Significant cell 
growth suppression, increased apoptosis, and reduced metastasis were also observed 
through biochemical and morphological analysis of lung cancer cells (NCl-H1299) treated 
with bee venom (Jang, Shin et al. 2003, Oršolić, Šver et al. 2003). Similarly, the inhibition 
of tumour growth by the venom was seen in the in vivo tests carried out by Liu, Chen et al. 
(2002) on solid melanoma tumours of mouse . 
The haemolytic nature of melittin is the restriction of its systematic administration as 
anticancer agent. Therefore, recent studies have focused on attaching nanoparticles to the 
peptide in order to protect it from hemolysis and be able to systematically deliver it to 
cancer cells (Zetterberg, Reijmar et al. 2011). Yet, the only successful nano carrier is 
perﬂuorocarbon nanoemulsion which has been designed by Soman, Baldwin et al. (2009) 
from lipid monolayer to safely deliver melittin without causing hemolysis. Through this 
carrier and for the first time melittin was applied via intravenous administration and was 
seen to inhibit tumour growth. However, the big size of the melittin-nanoparticle molecule 
(∼270 nm) is an obstacle and make it hard to be used with solid tumours because it cannot 
penetrate them (Minchinton and Tannock 2006, Cabral, Matsumoto et al. 2011). 
 
1.21.2 Mastoparan 
The term mastoparan (MP) describes a 14-amino acid (INLKALAALAKKIL) cationic and 
amphipathic peptide derived from wasp (Vespula lewisii) venom (Hirai, Yasuhara et al. 
1981). Mastoparan as a major component of wasp venom which has been extensively 
studied in the last three decades and important cytotoxic activities have been demonstrated 
from their natural and synthetic analogous (Higashijima, Burnier et al. 1990, Soomets, 
Haellbrink et al. 1997). Apart from antimicrobial activity, MP was found to induce 
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phospholipase A2 and C activation and perform cytotoxic activity in variety of cell types 
such as platelets, mast cells, and pancreatic islet β-cells (Hirai, Yasuhara et al. 1981, 
Argiolas and Pisano 1983, Yokokawa, Komatsu et al. 1989, Ozaki, Matsumoto et al. 
1990). 
Both natural and synthetic analogues of MP share similar activity which is binding to 
heterotrimeric G proteins especially Gi and Go and regulate them. In order to, perform this 
binding with G proteins or any other intracellular proteins, MP needs to cross cell 
membrane assisted in doing so by its amphipathic nature. The presence of lipid and their 
interaction with Gi/Go helps MP to adopt α-helical conformation, while it has disordered 
structure in aqueous solutions. The amino terminus of MP sequence if the hydrophilic face 
of MP and the three positively charged lysyl residues in the MP sequence is thought to 
interact with hetero- trimeric G proteins especially Gi and Go and stimulate the activity of 
GTPase which in turn catalyses the exchange of GDP/GTP (Weingarten, Ransnäs et al. 
1990, Shpakov and Pertseva 2006). 
More recently the anti-tumour activity of mastoparan and its analogues has also been 
demonstrated using different cancer cell lines such as human erythroleukemia (K562) and 
the results showed that MP cytotoxicity was based on membrane disruption (Yamada, 
Shinohara et al. 2005). Moreover, a significant difference was observed between treating 
normal and melanoma cells with mastoparan as the cytotoxicity of MP was attenuated in 
normal cells in comparison to the activity in cancer cells. The further analysis for this 
difference revealed that MP induces ROS (Reactive oxygen species) dependent oxidative 
stress which affects cancer cells more than normal cells because cancer cells are more 
dependent on their antioxidative systems which can be inhibited by MP and leads to severe 
ROS accumulation and cell death. However, in normal cells the basal output of ROS is low 
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and less oxidative stress occurs when they are treated with mastoparan (Irani, Xia et al. 
1997, Sattler, Verma et al. 2000, Trachootham, Zhou et al. 2006).  
Other studies showed that mastoparan induces the apoptosis of melanoma cells through the 
mitochondrial intrinsic pathway since the altered morphological properties of mitochondria 
confirmed that MP as a cell penetrating peptide can cross mitochondria membrane and 
leads to cell death. Therefore, mastoparan is suggested to be used as anticancer agent 
(Park, Lee et al. 2000, Armstrong 2006, Rocha, de Barros et al. 2010). 
 
Thus the objective of this study is to: 
1- Produce recombinant fusion proteins from the binding chain (MLB) of mistletoe 
lectin isoform I, the binding chain of elderberry lectin (SNA-B) and snowdrop 
lectin (GNA) fused to green fluorescent protein (GFP) as a fluorescent marker and 
express them in E. coli in order to demonstrate the glycan binding specificity of the 
lectins. 
2- Generate a range of Carrier:Cytotoxic peptide fusion constructs and express in E. 
coli in order to exploit the glycan binding specificity of the binding chain of 
mistletoe lectin (MLB) to deliver different cytotoxic peptides specifically to cancer 
cells. 
3- Screen the produced recombinant fusion proteins against different cancer cell lines, 
including primary and metastatic melanoma,so as to confirm their binding to cell 
membranes, internalisation and cytotoxic activity. 
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Chapter 2. Amplification and Cloning of MLA and MLB Chains of Mistletoe Lectin 
Isoform One (MLI) 
 
2.1 Introduction 
Mistletoe lectin (ML) is as a toxic glycoprotein (Lectin) derived from mistletoe (Viscum 
album) and a well-known representative of type II ribosome inactivation proteins (RIPII) 
with strong cytotoxic activity similar to ricin and abrin toxic glycoproteins (Barbieri, 
Battelli et al. 1993, Tonevitsky, Agapov et al. 1996). 
There are three isoforms among mistletoe lectin (MLI, MLII, MLIII) which are highly 
similar in their molecular weights but they are different in their amino acid sequences and 
glycan binding affinities (Urech, Schaller et al. 2006). 
The main and most abundant isoform among the three isoforms of mistletoe lectin is 
isoform one (MLI) which has been structurally and functionally studied in comparison 
with ricin lectin. The isoform is composed of two main chains with completely different 
functions. The first chain is a toxic chain (MLA) which is a 29kDa potent N-glycosidase 
and belongs to RIPII with the ability to disrupt protein synthesis through the modification 
of 28s RNA and it is the source of cytotoxicity of mistletoe lectin. The second chain is a 
binding chain (MLB) which is a 34kDa peptide folded to two homologous potential 
galactose binding domains and contain several glycan binding sites and is responsible for 
the binding property of mistletoe lectin (Krauspenhaar, Eschenburg et al. 1999).  
The homology between MLA chain of MLI and the toxic chain of ricin is 41% which is 
less than the significant 64% homology between the MLB chain of MLI and the binding 
chain of ricin. The two chains of MLI are bound to each other through a disulphide bond 
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between Cys 260A and Cys 5B and to activate the enzymatic activity of MLA chain this 
disulphide bond needs to be reduced so as to let the chain to be released from MLB chain 
(Tonevitsky, Agapov et al. 1996, Niwa, Tonevitsky et al. 2003).   
The glycan binding property of mistletoe lectin gives the lectin an ability to potentially 
bind to the living cell through cell surface glycans. While MLB chain of MLI binds to cell 
surface glycans, it also binds to the cell surface receptors which facilitates the 
internalization of the toxic MLA chain through triggering the endocytotic uptake of cells 
(Vervecken, Kleff et al. 2000). Recent work (Müthing, Meisen et al. 2004) has suggested 
that MLB is not actually galactose binding, but is in fact specific for sialic acid. 
As cancer cells are known to highly express sialic acid residues at the cell surface (Hoja-
Łukowicz, Link-Lenczowski et al. 2013, Kolasińska, Przybyło et al. 2016), the B-chain of 
mistletoe lectin may represent a potential cancer specific binding peptide. In an attempt to 
produce recombinant fusion proteins from the cytotoxic A-chain and the carbohydrate B-
chain of mistletoe lectin isoform I (MLI), a heterodimeric protein known as rViscumin was 
produced. The binding activity of rViscumin was later assessed through a solid phase 
binding assays and confirmed that the protein has a preferential binding to terminally α2-6-
sialylated neolacto-series gangliosides IV6Neu5Ac-nLc4Cer, VI6Neu5Ac-nLc6Cer, and 
VIII6Neu5Ac-nLc8Cer isolated from human granulocytes. The cytotoxicity of rViscumin 
was also assessed with human bladder carcinoma 5637 cells and was shown to have IC50 
value (half maximum cytotoxicity) of 2.1pM (Müthing, Burg et al. 2002). 
Trefzer, Gutzmer et al. (2014) also produced a recombinant protein from mistletoe lectin 
known as Aviscumine which was shown to enhance T-cell responses and cytokine release 
through inducing ribotoxic stress at the 28S ribosomal RNA subunit. Aviscumine has been 
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tested at phase II trial in patients with systemically pre-treated metastatic melanoma stage 
IV and significant results have been obtained. 
Thus the aim of this study is the amplification, cloning and sequencing the toxic chain 
(MLA) and the binding chain (MLB) of mistletoe lectin isoform I (MLI) from source and 
analysis of their coding sequences. 
A bioinformatics analysis of lectin sequences was also performed in order to design a PCR 
based screen in other tissues. However, homology between lectin sequences was poor. 
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2.2 Materials and Methods 
2.2.1 Bioinformatics Analysis 
Bioinformatic analysis was conducted to identify novel C-type lectins from plant and 
animal sources (C-lectins are identified in literature as binding molecules to cancer cells) 
(Yau, Dan et al. 2015).   
NCBI (http://www.ncbi.nlm.nih.gov/) was accessed and searched for C-lectins natural 
resources and the grape Vitis vinifer C-lectin was then used as the query sequence to align 
14 sequences using Clustal W2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Figure 8). The 
complete alignment result is shown in appendix 1. 
 
 
Figure 8. Snapshot of conserved regions in the multiple sequence alignment of C-lectin from different sources. 
 
Degenerate primers were designed corresponding to ((LGGHLA (black box), GCWVGGH 
(red box), EYLIILAVVSGLIL (purple box) and TTLAVVIWLLAYR (orange box))) and 
then used to amplify the conserved regions from cDNA generated from a range of plant 
and invertebrate tissues. 
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2.2.2 Sample Preparations 
Nucleic acids were extracted from fresh leaf tissue of the Mistletoe plant Viscum album. 
Ten leaves were frozen in liquid nitrogen and grounded to a fine powder with mortar and 
pestle. They were then divided to 100mg samples per eppendorf tube and stored at -20oC. 
 
2.2.3 RNA Extractions 
RNA was extracted using ISOLATE II RNA Plant Kit (Bioline, UK).  Approximately 
100mg of tissue was lysed using 350μl Lysis Buffer RLY (guanidium thiocyanate and 
guanidium HCl) and 3.5μl ß-mercaptoethanol. The rest of the protocol was performed 
according to the manufacturer’s instructions. The eluted RNA was then purified further 
using the Bioline silica column, DNase digestion as part of the RNA extraction kit was 
carried out according to the manufacturer’s instructions. RNA was eluted in RNase free 
water and stored at -80°C until further use.  
 
2.2.4 Agarose gel Electrophoresis Containing Formaldehyde 
Sambrook and Russell’s protocol (Sambrook and Russel 2006) was followed to perform 
agarose gel electrophoresis containing formaldehyde to separate RNA according to size. 
The RNA was denatured in a sterile RNAse-free microcentrifuge tube by mixing the 
following: 2μl of RNA (up to 20μg), 2μl of 10X MOPS electrophoresis buffer, 4μl of 
formaldehyde and 10μl of formamide. The RNA solution was incubated at 55Co for 60min 
and chilled immediately followed by centrifugation for 5 seconds to deposit all of the 
liquid to the bottom of the microfuge tube. Finally, 2μl of formaldehyde gel-loading buffer 
(50% (v/v) glycerol, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF and 
10 mM EDTA pH 8.0) was added to the sample and returned to the ice bucket. 
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Agarose gel (1.5%) containing 2.2M formaldehyde was used to resolve RNAs. 1.5g of 
agarose was dissolved in 72ml H2O and the solution was cooled to 55
oC and then 10ml of 
10X MOPS electrophoresis buffer and 18ml of deionized formamide were added. The gel 
was allowed to set for at least 1 hour at room temperature then covered with saran wrap 
until the sample was ready to be loaded. 
The agarose/formaldehyde gel was installed in a horizontal electrophoresis box. 1X MOPS 
electrophoresis buffer was added to cover the gel to a depth of approximately 1mm. The 
gel was run for 5 minutes at 5 volt/cm and then the RNA sample was loaded into the wells 
of the gel. The two outermost lanes on each side of the gel were left empty and the RNA 
size standard (Bioline, UK) was loaded in the outside lanes of the gel. The gel was run at 
4-5V/cm until the bromophenol blue migrates approximately 8cm. The RNA bands on the 
gel was visualised and photographed by G-box transilluminator (Syngene, UK). 
 
2.2.5 Two-Step Reverse Transcription Polymerase Chain Reaction 
cDNA Synthesis: Synthesis of cDNA was executed using SuperScriptTM-II Reverse 
Transcriptase kit (Invitrogen, UK) following the manufacturer’s instructions. Synthesis 
was performed in a total volume of 20µl and master mix preparation is shown below. Two 
mixtures were prepared in two different tubes. The first mixture was prepared from the 
components shown in table 3.  
Table 3. Master Mix I for cDNA Synthesis. 
Reagent         1 Sample 
 
Oligo (dT) (500 μg/ml) 
 
        1.0 μl 
RNA template         (1ng to 5μg) 
dNTPs 1.0 
Sterile Water 
 
        1.0 μl 
        to 12 μl 
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The mixture was incubated on a heating block at 65ºC for 5 minutes and immediately 
chilled on ice for 2 minutes. 
The second mixture was prepared from the components shown in table 4 
 
Table 4. Master Mix II for cDNA Synthesis. 
Reagent         1 Sample 
 
5X First-Strand Buffer 
 
        4.0 μl 
0.1 M DTT         2.0 μl 
Sterile Water 
RNaseOUT™ (40 units/μl) 
        1.0 μl 
        1.0 μl  
 
 
The two mixtures were then combined and incubated at 42ºC for 2 min followed by adding 
1μl (200 unit) of SuperScriptTM-II. The reaction was vortexed gently and incubated at 42ºC 
for 50min then followed by heating at 70ºC for 15 min to inactivate the reaction.  
 
2.2.6 Polymerase Chain Reactions 
Amplification of specific DNA products from reverse transcribed cDNA template was 
carried out using Phusion High-Fidelity PCR Master Mix (NEB, UK). The reaction was 
prepared from the following components; 10μl of 1x Phusion HF buffer mix (1.5 mM 
MgCl2), 0.02U μL-1 Phusion DNA Polymerase, 200μM dNTPs, < 250 ng DNA template 
and 0.5 μM primers (Primers used were identical to Soler, Stoeva et al. (1996) and Soler, 
Stoeva et al. (1998) Table 6). Parameters for the Phusion PCR reaction are shown in table 
5. The annealing temperatures were adjusted according to the primers used purchased from 
Eurofins Company (Eurofins-Germany) and shown in table 6. A no template control was 
used to check both RNA and DNA contamination in the reagents and consumables.  
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Table 5. Cycling parameters for PCR using the Phusion Taq system. Annealing temperatures (X) were modified 
depending on the primers used. 
Stage                                                         Conditions 
    
Heated Lid     All cycles        110 °C, constant 
        98 °C, 30 seconds Pre-denaturation     1 cycle 
 
Amplification 
 
     
    35 cycles 
        98 °C, 10 seconds (Denaturation) 
         X °C, 30 seconds (Annealing) 
        72 °C, 30 seconds (Elongation) 
Final extension 
Storage 
    1 cycle 
    1 cycle 
        72 °C, for 10 minutes 
        4 °C, Hold 
 
 
 
Table 6. Primers used for Polymerase chain reaction and Sequencing. 
Primers Sequences TM (°C) 
 
MLA-fwd  
MLA-rev 
MLB-fwd  
MLB-rev 
M13 Forward 
M13 Reverse 
 
 
AGAGGAAGATGGCCGCTCTC 
TACGAGAGGCTAAGACTCAGAG 
 GATGATGTTACCTGCAGTGCTTC 
TGGCACGGGAAGCCACATTTG 
GTAAAACGACGGCCAG 
CAGGAAACAGCTATGAC  
  
    60 
    61 
    60 
    61 
    55 
    55 
 
2.2.7 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was performed using a Tris/Borate/EDTA (TBE) buffering 
system. 0.5X TBE was made from a 5X stock solution contained 45 mM Tris-borate and 1 
mM EDTA. Gels were made using TBE with Agarose (Lonza, Tewkesbury, UK). The 
amount of agarose used was dependent on the matrix density required for specific DNA 
molecules. DNA was visualised using Gel Red® (Invitrogen, UK) at a final concentration 
of 0.075μl per ml of gel. DNA HyperLadder I (Bioline, London, UK) was used to quantify 
the size and amount of DNA molecules of the bands. The gel was visualised and 
photographed by UV G-box transilluminator (Syngene, UK). 
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2.2.8 Gel Extraction of DNA 
Gel purified PCR products were obtained from agarose gel using Promega Gel extraction 
kit (Promega, UK) following manufacturer’s instructions. Briefly, DNA bands were 
excised from the gels using sterile scalpel blades and put into separate 1.5ml pre-weight 
eppendorf tubes. 10μl of Membrane Binding Solution was added to 10mg of the gel slices. 
The mixture was gently vortexed and incubated at 55°C for 10 minutes or until the gel 
slices were completely dissolved. Samples were transferred to a SV spin column placed in 
provided 2ml tubes and incubated for 3min and then centrifuged for 1min at 16000g. Flow 
through was discarded while placing the SV spin column back in the same tube. The DNA 
was washed twice by 700μl and 500μl of Membrane Wash Solution (wash buffer, 10mM 
Tris-HCl, pH 7.5, 80% ethanol) respectively, and centrifuged for 1min at 16,000g both 
times. The flow through was discarded and the column assembly was centrifuged for 1min 
with the micro-centrifuge lid open to allow evaporation of any residual ethanol. 
The DNA was eluted by adding nuclease-free water to the centre of the SV membrane. 
The column was incubated for 1min at room temperature and centrifuged for 1min at 
16,000g. 
 
2.2.9 General Methods for Cloning of cDNA Fragments 
2.2.9.1 Ligation of Blunt Ends of Fragments into Vectors  
Purified PCR products (calculated according to the formula shown below) were ligated 
using Zero Blunt® PCR Cloning Kit (Invitrogen, UK) following the manufacturer’s 
instructions. The PCR Zero Blunt® system is based on lethal selection with untransformed 
cells (those lacking an insert) being unable to grow. The components shown in table 7 
were pipetted into an eppendorf tube for each ligation reaction and the 10:1 molar ratio of 
insert:vector was used in the ligation reaction using the formula shown below. 
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𝑥 𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 =
(10)(𝑦 𝑏𝑝 𝑃𝐶𝑅 𝑝𝑟𝑜𝑑𝑢𝑐𝑡)(25 𝑛𝑔 𝑙𝑖𝑛𝑒𝑎𝑟𝑖𝑧𝑒𝑑 𝑝𝐶𝑅® − Blunt)
(3500 𝑏𝑝 𝑝𝐶𝑅® − Blunt)
 
 
Table 7. Cloning of PCR products. 
Reagent  Quantity (μl) 
   
pCR®-Blunt (25 ng) vector        1 
Blunt PCR product        1-5 
5X ExpressLink ™ T4 DNA Ligase Buffer        2 
ExpressLink TM T4 DNA Ligase (5 U/μL) 
Water 
       1 
      X 
Total Volume        10 
 
 
The reaction was gently mixed by pipetting and incubated overnight at 16oC.  
 
 
2.2.9.2 Transformation of E. coli with Plasmid DNA 
All E. coli culturing was performed in LB broth medium (Sigma-Aldrich-USA) containing 
kanamycin (50ng/ul) antibiotic for the selection of transformants. The LB broth agar was 
prepared from 15.5 g L-1 of LB and 15 g L-1 agar (Fluka-Spain) and autoclaved for 15 
minutes at 121oC. 
TOP10 Chemically Competent E. coli were transformed with vector-cDNA constructs 
using the heat shock method. The TOP10 cells and the vector-cDNA constructs were 
mixed gently and left on ice for 30 minutes followed by heat shock for 30 seconds at 42°C. 
The cells were then incubated at 37 °C for 1 hour with 225rpm shaking to allow the 
expression of the kanamycin resistance gene in the vector. Transformed cells were selected 
by growth on LB broth agar containing 50μg/mL kanamycin (Invitrogen, UK) for 16 
hours. Colonies containing successfully transformed cells were grown overnight in 5mL of 
liquid LB broth medium with 50μg/mL kanamycin at 37 °C with shaking at 225 rpm. 
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2.2.10 Plasmid DNA Purification 
Plasmids were isolated from bacterial cells using ISOLATE Plasmid Mini kit (Bioline, 
UK) according to manufacturer’s instructions. The extraction of the recombinant plasmid 
DNA was performed to the overnight cultures of E. coli grown in LB broth medium 
(Sigma-Aldrich-UK) unless otherwise stated 0.5-5 ml of overnight cultures were 
centrifuged at 11,000 g for 1 min at room temperature. The bacterial cells were re-
suspended in 250 µl Resuspension Buffer and transferred into a new 1.5 ml microfuge 
tube. The cells were lysed by adding 250 µl of Lysis Buffer P and mixed by gently 
inverting 6-8 times. The plasmid DNA was precipitated using 350 µl Neutralization Buffer 
and mixed by vigorously inverting the tube 6-8 times and centrifuged at room temperature 
for 5 minutes at 11,000 g. The supernatant was recovered and applied to spin column P by 
pipetting. The samples were centrifuged for 1min at 11,000 g and the flow-through 
discarded. The spin column P washed by adding 500 µl of Wash Buffer AP and 
centrifuged at 11,000 g for 1 minute. The flow-through was discarded and the spin column 
P washed again by adding 700 µl of Buffer PE and centrifuged for 1minute at 11,000 g. 
The flow-through was discarded and column was centrifuged at 11,000 g for additional 
2min to remove all the traces of ethanol. Spin column P was placed in a clean 1.5ml 
microfuge tubes and 50 µl elution buffer was added to the centre of the column, allowed to 
stand for 3 minutes at room temperature and centrifuged for 1min at 11,000g. The eluted 
DNA was stored at -20°C for further analysis. 
 
2.2.11 Restriction Digestion Analyses 
The cloned PCR products were digested from the pCR®-Blunt plasmid with restriction 
endonuclease enzymes as instructed by the manufacturer (NEB, UK). Briefly, 1µg of 
vector was added to a sterile tube containing 10 units of each restriction enzyme (EcoRI) 
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and 2µl NE Buffer. The mixture was made up to 20µl with sterile water and incubated at 
37°C for 1hr. After the incubation time, samples were run on a 1.0% agarose gel at voltage 
100V with variable current. The gel was visualised and photographed by G-box 
transilluminator (Syngene, UK). 
 
2.2.12 Sequencing of Plasmid DNA 
Sequencing of the cloned MLA and MLB was carried out by The University of 
Manchester DNA Sequencing Facility. The sequencing facility utilised a Prism 3100 
Genetic Analyser (Applied Biosystems, Life Technologies) with BigDye Terminator cycle 
sequencing chemistries (Applied Biosystems, Life Technologies) and standard forward 
and reverse M13 primers. The analysis of the sequenced genes was carried out using 
Chroma Lite and CLC Sequence Viewer software (Qiagen, UK). 
 
 
 
 
 
 
 
 
 
 
Figure 9. The pCR®-Blunt vector map that summarizes its features and shows restriction sites found in the polylinker.  
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2.3 Results 
The full length DNA sequence of both the toxic A-chain (MLA) and glycan binding B-
chain (MLB) of mistletoe lectin I (Viscum album) were prepared through PCR 
amplification reactions utilizing specific primers in order to separately study their 
biological activity in the following experiments.  
2.3.1 C-type Lectin Amplification 
Degenerate primers were designed (Table 8) corresponding to the conserved regions 
[LGGHLA (black box), GCWVGGH (red box), EYLIILAVVSGLIL (purple box) and 
TTLAVVIWLLAYR (orange box)] shown in figure 8 and identified from a ClustalW2 
multiple sequence alignment of previously known C-type lectins from different natural 
sources. 
Table 8. Degenerate primers designed based on the conserved regions of C-type lectin sequences 
                       Conserved Regions                                     Primers 
  
1-  LGGHLA (NUY GGN GGN CAY YUN GCN)  
2-  GCWVGG (GGN UGY UGC GUN GGN GGN) 
3-  EYLIILAVVSGLIL (CAR UAY YUN AUH AUH YUN   
GCN GUN GUN WSN GGN YUN AUH YUN) 
4-  TTLAVVIWLLAYR (ACN CAN YUN GCU GUN GUN 
AUH UGG   YUN YUN GCN UAY MGV)                                        
A- Fwd 5’ ANG GNG GNC AYY ANG C 3’ 
B- Fwd 5’ GNA GYA GCG ANG GNG G 3’ 
        C-    Rev  5’ ACN ACN GCN ARD ATD ATN AR 3’ 
D- Rev   5’ CNA CNG CNA RDA TDA TNA RR 3’ 
E- Rev   5’ CKR TAN GCN ARN ARC C 3’ 
F- Rev   5’ ACN ACA GCN ARN GTN GT 3’ 
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Based on the multiple sequence alignment we predicted PCR products sizes of 330bp and 
390bp (Figure 10). 
                                                          Predicted product size 
                                                                      ~390bp 
 
     Forward primer A                                                                               Reverse primer A               Reverse primer B 
5’                                                                                                                                                                                                 
3’ 
 
                                               Predicted product size 
                                                                      ~330bp 
 
     Forward primer B                                                                               Reverse primer C               Reverse primer D 
5’                                                                                                                                                                                                 
3’ 
 
Figure 10. The illustration diagram of degenerate primers design. 
 
PCR was unsuccessful despite repeat attempts and it was decided not to pursue this 
approach. Based on a survey of the literature (Büssing, Wagner et al. 1999, Niwa, 
Tonevitsky et al. 2003, Müthing, Meisen et al. 2004) we decided to focus on mistletoe 
(Viscum album) lectin (ML) as a glycan binding molecule.  
 
2.3.2 Mistletoe RNA Extractions 
Total RNA was extracted from the leaf tissue of mistletoe (Viscum album) using the 
ISOLATE II RNA plant kit (Bioline, UK). Sufficient quantities of pure RNA were 
extracted as shown in table 9 and the A260/280 ratio was as expected for pure RNA 
(Fleige and Pfaffl 2006). 
Table 9. Spectrophotometrical determination of RNA concentrations and purity by NanoDrop 2000c (Thermo scientific, 
USA). 
 Mistletoe RNA sample 1 Mistletoe RNA sample 2 Mistletoe RNA sample 3 
    
Yield            297.9 ng/µl            90.9 ng/µl            290.3 ng/µl 
λ260            7.446             2.271            5.805 
λ280            3.735            1.064            2.851 
260/280 Ratio            1.99            2.13            2.04 
 
 61 
 
Formaldehyde gel electrophoresis was also used to check the purity and size of the 
extracted RNA, results shown in figure 11. As expected the major ribosomal bands were 
visualized and green tissue frequently yield chloroplast ribosomal bands. Minor 
degradation products are seen. 
                                          
   
 
Figure 11. Formaldehyde electrophoreses gel (1%). Lane 1: RNA size marker (Invitrogen, UK); Lane 2 and 3: two 
different total RNA samples from mistletoe (Viscum album). 
 
2.3.3 PCR Amplification of MLA and MLB 
PCR amplification was conducted for cDNA derived from extracted RNA. The targeted 
chains were the toxic chain (MLA) and binding chain (MLB) of mistletoe lectin which are 
762bp and 789bp respectively (Figure 12). Both chains were successfully amplified with 
sizes correspondent to the predicted sizes as shown in figure 13. 
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GAAGCAAGGAACAATGAATGCGCATTTGGCTTCAAGAAGGGCATGGGTTTGGTATTTT
CTAATGCTGTGCCTAGTTTTTGGTGCGACGGTCAAAGCTGAAACAAAATTCAGCTACG
AGAGGCTAAGACTCAGAGTTACGCATCAAACCACGGGCGAGGAATACTTCCGGTTCA
TCACGCTTCTCCGAGATTATGTCTCAAGCGGAAGCTTTTCCAATGAGATACCACTCTTG
CGTCAGTCTACGATCCCCGTCTCCGATGCGCAAAGATTTGTCTTGGTGGAGCTCACCA
ACCAGGGGGGAGACTCGATCACGGCCGCCATCGACGTTACCAATCTGTACGTGGTGGC
TTACCAAGCAGGCGACCAATCCTACTTTTTGCGCGACGCACCACGCGGCGCGGAAACG
CATCTCTTCACCGGCACCACCCGATCCTCTCTCCCATTCAACGGAAGCTACCCTGATCT
GGAGCGATACGCCGGACATAGGGACCAGATCCCTCTCGGTATAGACCAACTCATTCAA
TCCGTTACGGCGCTTCGTTTTCCGGGCGGCAGCACGCGTACCCAAGCTCGTTCCATTAT
AATCCTCGTTCAGATGATCTCCGAGGCCGCCAGATTCAATCCCATCTTATGGAGGGCT
CGCCAATACATTAACAGTGGGGCGTCATTTCTGCCAGACATGTACATGCTGGAGCTGG
AGACGAGTTGGGGCCAACAATCCACGCAAGTCCAGCAGTCAACCGATGGCGTTTTTAA
TAACCCAATTCGGTTGGCTATACCCCCCGGTAACTTCGTGACGTTGACCAATGTTCGCG
ACGTGATCGCCAGCTTGGCGATCATGTTGTTTGTATGCGGAGAGCGGCCATCTTCCTCT
GACGTGCGCTATTGGCCGCTGGTCATACGACCCGTGATAGCCGATGATGTTACCTGCA
GTGCTTCGGAACCTACGGTGCGGATTGTGGGTCGAAATGGCATGTGCGTGGACGTCCG
AGATGACGATTTCCACGATGGAAATCAGATACAGTTGTGGCCCTCCAAGTCCAACAAT
GATCCGAATCAGTTGTGGACGATCAAAAGGGATGGAACCATTCGATCCAATGGCAGC
TGCTTGACCACGTATGGCTATACTGCTGGCGTCTATGTGATGATCTTCGACTGTAATAC
TGCTGTGCGGGAGGCCACTATTTGGCAGATATGGGGCAATGGGACCATCATCAATCCA
AGATCCAATCTGGTTTTGGCAGCATCATCTGGAATCAAAGGCACTACGCTTACGGTGC
AAACACTGGATTACACGTTGGGACAGGGCTGGCTTGCCGGTAATGATACCGCCCCACG
CGAGGTGACCATATATGGTTTCAGGGACCTTTGCATGGAATCAAATGGAGGGAGTGTG
TGGGTGGAGACGTGCGTGAGTAGCCAACAGAACCAAAGATGGGCTTTGTACGGGGAT
GGTTCTATACGCCCCAAACAAAACCAAGACCAATGCCTCACCTGTGGGAGAGACTCCG
TTTCAACAGTAATCAATATAGTTAGCTGCAGCGCTGGATCGTCTGGGCAGCGATGGGT
GTTTACCAATGAAGGGGCCATTTTGAATTTAAAGAATGGGTTGGCCATGGATGTGGCG
CAAGCAAATCCAAAGCTCCGCCGAATAATTATCTATCCTGCCACAGGAAAACCAAATC
AAATGTGGCTTCCCGTGCCATGATTTAGGTTCATGGCTCGAAGATTGCTTGCATGCGA
CCATCCTTTCTATTTTCTCTTTTCTACCTTTTGAAATAATGTCTGTGGATAATGTGGCAC
GTTGAGGCCCGCCGGAAGAAGCCTTAGCCACCTTGTGTTTGAGAATAAATGAGTTAAT
GCAAGCAATCAACTTCATCCT 
 
 
 
Figure 12. The full sequence (AY377890.1) of mistletoe lectin, MLA and MLB sequences and are highlighted in blue 
and green colours respectively; The linker sequence between MLA and MLB is highlighted in yellow; Start and stop 
codons are underscored and red. 
 
 
 
 
 
MLA (762bp) MLB (789bp) 
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Figure 13. Agarose gel (1%) of PCR showing amplified chain A and chain B of mistletoe lectin. Lane 1: HyperLadder I; 
Lane 2: amplified chain A (MLA); Lane 3: amplified chain B (MLB). 
 
 
 
The PCR products were successfully excised and extracted from the gel and run once 
again on a separate 1% agarose gel to confirm extraction success. The sizes were again 
762bp and 789bp indicating the PCR products were not degraded during the extraction 
process (Figure 14). 
 
 
 
 
 
 
 
 
 
 
Figure 14. Agarose gel (1%) confirmation of gel purified (Wizard® SV, Peomega) MLA and MLB PCR products. Lane 
1: HyperLadder I (Bioline, UK); Lane 2: purified MLA; Lane 3: purified MLB. 
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The purified PCR products went on to be cloned using the Zero Blunt® cloning kit 
(Invitrogen) and an overnight culture was prepared from colonies containing a successfully 
transformed cells grown overnight in 5mL of liquid LB broth medium. Then, a diagnostic 
restriction digest of extracted plasmids was employed to determine the presence of 
targeted sequences (Figure 15), confirming successful cloning of the designed product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Restriction digest of plasmid pCR–Blunt II with EcoRI to confirm the presence of MLA and MLB PCR 
product inserts. Lane 1: HyperLadder I (Bioline, UK); Lane 2 and 4: undigested negative controls; Lane 3 and 5: the 
restriction digests of MLA and MLB respectively. 
 
 
Several sequencing reactions were performed to confirm the identity of the targeted PCR 
products, partial sequencing results are shown in figure 16 and figure 17, in order to 
illustrate the quality of the sequencing reactions. 
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Figure 16. Chromatogram showing the sequence quality of mistletoe lectin type A (MLA) (partial sequence data shown). 
The selected region is representative of overall sequencing quality and full sequence is shown in appendix 3. The 
Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red colours respectively. 
 
 
  
 
Figure 17. Chromatogram showing the sequence quality of mistletoe lectin type B (MLB) (partial sequence data shown). 
The selected region is representative of overall sequencing quality and full sequence is shown in appendix 3. The 
Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red colours respectively. 
 
 
The sequence data in figure 16 and figure 17 show clear peaks with very low levels of 
background ‘noise’. Each peak is well defined and fully resolved, giving a clear indication 
that the data are reliable. 
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2.3.4 Blast Results  
The cloned sequences (MLA and MLB) were queried against a nucleotide database 
(https://blast.ncbi.nlm.nih.gov) using the BLASTN (Altschul, Gish et al. 1990) search tool 
to align sequences. The results are shown in table 10 and 11 and confirm the identity of the 
cloned sequences. 
2.3.4.1 Mistletoe Lectin A chain (MLA) and Highly Similar Sequences 
Ten out of the top ten hits were from Viscum album with the top hit being Viscum album 
lectin A-chain isoform I precursor with a maximum identity of 99%.  All hits registered a 
0.0 E value (Table 10). Thus confirming the identity of our MLA clone. 
Table 10. The NCBI highly similar sequence BLASTN results for the MLA DNA sequence of mistletoe. The result 
shows that the cloned MLA sequence covers the whole query sequence and they are 99% identical with 0.0 expect value 
(E).  
Accession Description 
   Max 
score 
Total 
score 
Query 
cover 
   E 
value 
Ident 
AY081149.1 Viscum album lectin chain A isoform 1 
precursor, mRNA, partial cds 
1352 1352 100% 0.0 99% 
AY377890.1 Viscum album clone ml1p lectin I precursor, 
gene, complete cds 
1369 1369 100% 0.0 99% 
AY377891.1 Viscum album clone cml1p lectin I 
precursor, mRNA, complete cds 
1308 1308 100% 0.0 98% 
 
Figure 18 shows the alignment of the mistletoe lectin A-chain (MLA) sequence from 
NCBI GeneBank (AY377890.1) and three results of sequencing reactions carried out for 
the cloned MLA chain. The sequencing reactions were repeated several times to confirm 
that the mismatch between few base pairs of the sequencing results and the query sequence 
are not experimental errors. It can clearly be seen that the cloned sequence is almost 
identical to the reference sequence in NCBI, with 7 variations in bases. The first at 231 is a 
C substitution for a G in the NCBI accession, the second at position 417 is a C substitution 
for a T in the NCBI accession, the third at position 465 is a G substitution for a C in the 
NCBI accession, the forth at position 469 is a T substitution for an A in the NCBI 
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accession, the fifth at position 478 is an A substitution for a G in the NCBI accession, the 
sixth at position 568 is a G substitution for a A in the NCBI accession, the seventh at 
position 624 is a T substitution for a G in the NCBI accession. These base mutations are 
confirmed by sequencing in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Alignment of reference MLA chain sequence (NCBI: AY377890.1) with three sequencing results of the same 
DNA sample of cloned MLA chain. The matching residues are shown as dot and the mismatching residues as RED 
codon letters. The red bar plot represents the similarity between the sequences and indicates the mismatches between the 
sequences in blue spots.  
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2.3.4.2 Mistletoe Lectin B-chain (MLB) and Highly Similar Sequences 
Ten of the top ten BLASTN search hits were from the Viscum album with the top hit being 
Viscum album lectin I precursor with a maximum identity of 99%.  All hits registered a 0.0 
E value (Table 11). 
 
Table 11. The NCBI highly similar sequence blastn results for the MLB DNA sequence of mistletoe. The result shows 
that the cloned MLB sequence covers the whole query sequence and they are 99% identical with 0.0 expect value (E). 
Accession Description 
   Max 
score 
Total 
score 
Query 
cover 
   E 
value 
Ident 
AY377890.1 Viscum album clone ml1p lectin I precursor, 
gene, complete cds 
1441 1441 100% 0.0 99% 
AY377891.1 Viscum album clone cml1p lectin I 
precursor, mRNA, complete cds 
1402 1402 100% 0.0 99% 
AY081149.1 Viscum album lectin chain A isoform 1 
precursor, mRNA, partial cds 
1375 1375 100% 0.0 98% 
 
 
Figure 19 shows the alignment of the Mistletoe lectin B-chain (MLB) query sequence from 
NCBI GeneBank (AY377890.1) and three results of sequencing reactions carried out for 
the cloned MLB chain. The sequencing reactions were repeated several times so as to 
confirm that the mismatch between few base pairs of the sequencing results and the query 
sequence are not experimental errors. It can clearly be seen that the query sequence is 
almost identical to the sequencing date results, except for the following three base 
differences. The first at 26 is a G substitution for an A in the NCBI accession, the second 
at position 295 is a G substitution for an A in the NCBI accession, the third at position 479 
is a C substitution for a T in the NCBI accession. These base mutations are confirmed by 
sequencing in triplicate. 
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Figure 19. Alignment of reference MLB chain sequence (NCBI: AY377890.1) with three sequencing results of the same 
DNA sample of cloned MLB chain. The matching residues are shown as dots, the mismatching residues as RED codon 
letters and the gaps as red dashes. The red bar plot represents the similarity between the sequences and indicates the 
mismatches between the sequences in blue.  
 
Thus we confirmed the successful cloning of the MLA and MLB chains from source 
(Viscum album).  
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2.4 Discussion 
In this study mistletoe (Viscum album) lectin isoform one (MLI) was targeted to be 
amplified and cloned for further experiments. 
The immunomodulatory improvement and many other positive effects of mistletoe extract 
in the treatment of patients with different type of cancers have increased biomedical focus 
on this extract (Ding, Cartwright et al. 2014, Galun, Tröger et al. 2015, Lentzen and 
Witthohn 2016). However, the crude mistletoe extract is composed of a diversity of 
compounds with different activities, the lectin is believed to be the key compound in the 
activity of this extract  (Maletzki, Linnebacher et al. 2013). Mistletoe has three types of 
lectins (MLI, MLII, MLIII) which are slightly similar in their primary sequences but they 
are different in some core amino acids which give them different glycan binding affinity. 
Among these three isoforms, isoform one (MLI) is the most abundant one which is 
believed to play a crucial role in the functionality of mistletoe lectin. The MLI is 
composed of two different chains known as toxic chain (MLA) and binding chain (MLB) 
which are very similar to ricin A and B chain respectively (Niwa, Tonevitsky et al. 2003). 
The MLA chain of MLI is a 29kD ribosome inactivating protein type II (RIPII) consists of 
252 amino acids (756bp) and MLB chain is a 34kD galactose/sialic acid binding protein 
consists of 263 amino acids (789bp). MLA and MLB chains are linked together through a 
disulfide bond which keeps them attached to each other until B chain binds to the cell 
surface glycoproteins consisting of galactose/sialic acid residues and subsequently helps 
the endocytoses of MLA chain through modulating intracellular process such as protein 
phosphorylation and Ca+2 mobilization (Gabius, Walzel et al. 1991). 
In order to obtain the coding sequences of MLA and MLB chains separately, a set of 
primers correspondent to the start and end of each chain was designed so as to be able to 
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amplify the chains through polymerase chain reactions (PCR). The total RNA was first 
extracted from fresh leaf of European mistletoe as a start material and went under quality 
tests such as measuring the purity via using spectrophotometry and running the RNA 
samples on analytical agarose gel using formaldehyde as denaturing reagent. A reliable 
value of ~2.0 measured at 260/280nm was achieved from nanodrop readings for the 
extracted RNA samples (Table 9). Also, the expected plant RNA bands such as major 
ribosomal bands (28s, 18s) were clearly detected on the analytical gel (Figure 11) 
(Ghawana, Paul et al. 2011).   
The amplification of both MLA and MLB coding sequences from reverse transcribed 
complementary DNA (cDNA) of mistletoe was successfully performed through 
polymerase chain reactions (PCR) and using primers correlating to the start and end of 
MLA and MLB sequences. In order to avoid any possible base mutation during PCR 
reactions, Q5® High-Fidelity DNA polymerase (NEB, UK) was used which is a 
thermostable DNA polymerase with an error rate > 100-fold lower than Taq DNA 
polymerase. The predicted DNA bands of 756bp and 789bp of MLA and MLB 
respectively were successfully detected on 1% agarose gel (Figure 13) and they were both 
identical with the size of MLA and MLB bands detected by Eck, Langer et al. (1999) and 
Eck, Langer et al. (1999). 
To perform further analysis of MLA and MLB coding sequences and identify their 
nucleotide composition, both sequences were cloned into Zero Blunt® TOPO® cloning 
vector and transformed into Top10 E. coli chemical competent cells. The cloning and 
transformation reactions were successful and the replicated plasmid DNA containing MLA 
and MLB sequences were successfully isolated from the lysed E. coli cells and purified. 
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In order to confirm the size of the cloned MLA and MLB sequences, restriction digest 
analysis was performed with EcoRI restriction enzymes which cuts the two EcoRI 
restriction sites at the start and end of cloned sequences. The digested plasmids were run 
on agarose gel and the same sizes of 756bp and 789bp were detected for cloned MLA and 
MLB chains respectively as shown in figure 15. While agarose gel can only show the size 
of DNA bands and the nucleotide composition of the bands must be detected by 
sequencing reaction, several Sanger sequencing reactions were performed to analyse the 
sequences of the cloned MLA and MLB. The reactions were performed in triplicate so as 
to detect any particular mutation comes from experimental errors and very clear peaks in 
the sequencing chromatograms were achieved (Figure 16,17).  
The sequencing results were first assessed through conducting BLASTN using NCBI 
GeneBank server and the top 10 hits for both MLA and MLB were from mistletoe and the 
top hit of both of them scored 99% similarity with the cloned sequences (Table 10,11).  
The coding sequences of MLA and MLB achieved from the sequencing reactions were 
then aligned with the reference sequences derived from NCBI GeneBank (AY377890.1). 
The alignment of MLA nucleotide sequence with the reference sequence shows very high 
similarity between the two sequences apart from seven codon mismatches at the positions 
231, 417, 465, 469, 478, 568 and 624 shown in figure 18. However, the first three 
nucleotide mismatches are not counted as mutation because in the first and second 
positions GTC and GTT are replaced with GTG and GTC respectively and they are all 
representative codons of valine (Val) amino acid. Similarly, in the third position GTT is 
replaced with GTC and they are both representative codons of serine (Ser) amino acid. On 
the other hand, the other four mismatch are counted as mutation because the codons ATA 
(Isoleucine), GTT (Valine), ATG (Methionine), and CAG (Glutamine) are replaced with 
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TTA (Leucine), ATT (Isoleucine), GTG (Valine) and CAT (Histidine) respectively (Figure 
18).  
In the alignment of MLB nucleotide sequence with the reference sequence, only three 
codon mismatches were detected at the positions 26, 295 and 479 and they are all counted 
as mutation because the codons GAA (Glutamine acid), ATC (Isoleucine) and GTG 
(Valine) are replaced with GGA (Glycine), GTC (Valine) and GCG (Alanine) respectively 
(Figure 19).  
In conclusion, high quality sequences of MLA and MLB chains were amplified and cloned 
into a cloning vector so as to be used in the next experiments. 
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Chapter 3. Design of Lectin-GFP Fusion Proteins from Mistletoe, Elderberry and 
Snowdrop Lectins 
 
3.1 Introduction 
The Introduction of green florescent protein from jellyfish (Aequorea Victoria) into cell 
biology has increased the feasibility of tracking the subcellular distribution of proteins and 
monitoring their function on a cellular level. Producing fusion proteins with GFP is 
considered as a sufficient method of protein labelling beside ﬁxation and 
immunoﬂuorescence labelling (Reid and Flynn 1997).  
In molecular biology and biochemistry, GFP has been widely used as a biomarker for gene 
and protein expression. The expression level of the fused protein to GFP can thus be 
detected through the expression level of GFP and the localization of the target protein 
fused to GFP can also be tracked through visualization of tracking GFP excited under 
standard UV light (Kaether and Gerdes 1995, Ogawa, Inouye et al. 1995). The method is 
not without limitation and the main concerns about fusion proteins with GFP attached are 
the potential cleavage of GFP from the target protein which may cause non-identical 
distribution between them and also the incapability of the wild type of GFP to produce 
detectable fluorophore at physiological temperature. This was overcome by the use of 
mutant forms of GFP which has alleviated the problem through producing temperature-
insensitive GFP forms (Siemering, Golbik et al. 1996, Patterson, Knobel et al. 1997).  
The screening of lectin binding to glycans and detection of their localization is enhanced 
by reporter genes like fluorescent proteins fused with the lectin sequence. The availability 
of labelled lectins helps monitoring of tissue reactivity toward lectins and also extends the 
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scope of lectin applications beyond that which traditionally involved plant lectins. 
Previous studies have thus used GFP in a wide range of applications to produce Lectin-
GFP fusion proteins. For example, to investigate the glycan binding affinity of V. 
vulnificus hemolysin (VVH) lectin from Vibrio vulnificus and perform a glycan array, the 
VVH sequence was fused to GFPuv which also helped to improve the solubility of the 
expressed lectin (Kaus, Lary et al. 2014).  
Furthermore, in order to overcome the problems which face protein purification directly 
from natural resources such as cross contamination between the activity of a target protein 
and the activity of other similar proteins, it is also suggested to produce recombinant 
protein from the sequence of a target peptide alone or fused to a reporter peptide sequence 
such as GFP (Sørensen and Mortensen 2005). Medina-Bolivar, Wright et al. (2003) 
believed that the adjuvant activity of plant lectins purified form natural sources and used in 
vaccination studies was probably due to the contamination with the toxic subunits. 
Therefore, they produced a recombinant protein from the binding chain of ricin lectin 
(ricinB) fused to GFP to assess the potential of ricinB chain as an antigen delivery system 
without any side activities of other peptide especially the toxic chain of ricin lectin 
(ricinA). Thus a similar strategy will be employed with MLB lectin. 
We aim to produce a range of fusion proteins from the binding chain of mistletoe lectin 
(MLB, with the binding chain of elderberry lectin (SNA-B) and snowdrop lectin (GNA) 
also fused to GFPuv and expressed in E. coli (as positive and negative control) so as to 
assess their glycan binding activity in the further studies. 
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3.2 Material and Methods 
Green fluorescent protein (GFP) is a commonly used tag to assess the localization of 
proteins. Although GFP tagging has numerous advantages, it might alter the folding, 
function and the localization of the protein of interest because of protein-protein 
interactions. The location of the tag is believed to be the main reason of this alteration 
(Magliery, Wilson et al. 2005). Therefore, both N- and C- terminus cloning strategy were 
performed to avoid the effect of GFP on the properties and functions of the binding chain 
(MLB) of mistletoe lectin. 
3.2.1 Gene synthesis of Elderberry (Sambuca nigra) Lectin Chain B (SNA-B) 
The sequence of SNA lectin B-chain (SNA-B) from NCBI (U27122.1) was used as a 
template sequence for commercial synthesis. Two restriction sites (SacI and EcoRI) were 
also introduced to the start and end of the SNA-B respectively using SnapGene software 
(SnapGene-USA). The gene was synthesized by Eurofins Genomics Company (Eurofins, 
Germany) and sent back as a plasmid DNA in pEX-A2 vector (Table 12). 
 
Table 12. The full sequence of elderberry lectin chain B (SNA-B). The restriction sites are in red and the added 
nucleotides are in small letters. 
 
 
 
 
 
 
 
 
 
 
 
gatGAGCTCgctgcagctgcaGGGGGCGAGTACGAAAAAGTATGTTCGGTGGTAGAGGTAACAAGGCGCAT
CAGTGGTTGGGATGGATTGTGTGTGGACGTGAGGTATGGGCACTACATCGATGGGAATCCCGTCCAGC
TGCGGCCGTGTGGAAATGAATGTAACCAACTATGGACGTTCCGCACTGATGGAACAATCCGGTGGTTG
GGTAAATGCCTGACTGCCTCAAGCTCTGTCATGATATACGATTGTAATACTGTTCCTCCAGAGGCCACTA
AGTGGGTAGTATCTATTGACGGCACCATCACCAATCCTCACTCAGGACTCGTCCTTACAGCTCCTCAAGC
TGCAGAGGGAACCGCCCTGTCTCTGGAGAACAATATCCATGCCGCTAGGCAAGGTTGGACTGTAGGAG
ATGTAGAGCCCCTCGTTACTTTTATTGTGGGATATAAACAAATGTGCTTGAGGGAAAACGGTGAAAACA
ATTTTGTATGGTTGGAGGACTGCGTTCTCAACAGGGTGCAGCAAGAGTGGGCACTCTATGGCGACGGC
ACCATTCGAGTAAACAGTAATCGTAGCCTATGTGTGACCTCCGAAGACCACGAGCCCAGTGATCTTATC
GTCATTCTCAAGTGCGAAGGGTCGGGCAACCAGCGCTGGGTATTCAACACCAACGGTACCATCTCAAAC
CCAAACGCTAAACTACTTATGGACGTTGCACAACGCGATGTCTCTCTTCGAAAAATCATTCTCTATCGGC
CCACTGGGAATCCTAACCAGCAATGGATAACTACCACCCATCCAGCTgctgcataatGAATTCcaa 
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ATGGCTAAGGCAAGTCTCCTCATTTTGGCCGCCATCTTCCTTGGTGTCATCACACCATCTTGCCTGAGTG
ACAATATTTTGTACTCCGGTGAGACTCTCTCTACAGGGGAATTTCTCAACTACGGAAGTTTCGTTTTTAT
CATGCAAGAGGACTGCAATCTGGTCTTGTACGACGTGGACAAGCCAATCTGGGCAACAAACACAGGTG
GTCTCTCCCGTAGCTGCTTCCTCAGCATGCAGACTGATGGGAACCTCGTGGTGTACAACCCATCGAACA
AACCGATTTGGGCAAGCAACACTGGAGGCCAAAATGGGAATTACGTGTGCATCCTACAGAAGGATAG
GAATGTTGTGATCTACGGAACTGATCGTTGGGCTACTGGAACTCACACCGGACTTGTTGGAATTCCCGC
ATCGCCACCCTCAGAGAAATATCCTACTGCTGGAAAGATAAAGCTTGTGACGGCAAAGTAATGA 
 
3.2.2 Introducing Restriction Sites  
In order to be able to clone the genes of interest into pGFPuv expression vector, 
correlating restriction sites compatible to the targeted sites for the cloning in the expression 
vector were introduced to mistletoe lectin B-chain (MLB), elderberry lectin B-chain 
(SNA-B) and snow drop (Galanthus nivalis) lectin (Table 13) (Kindly provided by 
Professor Gatehouse - Newcastle University) using Q5 high-fidelity DNA polymerase 
(NEB, UK). The primers were designed using SnapGene software (SnapGene, USA) and 
are shown in table 14. The PCR reaction was performed in a total volume of 50μL, 
containing a total of <250ng of template DNA, 10μL of 5x Q5 reaction buffer (2mM 
MgCl2), 0.5μM primers, 200μM dNTPs, and 0.02U μL-1 Q5 High-Fidelity DNA 
Polymerase. All reactions followed the thermal cycling parameters: 30sec at 98°C 
followed by 35 cycles of 10sec at 98°C, 30sec at primer specific annealing temperatures, 
30sec at 72, then final denaturation at 72°C for 2min.  
Table 13. The full sequence of snow drop (Galanthus nivalis) lectin.  
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Table 14. Primers used in polymerase chain reaction, introduced restriction sites and added nucleotides shown in red, 
actual site underscored, main lectin sequence shown in black. 
 
3.2.3 Ligation and Transformation of Blunt Ends SNA-B and GNA Fragments into 
Zero Blunt Cloning Vector  
Gel Purified SNA-B and GNA PCR products were ligated into a cloning vector using Zero 
Blunt® PCR Cloning Kit (Invitrogen, UK) following the manufacturer’s instructions 
shown in section 2.2.9.1. The reaction was gently mixed by pipetting and incubated 
overnight at 16oC. The One Shot® TOP10 Chemically Competent E. coli strain was 
transformed with the cloning vectors contained SNA-B and GNA constructs using heat 
shock method described in section 2.2.9.2. 
3.2.4 Sequencing of Cloning Plasmid DNA 
SNA-B and GNA recombinant plasmid DNA were isolated from bacterial cells using 
ISOLATE Plasmid Mini kit (Bioline, UK) following manufacturer’s instructions described 
in section 2.2.10. After confirming the correct size band of both SNA-B and GNA 
sequences by diagnostic restriction digest, sequencing of the cloned SNA-B and GNA to 
the cloning vector was carried out by The University of Manchester DNA Sequencing 
Facility. The analysis of the sequenced genes was carried out using Chroma Lite and CLC 
Sequence Viewer software (Qiagen, UK). 
Primers  Sequences     TM(°C) 
 
MLB + SacI (fwd) 
MLB + EcoRI (rev) 
 
GGA GCT CGC TGC AGC TGC AGA TGA TGT TAC CTG  
CGA ATT CAT TAT GCA GCT GGC ACG GGA AGC CAC 
GCG TCT AGA AAA AGA TGA TGT TAC CTG CAG TGC TTC G 
GCA TGA GGT ACC TTT GGC ACG GGA AGC CAC 
TGA AAG CTT G GGG GGC GAG TAC GAA AAA  
TGA TCT AGA GT AGC TGG ATG GGT GGT AGT 
ACA GCG TCT AGA A GCT AAG GCA AGT CTC CTC ATT TTG 
GCA TGA GGT ACC TT CTT TGC CGT CAC AAG C 
G GAG CTC GCT GCA GCT AAG GCA AGT CTC 
C ACT AGT AG TTA TGC AGC CTT TGC CGT CAC AAG C                                                                 
  
 
73.2 
72 
MLB + XbaI (fwd) 
MLB + KpnI (rev) 
SNA-B + HindIII (fwd) 
SNA-B + XbaI (rev) 
GNA + XbaI (fwd) 
GNA + KpnI (rev) 
GNA + SacI (fwd) 
GNA + SpeI -rev 
 
71.7 
72.2 
 66.6 
 66.7 
 70.6 
 69.5 
 71 
70.7
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3.2.5 Cloning of Lectin Fragments to the N- and C- terminus of Green Fluorescent 
Protein (GFP) Sequence in the pGFPuv Expression Vector  
 
3.2.5.1 Ligation of MLB, SNA-B and GNA Fragments N-terminally to GFP Sequence 
The N-terminus of the purified lectin sequence products with the corresponded introduced 
restriction sites MLB (SacI+MLB+EcoRI), SNA-B (SacI+SNA-B+EcoRI) and GNA 
(EcoRI+GNA+ SpeI) from the restriction digest reactions were ligated in frame to the C-
terminus of GFP sequence between the correspondent restriction sites in the pGFPuv 
expression vector (Clontech, USA) using T4 ligase enzyme (Invitrogen, UK) following the 
manufacturer’s instructions (Figure 20, 21 and 22). The components of the ligation 
reaction (Table 15) were pipetted into a PCR tube and incubated overnight at 16oC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. The MLB sequence N-terminally cloned to the N-terminus of GFP sequence between SacI and EcoRI 
restriction sites in the pGFPuv expression vector. 
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Figure 21. The SNA-B sequence N-terminally cloned to the N-terminus of GFP sequence between SacI and EcoRI 
restriction sites in the pGFPuv expression vector. 
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Figure 22. The GNA sequence N-terminally cloned to the N-terminus of GFP sequence between SacI and SpeI 
restriction sites in the pGFPuv expression vector. 
 
 
3.2.5.2 Ligation of MLB, SNA-B and GNA Fragments C-terminally to GFP Sequence 
The C-terminus of the purified lectin sequence products with the corresponded introduced 
restriction sites MLB (XbaI+MLB+KpnI), SNA-B (HindIII+SNA-B+XbaI) and GNA 
(XbaI+GNA+KpnI) from the restriction digest reactions were ligated in frame to the N-
terminus of GFP sequence between the correspondent restriction sites in the pGFPuv 
expression vector (Clontech, USA) using T4 ligase enzyme (Invitrogen, UK) following the 
manufacturer’s instructions (Figure 23, 24 and 25). The components of the ligation 
reaction (Table 15) were pipetted into a PCR tube and incubated overnight at 16oC. 
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Table 15. Cloning of MLB, SNA and GNA products N- and C- terminally to GFP sequence in pGFPuv expression 
vector. 
Reagent  Quantity (μl) 
   
pGFPuv (50 ng) vector        1 
MLB product (37.5 ng)        1-5 
T4 DNA Ligase Buffer        2 
T4 DNA Ligase (10 U/μL)        1 
 
Total Volume        10 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. The MLB sequence C-terminally cloned to the C-terminus of GFP sequence between XbaI and KpnI 
restriction sites in the pGFPuv expression vector. 
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Figure 24. The SNA-B sequence C-terminally cloned to the C-terminus of GFP sequence between HindIII and XbaI 
restriction sites in the pGFPuv expression vector. 
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Figure 25. The GNA sequence cloned to the C-terminus of GFP sequence between XbaI and KpnI restriction sites in the 
pGFPuv expression vector. 
 
3.2.6 Transformation of BL21(DE3) E. coli Strain with the pGFPuv Expression 
Vector Containing Lectin-GFP Constructs  
All E. coli culturing was performed in LB broth (Luria low salt) medium (Sigma-Aldrich-
USA) containing ampicillin (100ng/ul) antibiotic for the selection of transformants. The 
LB broth agar was prepared from 15.5 g L-1 of LB and 15 g L-1 agar (Fluka-Spain) and 
autoclaved for 15 minutes at 121 oC. 
The BL21(DE3) E. coli strain was transformed with lectin-GFP constructs using the heat 
shock method. The chemically competent cells and the lectin-GFP products from the 
ligation reactions were mixed and left on ice for 30 minutes followed by heat shock for 10 
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seconds at 42°C. The cells were then incubated at 37 °C for 1 hour with 250rpm shaking to 
allow the expression of the ampicillin resistance gene in the vector. Transformed cells 
were selected by growth on LB broth agar plates containing 100μg/mL ampicillin (Fisher, 
UK) for 16 hours. Plates were screened under standard UV light (395nm-509nm) to 
visualise GFP expression in the colonies containing MLB, SNA-B and GNA inserts then 
the successfully transformed cells were grown overnight in 5mL of liquid LB broth 
medium with 100μg/mL ampicillin at 37 °C with shaking at 250 rpm. 
 
3.2.7 Restriction Digestion Analysis 
Plasmids were isolated from bacterial cells using ISOLATE Plasmid Mini kit (BIOLINE, 
UK) according to the manufacturers instruction shown in section 2.2.10. 
The lectin-GFP constructs were digested by restriction endonuclease enzymes as instructed 
by the manufacturer (NEB, UK). For the N-terminus digestion, 1µg of vectors was added 
to a sterile tube containing 10 units of each restriction enzymes (HindIII, XbaI and KpnI), 
2µl Cut Smart buffer and made up to 20µl with sterile water. For the C-terminus digestion, 
1µg of vector was added to a sterile tube containing 10 units of each restriction enzymes 
(SacI, EcoRI and SpeI), 2µl Cut Smart buffer and made up to 20µl with sterile water. All 
tubes were incubated at 37°C for 1hr. After incubation, samples were run on a 1.0% 
agarose gel at voltage 100V with variable current. The gel was visualised and 
photographed by UV G-box transilluminator (Syngene, UK). 
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3.2.8 Sequencing of plasmid DNA 
Sequencing of the lectin-GFP constructs (N- and C-terminus) was carried out by The 
University of Manchester DNA Sequencing Facility. Standard M13 Reverse primer was 
used for the sequencing reactions. The analysis of the sequenced genes was carried out 
using Chroma Lite and CLC Sequence Viewer software (Qiagen, UK). 
 
3.2.9 Expression of Recombinant MLB, SNI, GNA 
The recombinant expression vector pGFPuv (Clonthech, USA) was used to express the 
targeted mistletoe lectin B-chain, elderberry lectin B-chain and GNA lectin genes fuse to 
GFP. The vector also encodes Aequorea victoria green fluorescent protein (GFP) that has 
been optimized for brighter fluorescent when excited by standard UV light (360–400 nm). 
The vector is also under the control of strong T7 bacteriophage transcription signals when 
introduced in E. coli host strain BL21(DE3), means the expression of the system is 
repressed unless induced by IPTG. 
The cloned MLB+GFP, SNA-B+GFP and GNA+GFP in the pGFPuv expression vector 
were transformed into BL21(DE3) cell line then plated on antibiotic selection plates 
(Ampicillin 100μg/ml) and incubated for 72hrs at 30°C. Plates were screened under a 
standard UV light (360–400 nm) to visualize glowing colonies containing GFP with MLB, 
SNI and GNA inserts. The successfully transformed cells were grown overnight in 5mL of 
liquid LB broth medium conataining 100μg/mL ampicillin at 37°C with shaking at 250 
rpm. From the overnight incubated culture 1ml was added to 100 ml liquid culture with 
antibiotic and incubated at 30°C until OD600 reaches 0.4–0.8 followed by induction 
through addition of 500 µM IPTG for 18 hours at 30°C. The expression of the targeted 
genes in the total cell extract was confirmed by InstantBlue Coomassie (Expedeon, UK) 
stained SDS Page electrophoresis. 
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3.2.10 Protein Extraction using BugBuster® 
BugBuster Protein Extraction Reagent® was used to extract the total proteins from E. coli 
cells as per the manufacturer’s instructions. BugBuster is formulated for the gentle 
disruption of the E. coli cell wall, resulting in the liberation of soluble protein. Cells were 
harvested from liquid culture by centrifugation at 10,000g for 10 min using a pre-weighed 
centrifuge tubes. The wet weight of the pellet was calculated after removing as much 
supernatant as possible. The cell pellet was completely resuspended in BugBuster reagent 
through gentle vortexing at room temperature. The volume of BugBuster used for the 
extraction was 5 ml per g of cell pellets from the induced bacterial culture. The cell 
suspension was incubated on a shaking platform at a slow setting for 20 min at room 
temperature. Cell debris was then removed by centrifugation at 16,000g for 20 min at 4°C. 
Finally, the supernatant was transferred to a fresh universal tube and stored at –80°C until 
further use. 
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3.3 Results 
The sialic acid binding property of mistletoe lectin isoform I has been proven previously in 
addition its well-known affinity for galactose (Müthing, Meisen et al. 2004). However, the 
activity of the binding chain of mistletoe lectin (MLB) alone without the toxic A chain 
(MLA) has not been separately tested and has remained as a hypothesis. Therefore, fusion 
constructs were designed from the MLB chain alone fused to green florescent protein 
(GFP) to generate constructs and express fusion proteins in this study in order to 
subsequently test this hypothesis in the next study. The binding chain (SNA-B) of 
elderberry lectin (Sambucus nigra) as a sialic acid binding lectin was used to produce 
positive control fusion proteins and the mannose binding lectin (GNA) of snowdrop 
(Galanthus nivalis) was used produce negative control fusion proteins. 
 
3.3.1 MLB-GFP Construct Design 
Two fusion strategies were used to assemble constructs of the MLB chain fused to GFP in 
pGFPuv expression vector. These were MLB fused N-terminally and C-terminally to GFP. 
The cloning map and primers were designed using Snapgene program (Snapgene, USA). 
The MLB sequence was checked for the presence of internal restriction sites and to 
confirm that the restriction sites used were not present in the sequence using CLC 
Sequence Viewer program (Qiagen, UK). 
3.3.1.1 N-terminus cloning 
The MLB chain was successfully cloned N-terminally to GFP through fusing the N-
terminus of MLB to the C-terminus of GFP between SacI and EcoRI restrictions sites 
(Figure 26). The full sequence of pGFPuv expression vector is shown in appendix 2. 
Primers used to introduce the restriction sites to the start and end of MLB sequence are 
shown in table 14. 
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Figure 26. Cloned MLB chain (RED BAR) N-terminally fused to GFP protein sequence in the pGFPuv expression 
vector. The GREEN and MAGENTA parts of the arrow represent GFP and MLB sequences respectively; The light green 
and yellow arrows represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of 
pGFPuv vector. 
 
 
Figure 27 below shows a detailed view of the N-terminus cloning strategy, note that the 
MLB sequence is in frame with the GFP sequence and the stop codon (TAA). 
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Figure 27. The full nucleotide and deduced amino acid sequence of MLB chain N-terminally fused to GFP between SacI 
and EcoRI restriction sites in pGFPuv expression vector. The MLB sequence is indicated by a MAGENTA plot bar; The 
GFP sequence is indicated by a GREEN plot bar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
3.3.1.2 C-terminus cloning 
The MLB chain was cloned C-terminally to GFP through fusing the C-terminus of MLB to 
the N-terminus of GFP between XbaI and KpnI restriction sites (Figure 28). Primers used to 
introduce the restriction sites to the start and end of MLB sequence are shown in table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Cloned MLB chain (RED BAR) C-terminally fused to GFP protein sequence in the pGFPuv expression 
vector. The burgundy and green parts of the arrow represent MLB and GFP sequences respectively; The light green and 
yellow arrows represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv 
vector. 
 
 
Figure 29 below shows a detailed view of the C-terminus cloning strategy, note that the 
MLB sequence is in frame with the start codon (ATG) of the expression vector and with 
the GFP sequence. 
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Figure 29. The full nucleotide and deduced amino acid sequence of MLB chain C-terminally fused to GFP between XbaI 
and KpnI restriction sites in pGFPuv expression vector. The MLB sequence is indicated by a MAGENTA plot bar; The 
GFP sequence is indicated by a GREEN plot bar.  
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Following successful transformation of pGFPuv vector containing N- and C- terminally 
fused MLB sequence to GFP, several colonies were inoculated separately in 5ml LB 
medium and the plasmid DNA was extracted from the overnight culture. The diagnostic 
restriction digest of plasmids extracted was performed to determine the presence of 
targeted sequences. For N- and C- terminus fusion proteins a predicted DNA size of 801bp 
and 805bp was expected respectively and observed in figure 30. 
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Figure 30. Restriction digest of pGFPuv plasmid with XbaI: KpnI and SacI:EcoRI to confirm the presence of MLB PCR 
product inserts. Lane 1: HyperLadder I (Bioline, UK); Lanes 3 and 5: the restriction digests of MLB N- and C-
Terminally fused to GFP respectively; Lanes 2 and 4: the undigested negative controls. 
 
Several sequencing reactions were also performed to determine the success of the fusions 
of the targeted MLB chain. Partial results are shown in figure 31 and figure 32 which show 
the sequencing quality and the full sequences can be seen in appendix 3. 
  
Figure 31. Chromatogram showing the sequence quality of mistletoe lectin B chain (MLB) N-Terminally fused to GFP 
in pGFPuv vector (Partial sequence data shown). The selected region is representative of overall sequencing quality and 
full sequence is shown in appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, 
black, blue and red colours respectively. 
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Figure 32. Chromatogram showing the sequence quality of mistletoe lectin B chain (MLB) C-Terminally fused to GFP 
GFP in pGFPuv vector (Partial sequence data shown). The selected region is representative of overall sequencing quality 
and full sequence is shown in appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in 
green, black, blue and red colours respectively. 
 
 
The sequence data in figure 31 and figure 32 show clear peaks with very low levels of 
background ‘noise’. Each peak is well defined and fully resolved, giving a clear indication 
that the data are reliable enough to go on for further experiments. 
 
3.3.2 SNA-GFP and GNA-GFP Construct Design 
Both N- and C- terminus fusion strategies were used to assemble constructs of the SNA B-
chain (SNA-B) as positive control and GNA sequences as negative control fused to GFP 
sequence in pGFPuv expression vector. The sequences were both checked for the presence 
of internal restriction sites and to confirm that the restriction sites used were not present in 
the sequence using CLC Sequence Viewer program (Qiagen, UK). The cloning map and 
primers were designed using SnapGene software (SnapGene- USA).  
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3.3.2.1 N-terminus cloning 
The N-terminus of SNA-B and GNA sequences were fused to the C-terminus of GFP 
sequence between SacI:EcoRI and SacI:SpeI restrictions sites respectively as shown in 
figure 33 and figure 34. The partial sequences of pGFPuv expression vector containing 
SNA-B and GNA are also shown in figure 35 and figure 36. Primers used to introduce the 
restriction sites to SNA-B and GNA are shown in Table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Cloned SNA B-chain N-terminally fused to GFP protein sequence in the pGFPuv expression vector. The 
GREEN and RED parts of the arrow represent GFP and SNA-B sequences respectively; The light green and yellow 
arrows represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
. 
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Figure 34. Cloned GNA N-terminally fused to GFP protein sequence in the pGFPuv expression vector. The GREEN and 
RED parts of the arrow represent GFP and GNA sequences respectively; The light green and yellow arrows represent the 
ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
 
 
Figure 35 and 36 show a detailed view of the N-terminus cloning strategy, note that the 
SNA-B and GNA sequences are in frame with the GFP sequence and the stop codon 
(TAA). 
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Figure 35. The full nucleotide and deduced amino acid sequence of SNA-B chain N-terminally fused to GFP between 
SacI and EcoRI restriction sites in pGFPuv expression vector. The GFP sequence is indicated by a GREEN plot bar; The 
SNA-B sequence is indicated by a RED plot bar. 
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Figure 36. The full nucleotide and deduced amino acid sequence of GNA N-terminally fused to GFP between SacI and 
SpeI restriction sites in pGFPuv expression vector. The GFP sequence is indicated by a GREEN plot bar; The GNA 
sequence is indicated by a RED plot bar. 
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3.3.2.2 C-terminus cloning 
The C-terminus of SNA-B and GNA sequences were fused to the N-terminus of GFP 
sequence between HindIII:XbaI and XbaI:KpnI restrictions sites respectively as shown in 
figure 37 and figure 38. The partial sequences of pGFPuv expression vector containing 
SNA-B and GNA genes are also shown in figure 39 and figure 40. Primers used to 
introduce the restriction sites to SNA-B and GNA are shown in Table 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Cloned SNA-B C-terminally fused to GFP protein sequence in the pGFPuv expression vector. The RED and 
GREEN parts of the arrow represent SNA-B and GFP sequences respectively; The light green and yellow arrows 
represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 38. Cloned GNA C-terminally fused to GFP protein sequence in the pGFPuv expression vector. The RED and 
GREEN parts of the arrow represent GNA and GFP sequences respectively; The light green and yellow arrows represent 
the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
 
 
Figure 39, 40 below show a detailed view of the C-terminus cloning strategy, note that the 
SNA-B and GNA sequences are in frame with the start codon (ATG) of the expression 
vector and with the GFP sequence. 
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Figure 39. The full nucleotide and deduced amino acid sequence of SNA-B chain C-terminally fused to GFP between 
HindIII and XbaI restriction sites in pGFPuv expression vector. The SNA-B sequence is indicated by a RED plot bar; 
The GFP sequence is indicated by a GREEN plot bar. 
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Figure 40. The full nucleotide and deduced amino acid sequence of GNA C-terminally fused to GFP between XbaI and 
KpnI restriction sites in pGFPuv expression vector. The GNA sequence is indicated by a RED plot bar; The GFP 
sequence is indicated by a GREEN plot bar. 
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Following successful transformation SNA-B and GNA plasmid DNA was extracted and 
the diagnostic restriction digest of the plasmid DNA was performed to confirm the 
presence of targeted sequences (Figure 41)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Restriction digest of pGFPuv plasmid to confirm the presence of SNA-B and GNA product inserts. Lane 1: 
HyperLadder I (Bioline, UK); Lanes 2 and 6: the restriction digests of SNA-B and GNA samples C-Terminally fused to 
GFP respectively; lanes 4 and 8: the restriction digests of SNA-B and GNA samples N-Terminally fused to GFP 
respectively; Lanes 3, 5, 7 and 9: the undigested negative controls. 
 
Figure 41 confirmed the predicted band size of N- and C- terminus fusion proteins which 
are 810bp and 795bp for SNA-B fusions and 487bp and 481bp for GNA fusions 
respectively.  
Several sequencing reactions were also performed to determine the quality of the cloned 
sequences in the recombinant constructs. Partial results are as shown in figure 42, 43, 44, 
45 and the full sequences can be seen in appendix 3. 
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Figure 42. Chromatogram showing the sequence quality of SNA B-chain (SNA-B) N-Terminally fused to GFP in 
pGFPuv vector (Partial sequence data shown). The selected region is representative of overall sequencing quality and full 
sequence is shown in appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, 
black, blue and red colours respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. Chromatogram showing the sequence quality of SNA B-chain (SNA-B) C-Terminally fused to GFP in 
pGFPuv vector (Partial sequence data shown). The selected region is representative of overall sequencing quality and full 
sequence is shown in appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, 
black, blue and red colours respectively. 
 
 
 
 
 
 
 
 
Figure 44. Chromatogram showing the sequence quality of GNA N-Terminally fused to GFP in pGFPuv vector (Partial 
sequence data shown). The selected region is representative of overall sequencing quality and full sequence is shown in 
appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
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Figure 45. Chromatogram showing the sequence quality of GNA C-Terminally fused to GFP in pGFPuv vector (Partial 
sequence data shown). The selected region is representative of overall sequencing quality and full sequence is shown in 
appendix 3. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
3.3.3 Transformation of BL21(DE3) E. coli Cell Line with pGFPuv Vector 
Containing MLB, SNA-B and GNA N- and C- Terminally Fused to GFP 
The BL21(DE3) E. coli strain was transformed with both N- and C-Terminally fused 
MLB, SNA-B and GNA to GFP constructs using Chemically Competent BL21(DE3) and 
the heat shock method. The successfully grown colonies were screened under standard UV 
light (395nm-509nm) to visualise the emission of GFP in the colonies and successful 
transformation shown by GFP activity (Figure 46 and Figure 47). The successfully 
transformed cells were grown overnight in 5mL of liquid LB broth medium with 
100μg/mL Ampicillin at 37°C with shaking at 250 rpm. 
 
 
 
 
 
 
 
 
A B C 
 111 
 
 
 
 
 
 
 
 
 
 
Figure 46. Cloned N-terminally fused MLB, SNA-B and GNA to GFP conducted on an Agar and LB plates. Plate A: 
MLB; Plate B: SNA-B; Plate C: GNA. The emission of fused GFP to MLB and SNA-B means that the GFP is active and 
gives an indication that the fusion proteins are active. The fused GFP to GNA however showed no emission. 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Cloned C-terminally fused MLB, SNA-B and GNA to GFP conducted on an Agar and LB plates. Plate A: 
MLB; Plate B: SNA-B; Plate C: GNA. The emission of fused GFP to MLB and SNA-B means that the GFP is active and 
gives an indication that the fusion proteins are active. The fused GFP to GNA however showed no emission. 
 
Figure 46 and 47 shows that the fusion proteins made from C-terminally fused MLB and 
SNA-B to GFP has higher GFP activity (based on visualization of GFP) than the fusions 
made from N-Terminally fused MLB and SNA-B to GFP. The emission of GFP is higher 
in the former which is an indication that GFP was properly folded, similarly for MLB and 
SNA-B. However, the activity of GFP was almost absent in both N- and C-terminally 
fused GNA to GFP which indicates that the fusion protein was either not expressed or not 
correctly processed in E. coli. Therefore, protein expression was performed just for MLB 
and SNA-B fusion proteins. 
A B C 
A B C 
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3.3.4 Expression of Recombinant MLB+GFP and SNA-B+GFP 
The strain of E. coli BL21(DE3) harbouring the plasmid pGFPuv containing the MLB and 
SNA-B genes N- and C- terminally fused to GFP to be expressed were grown in LB Broth 
medium (Luria Low Salt) (Sigma-Aldrich, UK) for 18 hours at 30oC after which the total 
protein was harvested. The emission of GFP in the pellets made from harvested E. coli 
cells show that the fused GFP protein in the fusion proteins is active which gives an 
indication that the whole fusion proteins are active (Figure 48). 
 
 
 
 
 
 
 
 
 
Figure 48. Pelleted E.coli cells contain expressed Lectin+GFP fusions. Tube A: N-terminus MLB+GFP fusion; Tube B: 
C-terminus MLB+GFP fusion; Tube C: N-terminus SNA-B+GFP fusion; Tube D: C-terminus SNA-B+GFP fusion.  
 
The harvested proteins from each set of N- and C- terminus MLB and SNA-B cultures was 
analysed on 12% SDS-PAGE gel and the predicted band sizes of 58.41 kDa and 58.14 kDa 
for N- and C- terminus MLB fusions and 58.77 kDa and 58.08kDa for N- and C- terminus 
MLB fusions were detected respectively on the gel (Figure 49). 
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Figure 49. SDS PAGEof expressed N- and C-terminally fused MLB and SNA-B to GFP and their negative controls, the 
gel stained with instant blue coomassie stain. Lane 1: PageRuler™ Plus prestained protein ladder (Fisher, UK); Lane 2: 
Non-induced MLB+GFP fusion (N-Term); Lane 3: Induced MLB+GFP fusion (N-Term) (58.41kDa); Lane 4: Non-
induced MLB+GFP fusion (C-Term); Lane 5: Induced MLB+GFP fusion (C-Term) (58.14kDa); Lane 6: Non-induced 
SNA-B+GFP fusion (N-Term); Lane 7: Induced SNA-B+GFP fusion (N-Term) (58.77kDa); Lane 8: Non-induced SNA-
B+GFP fusion (C-Term); Lane 7: Induced SNA-B+GFP fusion (C-Term) (58.08kDa). 
 
 
 
Thus we confirm that both N- and C- terminus fusion proteins of MLB and SNA-B were 
successfully expressed in E. coli and the activity of GFP was detected which confirms the 
activity of other candidate proteins in the fusion constructs. 
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3.4 Discussion 
In this study a mutant green florescent gene known as GFPuv was used to produce Lectin-
GFP recombinant protein by fusing GFP to the binding chain of mistletoe lectin (MLB), 
the binding chain of elderberry lectin (SNA-B) or snowdrop lectin (GNA) so as to assess 
the expression level of these three peptides and to be able to screen their localization in 
cellular experiments. The coding sequences of the recombinant proteins were cloned into 
pGFPuv expression vector which has pUC E. coli replication origin, in order to express 
them in E. coli bacterial expression system. 
Since the main concern in the production of recombinant protein is protein-protein 
interaction between the fused genes especially between the core amino acids or domains 
which are at different locations in different genes, it is thus necessary to identify the 
location of these core portions and fuse the genes in an orientation that causes minimum 
interaction between the domains responsible for the main activity of the fused proteins 
such as hydrophobic domains in some membrane proteins important for protein folding 
and targeting (Zhang and Crandall 2007). Lectins as carbohydrate binding proteins have 
specific domains responsible for glycan binding activity. Therefore, these domains should 
be protected from any interaction with other proteins to preserve their binding function. 
Despite the fact that the structure of MLB, SNA-B and GNA lectins have been extensively 
studied and their well-documented 3D structures are available, the impact of fusing these 
peptides to other peptides on their functionality especially the glycan binding function 
needs to be assessed experimentally.  
In order to identify the optimum orientation of fusing MLB, SNA-B and GNA peptide 
sequences to GFP, both N- and C- terminus fusing strategy were applied. In the N-terminus 
constructs, the amino terminus of the lectin sequences was fused to the carboxyl terminus 
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of GFP sequence. On the other hand, the lectins were C-terminally fused to GFP through 
fusing their carboxyl terminus to the amino terminus of GFP. 
The introduction of restriction sites to the start and end of the lectin sequences 
corresponding the targeted sites on pGFPuv expression vector was successfully performed 
and few extra amino acids was also placed between lectins and GFP sequences as a linker 
so as to minimize protein-protein interaction as much as possible. In the N-terminus fusing 
strategy, the amino terminus of lectin sequence was successfully fused in frame with the 
GFP sequence and the carboxyl terminus was fused in frame with a stop codon as shown 
in figure 27, 35, 39. In contrast, in the C-terminus fusing strategy the lectin amino terminus 
was successfully fused in frame with a start codon and the carboxyl terminus with the 
coding sequence of GFP shown in figure 29, 36, 40. 
The analytical restriction digest of the recombinant constructs confirmed the correct size of 
the lectin sequences in the constructs (Figure 30, 41) and the triplicate sanger sequencing 
reactions also confirmed no mutation or gaps in the lectin coding sequences (Figure 31, 32, 
42, 43, 44, 45). 
In order to efficiently express the Lectin-GFP fusion constructs and prevent leaky 
expression, the BL21(DE3) E. coli strain was chosen because it has lacUV5 promoter 
which is less sensitive than wt lac promoter to catabolite repression. Thus, uninduced 
expression of the target protein can be prevented (Pan and Malcolm 2000). 
The expression time, temperature and IPTG concentration of the expression reactions were 
decided on the base of repeating small scale expressions many times at different 
conditions. The optimum expression condition was then chosen which was 18 hours, 30Co 
and 500μM IPTG. 
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In order to evaluate the expression level of Lectin-GFP fusion proteins, the successfully 
grown colonies containing recombinant proteins were first screened under standard UV 
light to excite the expressed GFP in the colonies. Different expression level was detected 
between different colonies of different constructs and also between different colonies of 
different orientations of the same construct (Figure 46, 47). The qualitative expression 
level of C-terminally fused MLB and SNA-B to GFP (Plate A&B in figure 46&47) was 
noticed to be higher than N-terminally fused MLB and SNA-B to GFP because a brighter 
emission of GFP was observed in the former constructs and it is possibly due to less 
protein-protein interaction in the C-terminal constructs and vice versa. However, in the 
colonies containing GNA-GFP fusion proteins, very low emission of GFP was detected in 
both N- and C- terminal cloning strategy. Therefore, the expression level of the fusion 
constructs was considered too low and the main reason is believed to be the toxicity of 
GNA lectin which affects E. coli cells proliferation and consequently affect the expression 
of the recombinant constructs and produce inclusion bodies since many very small and 
ununiformed colonies were observed on the plates containing the GNA-GFP constructs 
(Plate C in figure 46&47). This result agree with Luo, Zhangsun et al. (2005) who could 
only produce insoluble inclusion bodies from recombinant GNA expressed in E.coli. 
Thus, we decided to not proceed the expression of GNA+GFP fusion protein because the 
activity of GFP in the fusion protein was absent and the protein was considered as 
misfolded or unfolded. The reason behind a difficulty to express GNA fusion protein is 
believed to be the toxic effect of GNA which affect the expression process in E. coli 
because previous attempts to produce GNA recombinant fusion proteins for a "systemic" 
RNAi effect in insects faced the same difficulty and majority of their expressed fusion 
proteins in E. coli was in the insoluble fractions (Min 2016). 
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However, the expression of MLB+GFP and SNA-B+GFP was successfully carried out and 
the soluble fractions of MLB and SNA-B recombinant proteins present in both periplasm 
and cytoplasm of E. coli cells were successfully extracted by applying soluble fraction 
protocol of BugBusterTM protein extraction reagent (EMD Millipore, UK). Then, the 
fractions of both uninduced and induced Lectin-GFP fusion proteins were analysed on 
SDS PAGE and the predicted size bands of all the constructs were successfully detected 
(Figure 49).  
Although majority of host proteins-GFP fusions are simple tandem fusions in which the 
amino terminus (N-terminus) of one protein is genetically linked to the carboxyl terminus 
(C-terminus) of the other, the production of successful fusion proteins needs a general rule 
in order to predict when the host protein function will be preserved and when the 
fluorescence will be intact. It is common that sometimes one or neither concatenation (N- 
& C- terminus) produces functional chimeras. Tsien (1998) believed that the reason could 
be the splicing of GFP into the middle of the host protein and to prevent this he has 
suggested to move the N- and C-terminii of GFP as close to each other as possible through 
circular permutation or addition of spacers. 
In conclusion, recombinant fusion proteins from MLB and SNA-B fused to GFP were 
successfully designed and expressed in E. coli. However, attempts to express GNA-GFP 
fusion protein failed  
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Chapter 4. Purification of Expressed Lectin-GFP Fusion Proteins. Confirmation of 
Sialic Acid Affinity and Demonstration of Biological Activity. 
 
4.1 Introduction 
Affinity chromatography is one of the effective systems to purify biological compounds 
which has been widely used in protein purification because some proteins have the ability 
to non-covalently attach to a specific molecule in affinity columns known as the ligand. 
According to the type of the protein to be purified, different type of ligands can be used in 
affinity chromatography. Lectin as a carbohydrate binding protein needs a ligand that has 
carbohydrate attachment sites for example a type of ligands known as glycan adsorbent is 
considered as the most appropriate ligand for lectin purification (Voet and Voet 1995). 
The ligands for lectin purification are divided to three main groups as follow: (1) 
carbohydrates (Monosaccharide, Disaccharide and polysaccharide); (2) glycoproteins and 
(3) polysaccharide matrices. In the first two groups, the ligand is coupled to a pre-activated 
matrix but the third group does not need ligands because the matrix itself can be bound by 
lectins (Pohleven, Štrukelj et al. 2012).  
Over the last few decades many types of glycoprotein ligands have been identified and 
effectively used in protein purification such as glycoprotein ligands attached to cyanogen 
bromide activated Sepharose. Fetuin is an example of glycoprotein ligands which is a 
heavily glycosylated protein exists in a variety of glycoforms like bi-, tri-, and tetra-
antennary oligosaccharides with variable sialyation. It has been widely used in the 
purification of glycan binding proteins such as lectins (Nakagawa, Sakamoto et al. 2012). 
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Protein purification via affinity chromatography can be performed either through gravity 
flow column or using fast protein liquid chromatography system (FPLC). According to the 
stability and specificity of both the protein to be purified and the ligand, different eluent 
and elution techniques can also be used to elute the target protein in affinity purification. 
For example, elution can be performed through any of the following methods: (a) 
alternating the pH or ionic strength of the eluent; (b) using urea as eluent; (c) using a 
specific carbohydrate to perform competitive elution. However, the recommended method 
to elute lectins is competitive elusion with a carbohydrate which can be effectively bound 
by the lectin to be purified (Guzmán-Partida, Robles-Burgueno et al. 2004, Pohleven, 
Štrukelj et al. 2012). 
The majority of the previous studies on lectin-carbohydrate binding suggests that lectins 
primarily bind monosaccharides but lectin binding to complex determinants with higher 
affinity has also been detected (Cummings 1999). The lectin affinity to monosaccharides is 
often seen an order of magnitude lower than that for complex carbohydrates and for 
binding to carbohydrates, lectins require a specific anomeric configuration and certain 
sugar residues. The carbohydrate-metal binding is another point that needs to be 
considered in the lectin affinity purification because some lectin-carbohydrate binding 
often happen in the presence of a specific metal such as the binding of mannose-specific 
lectins to mannose residues which happens only in the presence of calcium ions (Ca+2). On 
the other hand, there are other lectins that do not need metal ion to perform binding to their 
saccharide counterparts such as plant lectins like the mistletoe lectin (Weis, Drickamer et 
al. 1992, Zheng, Ornstein et al. 1997). 
Earlier efforts to study the characteristics of mistletoe lectin Isoform-I (MLI) mainly relied 
on the extraction of the lectin from the plant (Büssing, Wagner et al. 1999, Hajtò, Krisztina 
et al. 2007). Also, any attempt to produce recombinant protein from the coding sequence 
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of mistletoe lectin were to study and confirm the galactose binding ability of MLI and not 
to study the sialic acid binding ability because MLI is classified as a galactose binding 
lectin (Wu, Chin et al. 1992, Eck, Langer et al. 1999). However, Müthing, Meisen et al. 
(2004) carried out comparative solid-phase binding assays along with electrospray 
ionization tandem mass spectrometry with MLI from the extract of mistletoe and 
suggested that MLI should be considered as a sialic acid binding lectin instead of galactose 
binding lectin because the lectin was seen to preferentially bind to terminally α2-6-
sialylated neolacto series gangliosides from human granulocytes and only marginal 
binding of ML-I to terminal galactose residues of neutral glycosphingolipids was detected. 
Elderberry (Sambucus nigra) lectin known as sambucus nigra agglutinin I (SNA-I) is also 
a well-known sialic acid binding lectin (Shibuya, Goldstein et al. 1987). The coding 
sequence of SNA-I has been extensively studied and showed that it is composed of a toxic 
chain (A chain) and a carbohydrate binding chain (B chain) linked by a disulphide bridge 
(Tejero, Jiménez et al. 2015). The A chain is a type 2 potent ribosome inactivating protein 
(RIP2) and the B chain has a specific affinity to terminal α-2,6 sialic acid (α-2,6Neu5Ac) 
(Damme, Barre et al. 1996). 
Altered glycosylation of the majority of the cancer cell surface adhesion proteins has been 
confirmed to significantly change the biological function of the cells such as cell spreading 
and signal transduction (Przybylo, Pochec et al. 2008). The most frequently observed 
altered glycosylation during tumorigenesis is the increased amount of sialylation of the cell 
surface glycoproteins results from the terminal capping of sialic acid on the additional 
antennas provided by acetyllactosamine residues (Ranjan and Kalraiya 2013). Human 
melanoma cancer has been reported as one of the cancers that have aberrant amount of α-
2,3 and α-2,6 sialic acid linkages on their cell surface glycoproteins which can be targeted 
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as a biomarker for the cancer prognosis and treatment (Hoja-Łukowicz, Link-Lenczowski 
et al. 2013, Kolasińska, Przybyło et al. 2016). 
Thus in this study we aim to perform affinity purification using activated-Sepharose bead 
coupled with fetuin to purify the produced recombinant fusion proteins from the binding 
chain of both mistletoe lectin (MLB) and positive control elderberry lectin (SNA-B) fused 
to GFPuv and thus confirm the sialic acid binding ability of the recombinant proteins 
through assessing their binding to the sialic acid residues of the fetuin based purification 
system. Finally, we aim to screen the ability of the purified recombinant proteins to 
specifically bind to melanoma cells and cross their membranes through binding to their 
cell surface sialic acid residues.  
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4.2 Material and Methods 
4.2.1 Recombinant Protein Purification 
Affinity columns were prepared in order to purify sialic acid binding MLB and SNA-B 
lectin via their binding to fetuin ligand.  
4.2.1.1 Column Preparation 
The affinity column bead was prepared from the pre-activated CNBr Sepharose 4B which 
is a good medium for immobilization of ligands containing primary amines (GE 
Healthcare, UK). The medium was also coupled with degalactosilated fetuin which is a 
heavily glycosylated protein existing in a variety of glycoforms containing bi-, tri-, and 
tetra-antennary oligosaccharides with variable sialyation (Sigma-Aldrich, UK). Briefly, the 
required amount of lyophilized CNBr powder was weighed and suspended in 1 mM HCL. 
The medium swelled immediately and was washed on a sintered glass filter (porosity G3) 
with 1mM HCl for 15 minutes. The required amount of fetuin (5–10 mg protein per ml 
medium) was also dissolved in dissolving buffer (0.1 M CH₃COONa pH 8.3 containing 
0.5 M NaCl) and incubated at 37 °C overnight with the required amount of β-
Galactosidase to remove galactose molecules from fetuin (Sigma-Aldrich, UK). The β-
Galactosidase treated fetuin was then extensively dialyzed against coupling buffer (0.1 M 
NaHCO3 pH 8.3 containing 0.5 M NaCl) and added to the suspended CNBr medium (5 ml 
coupling solution/g lyophilized powder) in a stoppered vessel. The mixture was rotated 
end over end overnight at 4 °C and washed with 5 medium (gel) volumes of coupling 
buffer to wash away the excess ligands. The mixture was incubated in blocking buffer (0.1 
M Tris-HCl,) pH 8.0 for 2 hours to block remaining active groups on Sepharose 4B and 
washed in three cycles of alternating pH with 5 medium volumes of 0.1 M acetic 
acid/sodium acetate, pH 4.0 containing 0.5 M NaCl and 0.1 M Tris-HCl, pH 8 containing 
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0.5 M NaCl. Finally, the coupled CNBr-fetuin was packed in HR 16/10 column (GE 
Healthcare, UK). 
4.2.1.2 Affinity Purification  
Following the expression of MLB+GFP and SNA-B+GFP (N- and C- terminus), the 
culture supernatant was clarified by centrifugation and the E.coli cell walls were gently 
disrupted by BugBuster reagent, resulting in the liberation of soluble protein. Affinity 
column chromatography was then conducted to purify targeted fusion proteins from the 
total extracted proteins from the E. coli cells using prepared affinity column described in 
section 4.2.1.1 and AKTA prime FPLC platform (GE Healthcare, UK). After purification 
the relevant fractions were analysed by SDS-PAGE and western blotting. 
 
4.2.2 Protein Biochemistry 
4.2.2.1 Protein Concentration Assay 
The BCA protein quantification assay kit (Merck Millipore, UK) was used to determine 
the concentration of the purified recombinant proteins in microassay size. The BCA 
working reagent was prepared according to the manufacturer’s instructions and a 7-point 
standard curve was prepared in triplicate from a serial dilution of stock BSA (2000 µg ml-
1). Samples were assayed using 96-well plates, 25µl from each standard and samples was 
added in replicated into individual wells of a 96-well plate followed by 200 μl BCA 
working reagent. The plate was covered and incubated at 37oC for 30 minutes. After the 
incubation time, the plate was cooled to room temperature and the absorbance was 
measured at 562 nm on Multiskan™ GO Microplate Spectrophotometer (Fisher, UK). The 
absorbance and known mass of the BSA were then plotted to generate the standard curve 
which was used to interpolate the measured absorbance of the samples by liner regression 
(Figure 50).  
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Figure 50. The standard curve of net absorbance at 562nm versus the concentration of a serial dilution of bovine serum 
albumin (BSA) ranging from 0-2000µm) after incubation with BCA reagent for 30minutes. 
 
The fusion protein sequences were also computationally analysed using ExPASy server 
(Gasteiger, Gattiker et al. 2003). The computed molecular weight and extinction 
coefficient of the fusion proteins are shown in table 16. 
Table 16. Computed parameters of MLB+GFP, SNA+GFP and GNA+GFP. 
 
 
4.2.2.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SDS-PAGE of protein samples was carried out using tris-glycine buffer system (25 mM 
Tris-HCl PH 6.8, 250 mM glycine, 1% w/v SDS) under denaturing conditions. 
Compositions of the polyacrylamide gels are shown in table 17. Samples were mixed with 
1X reducing sample buffer (50 mM Tris-cl PH 6.8, 100mM 2-mercaptoethanol, 2% w/v 
Fusion Proteins    Molecular Weight (g/mol)    Extinction Coefficient M-1 cm-1 
   
MLB+GFP (N-Terminal) 58023.4 82570 
MLB+GFP (C-Terminal) 58398.7 81080 
SNA+GFP (N-Terminal) 58762.3 81080 
SNA+GFP (C-Terminal) 58072.5 82570 
GNA+GFP (N-Terminal) 46251.4 47705 
GNA+GFP (c-Terminal) 46018.2 49195 
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SDS, 0.1% bromophenol blue, 10% v/v glycerol) and boiled at 100oC in a water bath for 3 
minutes. Samples were loaded onto the gel along with molecular weight marker 
PageRulerTM Prestained Protein Ladder (Fisher, UK). Gels were run with the appropriate 
running buffer with a voltage of 8 V/cm until the dye front moved into the resolving gel 
then the voltage was increased to 15 V/cm and run until the bromophenol blue reached the 
bottom of the resolving gel. The gels were stained with InstantBlue (Expedeon-Uk) for 15 
minutes and rinsed with water. Finally, the gel was photographed by G-box 
transilluminator (Syngene, UK). 
Table 17. Solutions for preparing 12% resolving gels and 5% stacking gels for Tris-glycin SDS-polyacrylamide gel 
electrophoresis. 
 
 
4.2.2.3 Immuno Assay by Western Blotting 
Following running the denatured protein samples on SDS PAGE as described in section 
4.2.2.2, the proteins were transferred to nitrocellulose membrane (Merck Millipore, UK) 
using the semi dry blotting technique (Kyhse-Andersen 1984). Briefly, a piece of 
nitrocellulose membrane the same size as the gel was activated on ice-cold methanol for 
10 minutes and the gel was washed in water to remove the traces of SDS. They were then 
placed on BioRad Mini Transblot blotting apparatus in the following order: ANODE; one 
sheet of sponge; two sheets of 3MM filter paper soaked in transfer buffer (192 mM 
Glycine, 25 mM Tris-HCl and 20 % (v/v) Methanol at pH 8.3); 1 sheet of nitrocellulose 
membrane soaked in PBS; the gel; two sheets of 3MM filter paper; one sheet of sponge 
Components 12% Resolving Gel (ml) 5% Stacking Gel (ml) 
   
1.5M Tris-HCL (pH8.8) 2.5 - 
1.0M Tris-HCL (pH6.8) - 0.38 
30% Acrylamide mix  4.0  0.5 
10% SDS 0.1 0.03 
10% Ammonium Persulafate 0.1 0.03 
TEMED  0.004 0.003 
H2O 3.3 2.1 
Total   10 ml 3 ml 
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soaked in transfer buffer (192 mM Glycine, 25 mM Tris-HCl and 20 % (v/v) Methanol at 
pH 8.3); CATHODE. 
The transfer was carried out for 120 minutes at a constant current of 400 mA in transfer 
buffer (192 mM Glycine, 25 mM Tris-HCl and 20 % (v/v) Methanol at pH 8.3). The 
middle reservoir of the tank was filled with ice to prevent overheating during running. 
Following the transfer, the membrane was washed in PBS and incubated on a rocker 
overnight at 4oC in blocking buffer (5% nonfat dry milk, 0.2% Tween-20 and PBS) to 
block the free sites on the membranes. The membrane was treated with primary antibody 
in 10 ml of blocking buffer containing Living Colors® A.v. Monoclonal Ani-GFPuv 
Antibody 1:5,000 (Clontech, USA) and incubated for 2 hours at room temperature with 
shaking followed by washing in washing buffer (0.2% Tween-20 and PBS) two times for 5 
minutes each wash. The membrane was then incubated for 1 hour in blocking buffer 
containing Goat IgG Anti-Mouse IgG-HRP conjugated secondary antibody 1:4000, 
(Sigma-Aldrich-UK) followed by washing in washing buffer (0.2% Tween-20 and PBS) 4 
times for 10 minutes each wash. Antibody binding was visualised using Pierce Enhanced 
chemiluminescence (ECL) substrate solution following the manufacturers instruction 
(Thermofisher Scientific). The membrane was visualised and photographed by G-box 
transilluminator (Syngene, UK). 
 
4.2.3 Cell Culture 
Human metastatic melanoma cells (WM 266-4) (ECACC, UK) (Table 20) were cultured in 
RPMI-1640 culture media (Sigma-Aldrich, UK) supplemented with 10% (v/v) fetal bovine 
serum (FBS) and 1% (v/v) glutamine at 37 ºC in a humidified atmosphere containing 5% 
carbon dioxide. 
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The cells were grown until 80% confluency achieved in about 72 to 96 hours followed by 
subculturing. The culture flask was decanted from the culture media and 0.5 ml 
trypsin/EDTA (Sigma-Aldrich, UK) was added and incubated for about 5 minutes at 37 ºC 
to detach the cell monolayer from the flask. The flask content was transferred into a 
universal tube and centrifuged at 500 x g for 5 minutes. The supernatant was discarded and 
the pellet was re-suspended in 5 ml of culture media. The split was carried out at 
recommended 1:3 ratio and transferred into 25 or 75 cm2 culture flasks according to the 
amount of cells needed for the further tests and the total volume of the media made up to 5 
or 15 ml respectively. 
 
4.2.4 Cell Counting 
The harvested cell pellet was suspended in 5-10ml of culture media and 40μl of the culture 
was transferred into a 1.5ml eppendorf tube to perform 1:2 dilutions with trypan blue dye 
(Sigma-Aldrich, UK). The diluted culture was then used in the cell counting using a 
haemocytometer (Labtech, UK) and both viable and dead cells were counted as the dye 
only stains dead cells blue. The cell number and cell viability were calculated according to 
the formula A and B shown below. 
 
A-Cells counting equation 
𝑇𝑜𝑡𝑎𝑙𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 = 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ∗
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
# 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
 ∗ 10,000 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 
 
B- Cell viability equation 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑙𝑖𝑣𝑒 + 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
∗ 100 
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4.2.5 MTS Cell Proliferation Assay 
A colorimetric method CellTiter 96®Aqueous One Solution Cell Proliferation Assay 
(Promega, UK) was used to determine the number of viable cells in the proliferation and 
cytotoxicity assays. The MTS solution was prepared according to the manufacturers 
instruction. 
A range of cell density (0.5-2 x 104 cells/cm2) was suggested by the cell supplier, therefore 
the cells were seeded at incremental levels of 1 x 103 cells in a range between 2-5 x 103 
cells/well (surface area, 0.35 cm2) in 100µl of appropriate culture media on 96-well plate 
and incubated at 37 ºC in humidified atmosphere containing 5% C02 for 24, 48 and 72 
hours. At the end of each period of time cells were treated with 20µl of the MTS solution 
and incubated at 37ºC for 3 hours. The colour of the mixture was changed during the 
incubation time because the MTS was reduced to formazan crystals by the living cells in 
which dissolved in the culture media and gave a purple colour. The amount of produced 
formazan crystals was thus directly proportional to cell viability as MTS could be reduced 
only by the respiring cells. The colour intensity was determined through measuring the 
absorbance at 490 nm and the blank absorbance at 650 nm using micro plate reader 
(Dynatech MR5000, USA). 
 
4.2.6 Assessing the Binding of Lectin-GFP Fusion Proteins to Human Melanoma Cells 
Human metastatic melanoma cancer cells (WM 266-4) were cultured on 96-well plate with 
the optimum seeding density 5000 cells/well (~1.4 x 104 cells/cm2) as determined in 
section 4.2.5 After 24hours incubation at 37 ºC in humidified atmosphere containing 5% 
C02, the media was changed to the same RPMI-1640 but with lower amount of FBS (2%). 
The cells were then treated with 0.3µM of MLB-GFP and SNA-B-GFP fusion proteins and 
incubated another 24 hours. The binding of the fusion proteins to the cell membrane was 
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visualised by luminescence imaging microscopy (Nikon, UK) using blue light (488nm) to 
excite the GFP tagged to the lectins. 
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4.3 Results 
To assess the binding of the lectin-GFP fusion proteins to sialic acid, affinity purification 
using degalactosilated fetuin was chosen to affinity purify the expressed proteins. Human 
melanoma cancer cell lines known to overexpress sialic acid on their cell membrane were 
also used to assess the activity and binding of the designed fusion proteins. 
Epifluorescence microscopy was employed to visualize binding and demonstrate cellular 
internalization of the fusion proteins.  
 
4.3.1 Protein Purification 
Following the expression of the fusions MLB+GFP and SNA+GFP in both N- and C- 
terminus direction and extraction of the soluble protein fractions from E. coli section 
3.2.10, recombinant proteins were partially purified from culture supernatant by affinity 
chromatography. A CNBr-activated Sepharose 4B medium was employed for 
immobilization of ligands containing primary amines (GE Healthcare, UK) and was 
coupled with fetuin which is a heavily glycosylated protein (Sigma-Aldrich, UK) 
following manufacturers instruction. Both N- and C- terminus fusion proteins showed 
binding activity and successfully bound to the sialic acid of the fetuin ligand on the column 
bead. However, as higher activity of GFP in the C-terminus fusion proteins was shown in 
the previous study, the similar result was also observed during the purification of the 
fusion proteins since the binding activity was seen to be higher with C-terminus fusion 
proteins in comparison to the N-terminus fusion proteins and in turn resulted in a higher 
amount of purified products.  
Similar purification profiles were shown by all the constructs during their purification of 
on the sepharose column. Following the addition of the eluent which was PBS containing 
0.5M sialic acid, a broad peak of eluted proteins was observed and fractioned into small 
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fractions so as to be assessed later by SDS page. A typical elution profiles from the 
sepharose column chromatography purification is shown in figure 51, 52, 53, and 54. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Typical purification profile of CNBr-Activated Sepharose affinity column purification. One elution peak (E) 
was collected from purified MLB+GFP (N-terminus) (~100ml).  
 
 
 
 
 
 
 
 
Figure 52. Typical purification profile of CNBr-Activated Sepharose affinity column purification. One elution peak (E) 
was collected from purified MLB+GFP (C-terminus) (~140ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. Typical purification profile of CNBr-Activated Sepharose affinity column purification. One elution peak (E) 
was collected from purified SNA-B+GFP (N-terminus) (~110ml). 
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Figure 54. Typical purification profile of CNBr-Activated Sepharose affinity column purification. One elution peak (E) 
was collected from purified SNA-B+GFP (C-terminus) (~225ml). 
 
 
4.3.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis and Western 
Blotting 
The predicted size of N-terminus MLB+GFP and SNA-B+GFP deduced from the amino 
acid sequences are 58.41kDa and 58.77kDa respectively and of C-terminus MLB+GFP 
and SNA-B+GFP are 58.14kDa and 58.08kDa respectively. The fractions of column 
eluates were analysed by SDS-PAGE and the predicted sizes of all constructs were 
observed (Figure 55a) The presence and activity of both N- and C- terminus MLB+GFP 
and SNA+GFP were also confirmed by western blotting of culture supernatant using 
mouse monoclonal anti-GFP antibodies and goat anti-mouse IgG secondary antibody 
(Figure 55b)  
The western blotting experiment also confirmed that all the fusion proteins were expressed 
and folded properly in E. coli since the anti-GFP primary antibody successfully bound to 
N- and C-terminus fusion proteins (Figure 55b). 
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Figure 55. (a). SDS PAGE of purifird MLB+GFP and SNA-B+GFP (N- and C- terminus) fusions stained with 
InstantBlue (Expedeon,UK) and (b) western blot of purified MLB+GFP and SNA-B+GFP (N- and C- terminus) fusions 
using Living Colors® GFPuv anti-GFP primary antibody (Clontech, USA) and goat anti-mouse IgG secondary antibody 
(Sigma, UK). Lane a1: PageRuler™ Plus prestained protein ladder (Fisher, UK); Lane a2&b1: purified MLB+GFP 
fusion (C-Term) (58.41kDa); Lane a3&b2: purified MLB+GFP fusion (N-Term) (58.14kDa); Lane a4&b3: purified 
SNA-B+MLB fusion (C-Term) (58.77kDa); Lane a5&b4: purified SNA-B+GFP fusion (N-Term) (58.08kDa). 
 
4.3.3 Assessing the Binding of Lectin-GFP Fusion Proteins to Human Melanoma Cells 
In order to assess the binding activity of the lectin-GFP fusion proteins to the sialic acid 
residues present on the surface of cancer cells, a melanoma cell line (WM 266-4) was 
used. Previous studies on this cell line have shown overexpression of sialic acid on their 
cell membranes and it can be used to test the activity of sialic acid binding fusion proteins. 
The WM 266-4 cells are metastatic melanoma cells with overexpressed α2-6 sialic acid 
which can be preferentially bound by mistletoe and elderberry lectins (Hoja-Łukowicz and 
Link-Lenczowsk, 2012). 
 The cells were prepared on 96-well plates as described in section 4.2.5 and treated with 
(0.3µM) of each MLB-GFP and SNA-B-GFP (N-terminus) fusion proteins. Following the 
incubation time and to visualise the binding and localization of the fusion proteins, the 
treated cells were screened and imaged under blue light (488nm) to excite the GFP fused 
to the lectins using epifluorescence microscope.  
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Both fusion proteins were successfully attached to the surface of the cancer cells and also 
crossed their membranes since the emission of GFP was detected not only on the cell 
surfaces but also inside the cells. 
Figure 56 and 57 show the WM 266-4 metastatic melanoma cells treated with MLB+GFP 
and SNA-B+GFP fusion proteins respectively. It can clearly be seen that the fusion 
proteins successfully attached to the surface of the cell membranes and caused the 
agglutination of the cells which is an indication of the activity of the lectins in the fusion 
proteins. Also, the fusion proteins successfully crossed the cell membranes and reached the 
cell interiors as the emission of GFP can be seen inside the cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56. Metastatic melanoma cells (WM 266-4) incubated with 0.3µM of MLB+GFP fusion protein overnight and 
screened under luminescence imaging microscopy. The RED arrows show the attachment of the fusion protein to the cell 
membranes and cell agglutination. The BLUE arrows show the cell internalization of the fusion protein.  
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Figure 57. Metastatic melanoma cells (WM 266-4) incubated with 0.3µM of SNA-B+GFP fusion protein overnight and 
screened under luminescence imaging microscopy. The RED arrows show the attachment of the fusion protein to the cell 
membranes and cell agglutination. The BLUE arrow show the cell internalization of the fusion protein.  
 
 
Thus biological activity of MLB-GFP fusion was demonstrated in terms of (a) sialic acid 
binding (b) activity against cancer cells. 
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4.4 Discussion 
In this study affinity column chromatography was applied to purify Lectin-GFP 
recombinant fusion proteins produced in the previous study from fusing the binding chain 
of mistletoe lectin (MLB) and elderberry lectin (SNA-B) to GFP and expressed in E. coli. 
Protein purification as a process, is a separation of a particular protein from a bulk of 
proteins or other molecules. There is a diversity of protein purification systems which are 
different in terms of functionality and application. The selection of an appropriate protein 
purification system mainly depends on the type of protein that needs to be purified. 
Proteins can be purified through targeting a specific feature which differentiate the protein 
of interest from surrounding molecules. This differentiation feature can be naturally 
possessed by the protein such as glycan binding property or can be added to the target 
protein such as the addition of six histidine tag (6-His). Therefore, to specifically target a 
particular property of a specific protein, a purification system should be selected which has 
ability to recognize this particular property. 
Affinity chromatography is one of the potent protein purification systems that relies on 
specific ligands to which protein of interest can bind. Lectins are well known for their 
glycan binding affinity and majority of lectins have affinity to one or more specific 
monosaccharide which can be used as a ligand to specifically isolate lectins from other 
molecules. Mistletoe and elderberry lectins are both known as sialic acid binding lectins 
(Müthing, Meisen et al. 2004, Shang and Van Damme 2014). Therefore, ligands 
containing sialic acid was used to purify both lectins.  
In order to minimize the interaction between the column matrix and the target Lectin-GFP 
fusion proteins during the purification process, pre-activated sepharose matrix was used 
which is proven to have less interaction with proteins during purification (You, Cao et al. 
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2015). However, sepharose alone cannot be bound by MLB and SNA-B because it does 
not have any attachment sites for the lectins. Thus, fetuin as a heavily glycosylated 
glycoprotein was coupled to the sepharose matrix so as to be bound by the lectins through 
binding to the sialic acid branches possessed on its glycosylation profile (Wu, Huang et al. 
2015).  
All the expressed recombinant fusion constructs were observed to successfully bind to the 
column matrix through binding to available sialic acid sites and they were later eluted 
through competitive elusion using PBS containing a high concentration of sialic acid as the 
elution peaks are shown in figure 51, 52, 53, 54. The purification chromatogram was found 
similar for all the recombinant constructs which was a broad peak. However, a broader 
peak was observed in the chromatogram of C-terminally fused MLB and SNA-B to GFP 
(Figure 52, 54) in comparison to their N-terminally fused counterparts (Figure 51, 53). 
The purified recombinant constructs were later analysed by SDS PAGE to assess the size 
of the purified proteins and to detect any possible degradation happened during the 
purification process. A correct size band was successfully detected for each construct as 
shown in figure 55a. Although, the expression of the recombinant constructs was 
previously confirmed via assessing the emission of GFP under UV light, western blotting 
was also performed and the anti-GFP primary antibody was observed to successfully bind 
to all the constructs (Figure 55b). 
While the main purpose of conducting purification of the expressed recombinant Lectin-
GFP fusions was to achieve pure fusion protein products for further experiments, the 
affinity purification also confirmed that the fused binding chains of both lectins MLB and 
SNA-B preserved their glycan binding affinity since they successfully bound to the sialic 
acid residues of fetuin. This result can thus be counted as a first attempt to experimentally 
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confirm the sialic acid binding affinity of MLB chain alone without MLA chain since the 
previous studies hypothetically suggested this affinity or essentially tested the sialic acid 
binding affinity of the whole mistletoe lectin (MLA+MLB) such as the study conducted 
Müthing, Meisen et al. (2004). 
Aberrant glycosylation during oncogenic transformation is observed in almost all the type 
of cancers and becomes a universal feature of cancer cells by which different cancer cells 
achieve different glycosylation profiles. For example, melanoma cancer cells have altered 
glycosylation profile compared to their healthy counterparts and a series of changes 
happens in their glycosylation profile during different progression stages. However, this 
alteration in glycosylation especially in cell surface glycosylation becomes stable at some 
progression stages and can be used as a biomarker to specifically recognize and target 
particular cancer cells (Hoja-Łukowicz, Link-Lenczowski et al. 2013). For example, the 
overexpression of a certain glycan on the surface of a type of cancer cells can targeted by a 
glycan binding agents such as lectin with affinity to this particular glycan (Rek, Krenn et 
al. 2009).  
In order to exploit the sialic acid binding property of mistletoe lectin in targeting cancer 
cells, a type of cancer can be targeted which has abundant sialic acid on their cell surface 
carbohydrates.  According to a study conducted by Hoja-Łukowicz, Link-Lenczowski et 
al. (2013) on N-linked glycans of L1 Cell Adhesion Molecule (L1CAM) of melanoma 
cancer cells, L1CAM of melanoma cells contains abundant amount of sialic acid branches 
especially on the cell surfaces. Therefore, a metastatic melanoma cell line (WM 266-4) 
was selected to be targeted by both MLB+GFP and SNA-B+GFP fusion proteins. 
Following the treatment of melanoma cells with an 0.3 μM of the fusion proteins, the 
binding of both fusion proteins to the cell surface glycans and their cell internalization was 
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successfully observed through performing florescence microscopy imaging using blue 
light (488nm) to excite the GFP fused to MLB and SNA-B (Figure 56, 57). 
The toxic side effects of conventional chemotherapeutic drugs on healthy tissues and 
organs has urged the need to discover alternative therapies for cancer treatment. To date, 
the immunococonjugates like monoclonal antibodies (mAbs) coupled with toxic agents 
like toxic drugs or radioisotopes have led to the development of approved therapies in 
many therapeutic areas especially anti-cancer treatment (Alley, Okeley et al. 2010). Many 
efforts are underway to increase the therapeutic benefit of cytotoxic agents and reduce 
their systematic toxicity which is the main limitation of their applications (Chari 2007). 
However, improvement is still needed to increase the curative potential of these conjugates 
because the potential of antibody–drug conjugates (ADCs) is still limited and it is not cost 
effective (Wu and Senter 2005).  
To increase the specificity of cytotoxic agents and also reduce their systematic side effects, 
recombinant fusion proteins can be produced by fusing cytotoxic peptides with known 
potential anti-cancer property to other peptides with the ability to be specifically directed 
to a specific site because of their affinity or recognition potential such as lectin affinity to 
glycans. For that, a less advanced technology and financial support needed because the 
production of fusion proteins is simple to engineer. Therefore, effective anti-cancer 
therapy with lower cost can be produced from fusion proteins since they can be produced 
via genetic engineering and using prokaryotic or eukaryotic expression systems such as the 
anti-ovarian cancer fusion protein produced by Qin, Zhou et al. (2016) from milk proteins 
and anti-solid tumours fusion protein produced by Niesen, Hehmann-Titt et al. (2016) 
from human serine protease granzyme B. 
The high level of selectivity of our fusion proteins makes the fusions to be more effective 
than the previous attempts in targeting cancer cells. Also, because the targeted moiety by 
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our fusion proteins is sialic acid and it is highly expressed on the surface of different type 
of cancer cells, the fusion proteins are not limited to target just one type of cancer cells but 
they can be used to target a range of cancer cells (Büll, Boltje et al. 2013, Büll, Stoel et al. 
2014). 
In conclusion, affinity purification was successfully carried out to purify MLB+GFP and 
SNA-B+GFP and sufficient amount of purified fusion proteins was achieved to conduct 
cellular experiments. The fusion proteins were confirmed to have ability to successfully 
bind to the surface of human melanoma cells and cross their membranes. 
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Chapter 5. Construction of a delivery system from MLB and its two putative sugar 
binding sites to specifically deliver cytotoxic peptides to human 
melanoma cells 
5.1 Introduction 
Lectin is a glycan binding moiety which has the ability to specifically attach to a certain 
glycan and can be used as a carrier vehicle to deliver other peptides to cancer cells through 
targeting cell surface glycans. Thus the binding chain of mistletoe lectin (MLB) was used 
to deliver a potent cytotoxic peptide to the surface of human melanoma cells.  
The therapeutic potential of two toxic peptides known as melittin and mastoparan from 
honey bee (Apis mellifera) and wasp venom (Vespula lewisii) respectively have been 
characterized for a long time but their application in biomedicine as a drug yet to be 
explored (Moreno and Giralt 2015). Many studies about whole bee and wasp venom have 
confirmed their anti-tumour activity and the same activity is expected from melittin and 
mastoparan as main components of these venoms (Gajski and Garaj-Vrhovac 2013, De 
Azevedo, Figueiredo et al. 2015).  
To date, the studies conducted on melittin as an anti-cancer agent have revealed that 
melittin has potential to inhibit tumour growth and induce apoptosis. The peptide was seen 
to mainly work on the disruption of phospholipid bilayers and disorder their function 
through forming tetramer aggregates. It also aggregates membrane proteins and induces 
hormone secretion (Ladokhin and White 1999). The disruption and disfunctioning of 
phospholipid bilayer by melittin consequently alters the cell enzymatic systems either 
directly or indirectly such as the alteration of protein kinase C and G-proteins (Fukushima, 
Kohno et al. 1998, Katoh 2002). Moreover, during in vivo tests and the treatments of 
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variety of cancer cells in vitro, antiproliferative and anti-angiogeneses activities of melittin 
were also demonstrated (Song, Lu et al. 2007, Yang, Zhu et al. 2014). 
Mastoparan also performs similar functions to melittin such as destabilization of 
membrane lipid bilayer which consequently causes membrane lysis and perturbing 
transmembrane signalling through interaction with G-proteins. Also, mastoparan is well-
known to interact with the mitochondria membrane and induce its permeability by which 
mastoparan mediates its cytotoxicity in tumour cells (Grześk, Malinowski et al. 2014, 
Yamamoto, Ito et al. 2014). 
However, the side effects of intravenous administration of both melittin and mastoparan 
such as hemolysis and liver injury have limited their direct application as a drug. In order 
to prevent or reduce these side effects, it is suggested to either shield the toxic peptides or 
attach them to a carrier molecule such as antibodies, targeting peptides, and synthesized 
carriers so as to keep the peptides inactive until they reach the target site and mediate their 
cytotoxicity (Dunn, Weston et al. 1996, Jin, Li et al. 2013). For example, Yamada, 
Shinohara et al. (2005) showed an effective method to encapsulate mastoparan in 
transferrin (Tf)-modified liposomes decorated with endosomolytic GALA peptides so as to 
reduce the side effect of mastoparan during targeting Tf receptor of tumour cells. 
 Regarding attaching the toxic peptides to carrier molecules, many studies have been 
conducted to produce fusion proteins from fusing melittin and mastoparan sequences to the 
sequence of other peptides. For example, a recombinant protein was produced from fusing 
the melittin oligonucleotide with a fragment of murine monoclonal K121 antibody (Dunn, 
Weston et al. 1996). As well as, the significant results have been achieved from pro-
cytotoxic systems produced from fusing mastoparan to a targeting peptide through 
biodegradable linkers such as matrix metallopeptidase 2 (MMP-2) and cathepsin B (CatB) 
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which are sensitive to the overexpressed tumour enzymes and allow spatiotemporal control 
to release the toxic peptides from the polymer on a target site (Moreno, Zurita et al. 2014). 
Thus we aim to produce a range of recombinant fusion proteins from fusing the coding 
sequence of melittin (MLT) and mastoparan (MP) to the coding sequence of the binding 
chain of mistletoe lectin (MLB) and its two putative sugar binding sites so as to be able to 
specifically deliver the cytotoxic peptides to the human melanoma cells through the sialic 
acid binding ability of MLB and exploit their anti-tumour property. 
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5.2 Material and Methods 
The Lectin-GFP fusion constructs showed binding and internalization activity. Therefore, 
two cytotoxic peptides were selected from literature to generate Lectin-Toxin fusion 
proteins (Huang, Jin et al. 2013, De Azevedo, Figueiredo et al. 2015). 
 
5.2.1 Conserved Domain Analysis  
The binding chain of mistletoe lectin (MLB) was analysed on NCBI conserved domain 
database and two separate glycan binding domains (1st domain and 2nd domain) were found 
as shown in figure 68. Therefore, fusion constructs were designed not only for the whole 
MLB chain fused to the toxin peptides but also each domain separately fused to the toxin 
peptides because one of these domains might be specifically responsible for the sialic acid 
binding property of MLB. 
 
5.2.2 Codon Optimization 
In order to change the sequence codons of the targeted genes to optimal codons for 
bacterial expression and efficiently express them in E. coli, codon optimization was 
performed to mistletoe lectin B-chain (MLB), melittin (MLT) and mastoparan (MAS) 
sequences using GeneOptimizer® facility (Invitrogen, UK) (Figure 72, 73, 74). 
 
5.2.3 Designing and Synthesis of Lectin-Toxin Fusions  
Different constructs were designed from mistletoe lectin B-chain (MLB) and its two 
separate glycan binding domains (1st and 2nd domains) using Snapgene software 
(Snapgene, USA). They were all C-terminally fused through a cathepsin-B (CatB) 
biodegradable linker peptide to two different toxin peptides namely melittin (MLT), a 
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toxin peptide consisting of 26 amino acids GIGAVLKVLTTGLPALISWIKRKRQQ, from 
honey bee (Apis mellifera) venom and mastoparan (MAS), a toxin peptide consisting of 14 
amino acids INLKALAALAKKIL, from wasp (Vespula vulgaris) venom (Huang, Jin et al. 
2013, De Azevedo, Figueiredo et al. 2015). A proline rich linker consist of nine proline 
(Pro) residues was also placed between the lectin sequence and the CatB linker so as to 
prevent the biodegradable linker to be covered by lectin during folding and to be easily 
cleaved by cell enzymatic activity. Finally, a (His)6 tag added to the end of C-terminus of 
each construct sequence for purification purpose. Two different restriction sites 
correspondent to the sites on the pGFPuv expression vector were also introduced to the `5 
and 3` primes of each construct as follow: HindIII and EcoRI sites were added respectively 
to the `5 and 3` primes of the constructs designed from 1st domain and 2nd domain of 
MLB fused to melittin; XbaI and EcoRI sites were added respectively to the `5 and 3` 
primes of the constructs designed from MLB fused to melittin and mastoparan, 1st 
domain, and 2nd domain fused to mastoparan. The designed constructs were synthesized 
by Genescript Company (Genescript, USA) and they were sent back as plasmid DNA in 
pUC18 vector as shown in figure 58, 59. 
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Figure 58. Cloned Lectin-Toxin fusion constructs (RED BAR) pUC18 cloning vector. The BLUE bar represents 1st 
Domain-Melittin fusion construct; The GREEN bar represents MLB-Melittin 1 fusion construct. The YELLOW bar 
represents Melittin sequence alone; The PINK bar represents 1st Domain-Mastoparan fusion construct; The BLACK and 
ORANGE arrows represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of pUC18 
vector. 
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Figure 59. Cloned Lectin-Toxin fusion constructs (RED BAR) pUC18 cloning vector. The BLUE bar represents 2nd 
Domain-Melittin fusion construct; The GREEN bar represents MLB-Mastoparan 1 fusion construct. The YELLOW bar 
represents Mastoparan sequence alone; The PINK bar represents 2nd Domain-Mastoparan fusion construct; The BLACK 
and ORANGE arrows represent the ampicillin resistant (AmpR) and signal of origin of replication (ori) sequences of 
pUC18 vector. 
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5.2.4 Restriction Digestion Analyses 
The pUC18 containing Lectin-Toxin constructs and the expression vector (pGFPuv) were 
both digested with appropriate restriction endonuclease enzymes (NEB, UK) so as to sub-
clone the fusion constructs from the cloning vector (pUC18) to the expression vector 
(pGFPuv). Briefly, 1µg of vector was added to different sterile tube containing 10 units of 
different restriction enzymes (HindIII, XbaI and EcoRI), 2µl Cut Smart buffer and made 
up to 20µl with sterile water. All tubes were incubated at 37°C for 1hr. After incubation, 
samples were run on a 1.5% agarose gel at voltage 100V with variable current. The gel 
was visualised and photographed by UV G-box transilluminator (Syngene, UK). 
 
5.2.5 Ligation of Lectin-Toxin Constructs into pGFPuv Vector 
Gel purified Lectin-Toxin fusions (Gel extraction kit, Promega, UK) from the restriction 
digest reactions were ligated in frame between HindIII, XbaI and EcoRI in the expression 
vector pGFPuv (Clontech, USA) using T4 ligase enzyme (Invitrogen, UK) following the 
manufacturers instruction (Figure 60, 61, 62, 63, 64, 65, 66, 67). The components of the 
ligation reaction table 15 were pipetted into a PCR tube and incubated at 16oC for 
overnight. 
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Figure 60. The sub-cloning map of MLB-Melittin 1 fusion construct from pUC18 cloning vector to pGFPuv expression 
vector. The DARK GREEN arrow represents the MLB-Melittin 1 construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. The sub-cloning map of MLB-Melittin 2 fusion construct from pUC18 cloning vector to pGFPuv expression 
vector. The BURGUNDY arrow represents MLB sequence and the YELLOW arrow represents melittin sequence. 
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Figure 62. The sub-cloning map of 1st Domain-Melittin fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The BLUE arrow represents the 1st Domain-Melittin construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. The sub-cloning map of 1st Domain-Mastoparan fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The PINK arrow represents the 1st Domain-Mastoparan construct. 
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Figure 64. The sub-cloning map of MLB-Mastoparan 1 fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The DARK GREEN arrow represents the MLB-Mastoparan 1 construct. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 65. The sub-cloning map of MLB-Mastoparan 2 fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The BURGUNDY arrow represents MLB sequence and the YELLOW arrow represents mastoparan 
sequence. 
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Figure 66. The sub-cloning map of 2nd Domain-Melittin fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The BLUE arrow represents the 2nd Domain-Melittin construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. The sub-cloning map of 2nd Domain-Mastoparan fusion construct from pUC18 cloning vector to pGFPuv 
expression vector. The PINK arrow represents the 2nd Domain-Mastoparan construct. 
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5.2.6 Transformation of E. coli Lemo21 (DE3) with pGFPuv Vector Containing 
Lectin-Toxin Fusions 
To overcome the difficulties in the expression of genes that encode membrane and toxic 
proteins, a new strain of BL21(DE3) Escherichia coli cell line has been constructed known 
as Lemo21(DE3) which has improved the control over gene expression from T7 promoter. 
All growth of E. coli was performed in LB broth (Luria low salt) medium (Sigma-Aldrich-
USA). Ampicillin (100 µg/µl) and chloramphenicol (30 µg/µl) antibiotics were used for 
the selection of transformants and to maintain pLemo gene encodes T7 lysozyme which is 
T7 RNA polymerase (RNAP). The LB broth agar was prepared from 15.5 g L-1 of LB and 
15 g L-1 agar (Fluka-Spain) and autoclaved for 15 minutes at 121oC. 
The E. coli strain was transformed with pGFPuv expression vector containing Lectin-
Toxin constructs using the heat shock method. The Lemo21(DE3) chemically competent 
cells and the ligation reaction products from section 5.2.5 were mixed and left on ice for 
30 minutes followed by heat shock for 10 seconds at 42°C. The cells were then incubated 
at 37 °C for 1 hour with 250rpm shaking to allow the expression of the ampicillin and 
chloramphenicol resistance genes in the vector. Transformed cells were selected by growth 
for 16 hours on LB broth agar containing 100 μg/mL ampicillin and 30 µg/µl 
chloramphenicol (Fisher, UK). The successfully transformed and grown cells were grown 
overnight in 5mL of liquid LB broth medium with 100 μg/mL ampicillin and 30 µg/µl 
chloramphenicol at 37 °C with shaking at 250 rpm. 
 
5.2.7 Plasmid DNA Purification 
Plasmids were isolated from bacterial cells using ISOLATE Plasmid Mini kit (BIOLINE, 
UK), according to manufacturer’s instructions shown in section 2.2.10. 
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5.2.8 Sequencing and Analytical Restriction Digestion 
After diagnostic restriction digest and confirming the right size insert in the purified 
plasmid DNA of all the Lectin-Toxin constructs, sequencing of the constructs was carried 
out by the Sanger sequencing facility of Source Bioscience Company (Source Bioscience-
UK). The standard M13 Reverse primer and PGEX Reverse were used for the sequencing 
reactions. The sequencing results were analysed through the alignment of the DNA 
sequences and there translated amino acids with the reference sequences using Snapgene 
(Snapgene, USA) and CLC Sequence Viewer softwares (Qiagen, UK). 
 
5.2.9 Expression of Recombinant Lectin-Toxins 
The recombinant expression vector pGFPuv (Clonthech, USA) was used to express the 
targeted Lectin-Toxin fusion constructs. The overnight culture was prepared for all the 
constructs as described in section 3.2.6 and 1ml from the culture was added to 100 ml 
liquid culture with ampicillin (100 µg/µl) and chloramphenicol (30 µg/µl) antibiotics and 
incubated at 30°C until OD600 reaches 0.4–0.8 followed by the induction through adding 
400 µM IPTG and incubation for 18 hours at 30°C. The expression level of the targeted 
genes in the total cell extracts was checked by InstantBlue Coomassie (Expedeon, UK) 
stained SDS PAGE. 
 
5.2.10 Recombinant Protein Purification 
Following the expression of Lectin-Toxin fusion proteins, culture supernatant was clarified 
by centrifugation and the E. coli cell pellets were gently resuspended and shaken in 
BugBuster reagent to disrupt the cell walls resulting in the liberation of soluble protein. To 
separate the protein of interest from the bulk of total other bacterial protein, a string of 
nucleotides encode six histidine amino acids can be added to the sequence of the protein to 
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be purified so as to conduct His-Tag metal ion purification procedure. The affinity of 
histidine to ions like Ni2+ and Co2+ makes the expressed gene construct to easily bind to 
matrix containing these ions and to be easily detached by using solution containing 
competing ions such as imidazole and EDTA (Hengen 1995). 
Immobilized metal ion affinity chromatography (IMAC) was conducted to purify targeted 
lectin-toxin fusions from the total extracted proteins using the prepacked HiTrap™ column 
and AKTA Start FPLC platform (GE Healthcare, UK). The relevant fractions were finally 
analysed by SDS-PAGE and western blotting. 
 
5.2.11 Protein Biochemistry 
5.2.11.1 Protein Concentration Assay  
The BCA protein assay kit was used to determine the concentration of the purified 
recombinant fusion proteins in microassay size as described in section 4.2.2.1. 
The fusion proteins sequences were also computationally analysed using ExPASy server 
(Gasteiger, Gattiker et al. 2003). The computed molecular weight and extinction 
coefficient of the fusion proteins are shown in table 18. 
Table 18. Computed parameters of Lectin-Toxin fusion proteins. 
 
 
 
Fusion Proteins    Molecular Weight (g/mol)    Extinction Coefficient M-1 cm-1 
   
MLB-Melittin 1 36028.9 66055 
MLB-Melittin 2 35329.1 66055 
MLB-Mastoparan 1 34661.4 60555 
MLB-Mastoparan 2 33609.1 60555 
1st Domain-Melittin 18309.9 33585 
1st Domain-Mastoparan 17840.3 28085 
2nd Domain-Melittin 17595.2 25230 
2nd Domain-Mastoparan 17125.6 19730 
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5.2.11.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SDS-PAGE of the protein samples was carried out using Tris-glycin buffer system under 
denaturing conditions as described in section 4.2.2.2.  
 
5.2.11.3 Western Blot 
Following separation of the denatured protein samples on SDS PAGE as described in 
section 4.2.2.2, the proteins were transferred to nitrocellulose membrane using semi dry 
blotting technique as described in section 4.2.2.3. The monoclonal Ani-His Antibody 
1:2,000 (Invitrogen, UK) that recognizes the His-tag fused to the C- terminus of the 
targeted proteins was used as a primary antibody and for the secondary antibody Goat IgG 
Anti-Mouse IgG-HRP conjugated secondary antibody 1:1000, (Sigma-Aldrich-UK) was 
used. Antibody binding was visualised using Pierce ECL substrate solution as described by 
the manufacturer (Thermofisher Scientific). The membrane was visualised and 
photographed by G-box transilluminator (Syngene, UK). 
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5’GATGATGTTACCTGTAGCGCAAGCGAACCGACCGTTCGTATTGTTGGTCGTAATGGTATGTGTGTTGATGTGCGT
GATGATGATTTTCATGATGGCAATCAGATTCAGCTGTGGCCGAGCAAAAGCAATAATGATCCGAACCAGCTGTGG
ACCATTAAACGTGATGGCACCATTCGTAGCAATGGTAGCTGTCTGACCACCTATGGTTATACCGCAGGCGTTTATG
TTATGATCTTTGATTGTAATACCGCAGTTCGTGAAGCAACCATTTGGCAGATTTGGGGTAATGGTACAATTATCAA
TCCGCGTAGCAATCTGGTTCTGGCAGCAAGCAGCGGTATTAAAGGCACCACCCTGACCGTTCAGACCCTGGATTAT
ACCCTGGGTCAGGGTTGGCTGGCAGGTAATGATACCGCACCGCGTGAAGTTACCATTTATGGTTTTCGTGATCTGT
GCATGGAAAGCAATGGTGGTAGCGTTTGGGTTGAAACCTGTGTTAGCAGCCAGCAGAATCAGCGTTGGGCACTG
TATGGTGATGGTAGCATTCGTCCGAAACAGAATCAGGATCAGTGTCTGACCTGTGGTCGTGATAGCGTTAGCACC
GTTATTAACATTGTTAGCTGCAGCGCAGGTAGCAGCGGTCAGCGCTGGGTTTTTACCAATGAAGGTGCAATTCTG
AACCTGAAAAATGGTCTGGCAATGGATGTTGCACAGGCAAATCCGAAACTGCGTCGTATTATCATTTATCCGGCAA
CCGGTAAACCGAATCAGATGTGGCTGCCGGTTCCG3’ 
5.3 Results 
Following the confirmation of cellular binding and visualization of cellular internalization 
of the mistletoe lectin-GFP fusion proteins, a reductionist approach was taken to determine 
the minimal number of glycan binding domains in the MLB chain needed to retain 
biological activity. Furthermore, GFP was replaced in the fusion protein with a known 
cytotoxic peptide and fusion proteins expressed to achieve a toxic moiety to cancer cells. 
5.3.1 Conserved Domain Analysis 
Conserved domain analysis was carried out for the MLB sequence using NCBI Conserved 
Domain Database. The analysis revealed that the MLB sequence consists of two separate 
ricin type beta-trefoil glycan binding sites shown in figure 68 and the biological activity of 
both domains were also studied separately. In order to easily differentiate and recognize 
the domains in this study, the names 1st Domain and 2nd Domain have been given to the 
first and second glycan binding sites respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68. The conserved domain analysis of the full sequence of the glycan binding chain (MLB) of mistletoe lectin. 
The 1st Domain sequence is in blue and the 2nd Domain sequence is in brown. 
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5.3.2 Codon Optimization 
Protein production through heterologous gene expression often faces difficulties because 
of inefficient level of transcription and translation of a particular coding sequence placed 
in a non-native context. The main reason is that the tRNA pools are different between 
organisms and to overcome this problem the codons of a heterologous gene can be 
optimized for tRNA pools in a specific host. The sequence of MLB, melittin and 
mastoparan were optimized to E. coli tRNA pools so as to increase their expression and 
differences between the original sequences and the optimized sequences are shown in 
figure 69, 70, 71. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69. Alignment of reference MLB chain sequence (NCBI: AY377890.1) with the optimized MLB chain. The 
matched nucleotides are in BLACK; the mismatched (Optimized) nucleotides are in RED and also indicated as gap in the 
plot bar.  
 
 
5’ 
5’ 
3’ 
3’ 
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Figure 70. Alignment of reference Melittin sequence (NCBI: AY745248.1) with the optimized Melittin sequence. The 
matched nucleotides are in BLACK; the mismatched (Optimized) nucleotides are in RED and also indicated as gap in the 
plot bar. 
 
 
 
 
 
Figure 71. Alignment of reference Mastoparan sequence (NCBI: DQ865260.1) with the optimized Mastoparan 
sequence. The matched nucleotides are in BLACK; the mismatched (Optimized) nucleotides are in RED and also 
indicated as gap in the plot bar. 
 
It can clearly be seen in the figures that many of the nucleic acids in the sequences have 
been changed so as to give them better consistency which consequently improve the 
expression of the genes in E. coli. Also, codon optimization reduces the number of codon 
class and makes the sequence codons to fall into a certain quality class. Figure 72, 73, 74 
show the codon quality distribution of MLB, melittin and mastoparan respectively before 
and after codon optimization. In the unoptimized sequences, the codons are distributed to 
several class (Figure 72, 73, 74 A). However, in the unoptimized sequences majority of the 
codons belongs to one class (Figure 72, 73, 74 B) which helps successful expression in E. 
coli (Sharp and Li 1987). 
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Figure72. Histograms show the percentage of unoptimized and optimized sequence codons of MLB which fall into a 
certain quality class. The quality value of the most frequently used codon for a given amino acid in the desired 
expression system is set to 100, the remaining codons are scaled accordingly. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure73. Histograms show the percentage of unoptimized and optimized sequence codons of melittin (ML) which fall 
into a certain quality class. The quality value of the most frequently used codon for a given amino acid in the desired 
expression system is set to 100, the remaining codons are scaled accordingly. 
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Figure74. Histograms show the percentage of unoptimized and optimized sequence codons of mastoparan (Mas) which 
fall into a certain quality class. The quality value of the most frequently used codon for a given amino acid in the desired 
expression system is set to 100, the remaining codons are scaled accordingly. 
 
5.3.3 Lectin-Toxin Fusion Proteins  
To assess the suitability of mistletoe lectin B chain (MLB) to be used as a ‘carrier’ to 
deliver cytotoxic agents specifically to cancer cells, recombinant fusion proteins were 
designed from MLB and its two glycan binding domains C- terminally fused to two 
different toxin peptides derived from Apis mellifera (Honey bee) and Vespula vulgaris 
(Wasp). 
 
Due to the large number of Lectin-Toxin fusion proteins produced and large amount of 
data generated, Table 19 summarises the name and composition of the fusion proteins. 
 
 
 
 
 
 
 162 
 
Table 19. Names and summary of the fusion proteins produced from MLB and the toxin peptides. 
Fusion Proteins Linker                          Detail 
MLB-Melittin 1     No Linker The whole MLB chain fused to Melittin 
MLB-Melittin 2                                        CatB The whole MLB chain fused to Melittin 
MLB-Mastoparan 1                                No Linker The whole MLB chain fused to Mastoparan 
MLB-Mastoparan 2                                CatB The whole MLB chain fused to Mastoparan 
1st Domain-Melittin                                                                                                                                            CatB The 1st glycan binding domain of MLB chain fused 
to Melittin 
1st Domain-Mastoparan                         
                  
CatB The 1st glycan binding domain of MLB chain fused 
to Mastoparan 
2nd Domain-Melittin                               
                   
CatB The 2nd glycan binding domain of MLB chain fused 
to Melittin 
2nd Domain-Mastoparan                        
                 
CatB The 2nd glycan binding domain of MLB chain fused 
to Mastoparan 
 
 
 
5.3.3.1 Production of the MLB-Melittin and MLB-Mastoparan Fusion Proteins 
Expression Constructs 
Expression constructs for four MLB-Toxin fusion proteins (designated MLB-Melittin 1, 
MLB-Melittin 2, MLB-Mastoparan 1 and MLB-Mastoparan 2) were designed and 
produced by the cloning strategy described in section 5.2.5  
The MLB-Melittin 1 construct contains MLB C-terminally fused to Melittin toxin peptide 
(GIGAVLKVLTTGLPALISWIKRKRQQ) via a cathepsin-B (CatB) (GIPVSLRSK) 
biodegradable linker. The MLB-Melittin 2 construct contains MLB C-terminally fused to 
Melittin toxin peptide without cathepsin-B (CatB) biodegradable linker. The MLB-
Mastoparan 1 construct contains MLB C-terminally fused to Mastoprant toxin peptide 
(INLKALAALAKKIL) via a cathepsin-B (CatB) (GIPVSLRSK) biodegradable linker. 
The MLB-Mastoparan 2 construct contains MLB C-terminally fused to Mastoprant toxin 
peptide without cathepsin-B (CatB) biodegradable linker. All the expression constructs 
also had a C-terminal extension encoding a (His)6 tag. The complete expression constructs 
of the four fusion proteins were cloned in-frame with the start codon (ATG) within the 
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pGFPuv expression vector. The nucleotide, translated amino acid sequences and schematic 
diagrams of the expression constructs are shown in figures 75, 76, 77, 78. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure75. Nucleotide sequence, deduced amino acid sequence and schematic representation of the MLB-Melittin 1 
fusion protein construct. The gene encoding MLB is highlighted in GREEN (bp 265-1053). The poly-L-proline-rich 
linker is highlighted in BLUE (bp 1054-1080). The cathepsin-B (CatB) biodegradable linker is highlighted in ORANGE 
(bp 1081-1107). The gene encoding Melittin is highlighted in YELLOW (bp 1108-1185). The (His)6 tag is highlighted in 
BLACK (bp 1186-2204). The stop codon is highlighted in a red star. 
 
 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure76. Nucleotide sequence, deduced amino acid sequence and schematic representation of the MLB-Melittin 2 
fusion protein construct. The gene encoding MLB is highlighted in Green (bp 265-1053). The poly-L-proline-rich linker 
is highlighted in BLUE (bp 1054-1080). The gene encoding Melittin is highlighted in YELLOW (bp 1081-1158). The 
(His)6 tag is highlighted in BLACK (bp 1159-1176). The stop codon is highlighted in a red star. 
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Figure77. Nucleotide sequence, deduced amino acid sequence and schematic representation of the MLB-Mastoparan 1 
fusion protein construct. The gene encoding MLB is highlighted in GREEN (bp 265-1053). The poly-L-proline-rich 
linker is highlighted in BLUE (bp 1054-1080). The cathepsin-B (CatB) biodegradable linker is highlighted in ORANGE 
(bp 1081-1107). The gene encoding Mastoparan is highlighted in YELLOW (bp 1108-1149). The (His)6 tag is 
highlighted in BLACK (bp 1150-1167). The stop codon is highlighted in a red star. 
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Figure78. Nucleotide sequence, deduced amino acid sequence and schematic representation of the MLB-Mastoparan 2 
fusion protein construct. The gene encoding MLB is highlighted in GREEN (bp 265-1053). The poly-L-proline-rich 
linker is highlighted in BLUE (bp 1054-1080). The gene encoding Mastoparan is highlighted in YELLOW (bp 1081-
1122). The (His)6 tag is highlighted in BLACK (bp 1123-1140). The stop codon is highlighted in a red star. 
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5.3.3.2 Glycan Binding Domains -Toxin Fusion Proteins 
In order to explore which domain is responsible for the sialic acid binding ability of MLB 
chain, fusion proteins were also designed for the two glycan binding domains (1st & 2nd 
Domains) separately. 
 
5.3.4.2.1 Production of the 1st Domain-Melittin and 1st Domain-Mastoparan Fusion 
Proteins Expression Constructs 
Expression constructs for two 1st Domain-Toxin fusion proteins (designated 1st Domain-
Melittin and 1st Domain-Mastoparan) were designed and produced by the cloning strategy 
described in section 5.2.5.  
The 1st Domain-Melittin construct contains 1st Domain C-terminally fused to Melittin 
toxin (GIGAVLKVLTTGLPALISWIKRKRQQ) via a cathepsin-B (CatB) (GIPVSLRSK) 
biodegradable linker. The 1st Domain-Mastoparan construct contains 1st Domain C-
terminally fused to Mastoparan toxin (INLKALAALAKKIL) via cathepsin-B (CatB) 
(GIPVSLRSK) biodegradable linker. Both expression constructs also had a C-terminal 
extension encoding a (His)6 tag. The complete expression constructs of the four fusion 
proteins were cloned in-frame with the start codon (ATG) within the pGFPuv expression 
vector. The nucleotide, translated amino acid sequences and schematic diagrams of the 
expression constructs are shown in figures 79, 80. 
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Figure79. Nucleotide sequence, deduced amino acid sequence and schematic representation of the 1st Domain-Melittin 
fusion protein construct. The gene encoding 1st Domain of MLB is highlighted in GREEN (bp 241-564). The poly-L-
proline-rich linker is highlighted in BLUE (bp 565-591). The cathepsin-B (CatB) biodegradable linker is highlighted in 
ORANGE (bp 592-618). The gene encoding Melittin is highlighted in YELLOW (bp 619-696). The (His)6 tag is 
highlighted in BLACK (bp 697-714). The stop codon is highlighted in a red star. 
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Figure80. Nucleotide sequence, deduced amino acid sequence and schematic representation of the 1st Domain-
Mastoparan fusion protein construct. The gene encoding 1st Domain of MLB is highlighted in GREEN (bp 265-588). The 
poly-L-proline-rich linker is highlighted in BLUE (bp 589-615). The cathepsin-B (CatB) biodegradable linker is 
highlighted in ORANGE (bp 616-642). The gene encoding Mastoparan is highlighted in YELLOW (bp 643-684). The 
(His)6 tag is highlighted in BLACK (bp 685-702). The stop codon is highlighted in a red star. 
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5.3.4.2.2 Production of the 2nd Domain-Melittin and 2nd Domain-Mastoparan 
Fusion Proteins Expression Constructs 
Expression constructs for two 2nd Domain fusion proteins (designated 2nd Domain-Melittin 
and 2nd Domain-Mastoparan) were designed and produced by the cloning strategy 
described in section 5.2.5.  
The 2nd Domain-Melittin construct contains 2nd Domain C-terminally fused to Melittin 
toxin (GIGAVLKVLTTGLPALISWIKRKRQQ) via a cathepsin-B (CatB) (GIPVSLRSK) 
biodegradable linker. The 2nd Domain-Mastoparan construct contains 1st Domain C-
terminally fused to Mastoparan toxin (INLKALAALAKKIL) via cathepsin-B (CatB) 
(GIPVSLRSK) biodegradable linker. Both expression constructs also had a C-terminal 
extension encoding a (His)6 tag. The complete expression constructs of the four fusion 
proteins were cloned in-frame with the start codon (ATG) within the pGFPuv expression 
vector. The nucleotide, translated amino acid sequences and schematic diagrams of the 
expression constructs are shown in figures 81, 82. 
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Figure81. Nucleotide sequence, deduced amino acid sequence and schematic representation of the 2nd Domain-Melittin 
fusion protein construct. The gene encoding 2nd Domain of MLB is highlighted in GREEN (bp 241-552). The poly-L-
proline-rich linker is highlighted in BLUE (bp 553-579). The cathepsin-B (CatB) biodegradable linker is highlighted in 
ORANGE (bp 580-606). The gene encoding Melittin is highlighted in YELLOW (bp 607-684). The (His)6 tag is 
highlighted in BLACK (bp 685-702). The stop codon is highlighted in a red star. 
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Figure82. Nucleotide sequence, deduced amino acid sequence and schematic representation of the 2nd Domain-
Mastoparan fusion protein construct. The gene encoding 2nd Domain of MLB is highlighted in GREEN (bp 265-576). 
The poly-L-proline-rich linker is highlighted in BLUE (bp 577-603). The cathepsin-B (CatB) biodegradable linker is 
highlighted in ORANGE (bp 604-630). The gene encoding Mastoparan is highlighted in YELLOW (bp 631-672). The 
(His)6 tag is highlighted in BLACK (bp 673-690). The stop codon is highlighted in a red star. 
 
 
After successful transformation of Lemo21(DE3) E. coli cells with the pGFPuv expression 
vector containing Lectin-Toxin fusions, diagnostic restriction digest was performed to the 
plasmid DNA extracted from overnight grown cultures with appropriate restriction 
enzymes to confirm the existence of the targeted fusion constructs in the expression vector 
(Figure 83, 84). 
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Figure 83. Restriction digest of pGFPuv plasmid to confirm the presence of Lectin-Toxin inserts. Lane 1: HyperLadder I 
(Bioline, UK); Lanes 3,5,7 and 9: the restriction digests of MLB-Melittin 2, MLB-Melittin 1, 1st Domain-Melittin and 1st 
Domain-Mastoparan fusion constructs respectively; Lanes 2, 4, 6 and 8: the undigested negative controls. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84. Restriction digest of pGFPuv plasmid to confirm the presence of Lectin-Toxin inserts. Lane 1: HyperLadder I 
(Bioline, UK); Lanes 3,5,7 and 9: the restriction digests of MLB-Mastoparan 2, MLB-Mastoparan 1, 2nd Domain-
Melittin and 2nd Domain-Mastoparan fusion constructs respectively; Lanes 2, 4, 6 and 8: the undigested negative 
controls. 
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The sequence of the Lectin-Toxin constructs in the pGFPuv expression vector was 
confirmed through sequencing reactions. The partial results are shown in figure 85-92 and 
the full results are shown in appendix 4.    
 
 
 
 
 
 
 
 
Figure 85. Chromatogram showing the sequence quality of MLB-Melittin 1 fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
 
 
Figure 86. Chromatogram showing the sequence quality of MLB-Melittin 2 fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
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Figure 87. Chromatogram showing the sequence quality of 1st Domain-Melittin fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
 
Figure 88. Chromatogram showing the sequence quality of 1st Domain-Mastoparan fusion construct (Partial sequence 
data shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 89. Chromatogram showing the sequence quality of MLB-Mastoparan 1 fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
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Figure 90. Chromatogram showing the sequence quality of MLB-Mastoparan 2 fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 91. Chromatogram showing the sequence quality of 2nd Domain-Melittin fusion construct (Partial sequence data 
shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 92. Chromatogram showing the sequence quality of 2nd Domain-Mastoparan fusion construct (Partial sequence 
data shown). The selected region is representative of overall sequencing quality and the full sequencing result is shown in 
appendix 4. The Adenine (A), Guanine (G), Cytosine (C) and Thymine (T) codons are in green, black, blue and red 
colours respectively. 
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5.3.5 Recombinant Expression of the Fusion Proteins 
The confirmation of the correct size and the sequence confirmation of the Lectin-Toxin 
constructs gave an indication that the constructs were reliable enough to go on for protein 
expression. To alleviate growth inhibitory effects from the toxic genes in the fusion 
constructs and formation of inclusion bodies during the expression, Lemo21 (DE3) E.coli 
cells were used in which has tunable T7 polymerase that allows an efficient expression of 
difficult clones especially toxic and membrane proteins. 
All the fusion constructs were expressed successfully and the total harvested proteins from 
each set of culture was analysed on 12% SDS-PAGE gel and the expected bands of the 
constructs were detected on the gels. Western blotting analysis was also used to identify 
clones expressing the fusion proteins using anti-His primary antibodies. The antibody 
successfully bound to all the fusion protein bands transferred to the nitrocellulose 
membrane and strong signals were detected from chemiluminescent substrate (Figure 93). 
 
  
 
 
Figure 93. Western blot of Lectin-Toxin fusions proteins using Anti-His(C-term) primary antibody (ThermoFisher, UK) 
and goat anti-mouse IgG secondary antibody (Sigma, UK). Lane 1: MLB+Melittin 1 fusion; Lane 2: MLB+Melittin 2 
fusion; Lane 3: MLB+Mastoparan 1 fusion; Lane 4: MLB+Mastoparan 2 fusion; Lane 5: 1st Domain-Melittin fusion; 
Lane 6: 1st Domain-Mastoparan fusion; Lane 7: 2nd Domain-Melittin fusion; Lane 8: 2nd Domain-Mastoparan fusion. 
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Figure 94. Cloned MLB chain C-terminally fused to melittin toxin peptide through cathepsin B biodegradable linker 
(CatB) in the pGFPuv expression vector. The green, orange and yellow parts of the first arrow represent MLB, CatB and 
melittin sequences respectively; The light green and yellow arrows represent the ampicillin resistant (AmpR) and signal 
of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 95. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed MLB fused to melittin through cathepsin B 
linker. Lane 1: Protein marker; Lane 2: Uninduced MLB-Melittin 1 fusion; Lane 3: Induced MLB-Melittin 1 fusion; 
Lane 4: Purified MLB-Melittin 1 fusion (~36kDa). 
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Figure 96. Cloned MLB chain C-terminally fused to melittin toxin peptide without cathepsin B biodegradable linker 
(CatB) in the pGFPuv expression vector. The green and yellow parts of the first arrow represent MLB and melittin 
sequences respectively; The light green and yellow arrows represent the ampicillin resistant (AmpR) and signal of origin 
of replication (ori) sequences of pGFPuv vector. 
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Figure 97. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed MLB fused to melittin without cathepsin B 
linker. Lane 1: Protein marker; Lane 2: Uninduced MLB-Melittin 2 fusion; Lane 3: Induced MLB-Melittin 2 fusion; 
Lane 4: Purified MLB-Melittin 2 fusion (~36kDa). 
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Figure 98. Cloned MLB chain C-terminally fused to mastoparan toxin peptide through cathepsin B biodegradable linker 
(CatB) in the pGFPuv expression vector. The green, orange and yellow parts of the first arrow represent MLB, CatB and 
mastoparan sequences respectively; The light green and yellow arrows represent the ampicillin resistant (AmpR) and 
signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 99. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed MLB fused to mastoparan through 
cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced MLB-Mastoparan 1 fusion; Lane 3: Induced MLB-
Mastoparan 1 fusion; Lane 4: Purified MLB-Mastoparan 1 fusion (~35kDa). 
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Figure 100. Cloned MLB chain C-terminally fused to mastoparan toxin peptide without cathepsin B biodegradable 
linker (CatB) in the pGFPuv expression vector. The green and yellow parts of the first arrow represent MLB and 
mastoparan sequences respectively; The light green and yellow arrows represent the ampicillin resistant (AmpR) and 
signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 101. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed MLB fused to mastoparan without 
cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced MLB-Mastoparan 2 fusion; Lane 3: Induced MLB-
Mastoparan 2 fusion; Lane 4: Purified MLB-Mastoparan 2 fusion (~35kDa). 
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Figure 102. Cloned 1st domain of MLB chain C-terminally fused to melittin toxin peptide through cathepsin B 
biodegradable linker (CatB) in the pGFPuv expression vector. The green, orange and yellow parts of the first arrow 
represent MLB, CatB and melittin sequences respectively; The light green and yellow arrows represent the ampicillin 
resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 103. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed 1st domain of MLB fused to melittin 
through cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced 1st Domain-Melittin fusion; Lane 3: Induced 1st 
Domain-Melittin fusion; Lane 4: Purified 1st Domain-Melittin fusion (~19kDa). 
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Figure 104. Cloned 1st domain of MLB chain C-terminally fused to mastoparan toxin peptide without cathepsin B 
biodegradable linker (CatB) in the pGFPuv expression vector. The green and yellow parts of the first arrow represent 
MLB and mastoparan sequences respectively; The light green and yellow arrows represent the ampicillin resistant 
(AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 105. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed 1st domain of MLB fused to mastoparan 
through cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced 1st Domain-Mastoparan fusion; Lane 3: Induced 
1st Domain-Mastoparan fusion; Lane 4: Purified 1st Domain-Mastoparan fusion (~18kDa). 
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Figure 106. Cloned 2nd domain of MLB chain C-terminally fused to melittin toxin peptide through cathepsin B 
biodegradable linker (CatB) in the pGFPuv expression vector. The green, orange and yellow parts of the first arrow 
represent MLB, CatB and melittin sequences respectively; The light green and yellow arrows represent the ampicillin 
resistant (AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 107. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed 2nd domain of MLB fused to melittin 
through cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced 2nd Domain-Melittin fusion; Lane 3: Induced 2nd 
Domain-Melittin fusion; Lane 4: Purified 2nd Domain-Melittin fusion (~18kDa). 
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Figure 108. Cloned 2nd domain of MLB chain C-terminally fused to mastoparan toxin peptide without cathepsin B 
biodegradable linker (CatB) in the pGFPuv expression vector. The green and yellow parts of the first arrow represent 
MLB and mastoparan sequences respectively; The light green and yellow arrows represent the ampicillin resistant 
(AmpR) and signal of origin of replication (ori) sequences of pGFPuv vector. 
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Figure 109. SDS PAGE stained with InstantBlue (Expedeon,UK) of expressed 2nd domain of MLB fused to mastoparan 
through cathepsin B linker. Lane 1: Protein marker; Lane 2: Uninduced 2nd Domain-Mastoparan fusion; Lane 3: Induced 
2nd Domain-Mastoparan fusion; Lane 4: Purified 2nd Domain-Mastoparan fusion (~18kDa). 
 
 
All the recombinant fusion proteins were purified from culture supernatant by immobilized 
nickel ion affinity chromatography utilising the added (His)6 tag. A typical elution profile 
of purifications by nickel affinity chromatography is shown in figures 110. 
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Figure 110. Typical purification profile of nickel affinity column purification of the fusion proteins tagged with (His)6 
tag. The gradient elution fractions are (E) (~13ml) and the purified MLB-Melittin 1 fraction is pointed with a red arrow.  
 
From the amino acid sequences, the predicted sizes of MLB-Melittin 1, MLB-Melittin 2, 
MLB-Mastoparan 1, MLB-Mastoparan 2, 1st Domain-Melittin, 1st Domain-Mastoparan, 
2nd Domain-Melittin and 2nd Domain-Mastoparan are 36.0kDa, 35.3kDa, 34.7kDa, 
34.0kDa, 18.3kDa, 17.8kDa, 17.6kDa and 17.3kDa respectively. The protein expression 
was successfully performed and the presence of all the fusion constructs was confirmed by 
sodium dodecyl sulphate gel electrophoresis (SDS-PAGE) and western blotting using anti-
His primary antibodies  
 
Thus, we demonstrate recombinant expression of cytotoxic peptides fused to full length 
MLB or 1st and 2nd domain truncations of MLB. 
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5.4 Discussion 
This study presents the experiments carried out with the aim of producing fusion 
conjugates using the binding chain of mistletoe lectin (MLB) and the toxic peptides 
melittin and mastoparan. 
Following confirming the ability of MLB+GFP fusion protein to successfully bind to 
human melanoma cancer cells, further experiments were carried out to exploit this ability 
to deliver different cytotoxic peptides specifically to cancer cells. Since MLB has a long 
coding sequence of 789bp which is not a desired feature in peptides to be used in drug 
design, the sequence was further analysed through bioinformatics to identify any possible 
truncations that could be performed (Torchilin 2008). The analysis revealed that the 
sequence comprised of two very similar putative sugar binding domains with Q-X-W 
motif and they are both very similar to the domains of the binding site of ricin lectin 
(Figure 69). Therefore, a range of Lectin-Toxin conjugates were designed not only from 
the whole MLB but also from the putative sugar binding domains separately because it 
was believed that one of the domains might be responsible for the sialic acid binding 
activity and could be as active as the whole MLB in binding to cancer cells. 
In order to efficiently express the fusion proteins in E. coli and avoid the difficulties of 
heterologous gene expression, the sequences of MLB, melittin and mastoparan were 
optimized to E. coli tRNA pools through optimizing majority of their nucleotides and 
better nucleic acid consistency was achieved (Figure 72, 73, 74) which potentially 
improved the expression of the recombinant constructs and was previously suggested by 
Nørholm, Toddo et al. (2013) that high-level of expression can be achieved for membrane 
proteins expressed in E. coli through codon optimization. The codon optimization thus 
helped to successfully express soluble fractions of the fusion proteins, despite a high level 
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of toxicity of the cytotoxic peptides in the fusion constructs which was previously shown 
to cause insolubility in the production of fusion proteins (Peng, Hong et al. 2012, 
Buhrman, Rayahin et al. 2013).   
Despite the demonstrated role of mistletoe lectin in the Lectin-Toxin conjugates as a 
recognition molecule to specifically recognize cancer cells and avoid healthy cells, further 
specificity of the conjugates toward cancer cells was attempted through placing a 
biodegradable linker between the binding chains and the cytotoxic peptides. Cathepsine-B 
(Cat-B) linker was thus chosen to link lectin peptides with the toxic peptides because this 
linker can be cleaved by cathepsin-B enzyme which is overexpressed in human melanoma 
cancer cells especially metastatic melanoma according to Matarrese, Ascione et al. (2010). 
In addition of its main function as a biodegradable linker, Cat-B also keeps melittin and 
mastoparan attached to MLB in inactive form until they reach the target site by which 
reduces the side effects of the toxic peptides since the active form of melittin and 
mastoparan was shown by Huang, Jin et al. (2013) and Kim, Son et al. (2016) respectively 
to cause strong haemolysis in the body and to avoid this side effect as suggested by 
Moreno and Giralt (2015) to utilise toxic peptides in recombinant fusion proteins.  
Therefore, two sets of recombinant fusion proteins were produced. In the first set, MLB-
Melittin 1 and MLB-Mastoparan 1 fusion proteins (Figure 75, 77) were produced based on 
the whole sequence of MLB fused to melittin and mastoparan respectively through a Cat-B 
linker. Also, two more fusion proteins (MLB-Melittin 2 and MLB-Mastoparan 2) similar 
to the previous ones were designed but without Cat-B linker (Figure 76, 78) so as to 
evaluate the role of Cat-B linker in the conjugates. 
The second set of recombinant fusion proteins was produced based on the two putative 
sugar binding domains of MLB (1st Domain and 2nd Domain). Two conjugates (1st 
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Domain-Melittin and 1st Domain-Mastoparan) were designed from fusing the 1st Domain 
of MLB to melittin and mastoparan respectively through a Cat-B linker (Figure 79, 80). 
Another two conjugates (2nd Domain-Melittin and 2nd Domain-Mastoparan) were 
designed from fusing the 2nd Domain of MLB to melittin and mastoparan respectively 
through a Cat-B linker (Figure 81, 82). While Cat-B linker keeps the toxic peptides 
inactive until the conjugate binds to melanoma cells, the overexpressed Cat-B enzyme on 
the cancer cells was supposed to cleave the linker and releases the toxic peptides from the 
conjugates and trigger their cytotoxicity as a similar experiment was previously 
demonstrated by Moreno and Giralt (2015). 
All the recombinant conjugates were successfully cloned into pGFPuv expression vector 
with a (His)6 tag and the correct size of the cloned constructs was confirmed by restriction 
digest reactions with appropriate enzymes (Figure 83, 84). Sequencing reaction results also 
confirmed the complete sequences of all the conjugates without any mutation and gaps 
(Figure 85-92). 
To express toxic peptides like melittin and mastoparan in E. coli cells, a specific cell line 
has to be selected which has potential to express toxic genes because the cytotoxicity of 
the expressed peptides might inhibit the proliferation of the bacterial cells and halt the 
expression process. Therefore, Lemo21(DE3) was selected which is a derivative of 
BL21(DE3) and highly suggested for the expression of toxic and membrane proteins 
(Schlegel, Löfblom et al. 2012). 
The lectin-toxin conjugates were successfully expressed and purified through immobilized 
metal affinity chromatography (IMAC). The induced, uninduced and purified products of 
the conjugates were then analysed by SDS PAGE. The predicted size bands of the 
conjugates made from the whole MLB sequence fused to melittin and mastoparan which 
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are MLB-Melittin 1 (36.04kD), MLB-Melittin 2 (35.34), MLB-Mastoparan 1 (34.67kD), 
MLB-Mastoparan 2 (33.97kD) were successfully detected on SDS gels as shown in figure 
95, 97, 99, 101. 
Also, the correct size bands of the conjugates made from 1st Domain of MLB fused to 
melittin and mastoparan named as 1st Domain-Melittin (18.31kD) and 1st Domain-
Mastoparan (17.84kD) and the conjugates made from 2nd Domain of MLB fused to 
melittin and mastoparan named as 2nd Domain-Melittin (17.60kD) and 2nd Domain-
Mastoparan (17.30kD) were successfully detected (Figure 103, 105, 107, 109). However, 
all the constructs made from 1st and 2nd domains of MLB showed slightly (~3kD) bigger 
size bands on the SDS gels which may be due to “Gel shifting”. The main reason of gel 
shifting observations is believed to be the tertiary structure of the expressed proteins which 
affects the level of detergent-loading on protein and consequently affects the migration 
rates of polypeptide on SDS-PAGE and this result agree with Rath, Glibowicka et al. 
(2009). 
Western blotting reactions of Lectin-Toxin conjugates confirmed the identity of the 
conjugates since correct bands were detected for all the fusion proteins transferred to 
nitrocellulose membranes and treated with Anti-His primary antibody (Figure 93). 
In conclusion, two sets of fusion proteins were successfully designed from the whole MLB 
chain and its two putative sugar binding sites (1st Domain and 2nd Domain) fused to 
melittin and mastoparan toxic peptides. The fusion proteins were successfully expressed 
and purified for further cell experiments.  
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Chapter 6. Cellular cytotoxicity of Lectin-Toxin Fusion Proteins 
 
6.1 Introduction 
The specific biological activities of some peptides have given them potential to be used as 
therapeutic agents especially in cancer biomedicine. Research to produce effective drugs 
from these peptides are at different stages of progression for examples the lanreotide 
peptide, a synthetic analogue of Somatostatin which is a naturally occurring inhibitory 
hormone which blocks the release of several other hormones, is at clinical stage for the 
treatment of gastrointestinal tumours but there are many other peptides under investigation 
such as depsipeptides found in microorganisms and have recently been characterized as 
potent anticancer agents (Pokuri, Fong et al. 2016, Serrill, Wan et al. 2016). 
To improve the efficiency of chemotherapies, the main recent focus has been on the 
identification of appropriate carrier vehicles to incorporate with the existence 
chemotherapies so as to alter their pharmacokinetics and/or attach the chemotherapies to 
targeting moieties to shift their pharmacodynamics (Kurrikoff and Suhorut 2012). The 
effective way to perform these improvements is the attachment of the drugs to a tumour 
specific moiety such as receptor ligand, monoclonal antibodies and targeting peptide. 
However, a large-scale screening also needs be conducted to identify an appropriate 
moiety. For example, extensive screening of peptide libraries is needed to characterize an 
efficient targeting peptide with selectivity only to cancer cells (Pasqualini, Koivunen et al. 
1997).  
While the combination of drugs and targeting vehicles often faces difficulties in 
penetrating tumours to reach their interior, cell internalization capacity also needs to be 
added to the drug targeting moiety through adding other molecules with the ability to cross 
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cells membranes such as cell penetrating peptides (CPPs) (Essler and Ruoslahti 2002, 
Myrberg, Zhang et al. 2007). 
The binding chain of mistletoe lectin (MLB) has ability to bind to specific cell surface 
oligosaccharides containing sialic acid and has been shown to be internalised by the cells. 
Therefore, MLB can be used as a carrier vehicle to deliver therapeutic agents like 
cytotoxic peptides specifically to cancer cells which have sialic acid on their cells surface 
oligosaccharides (Lyu, Kwon et al. 2004). 
The aim of this study is the in vitro assessment of the ability of the recombinant fusion 
proteins produced from melittin and mastoparan cytotoxic peptides fused to the binding 
chain of mistletoe lectin (MLB), and to truncated peptides containing its two putative 
sugar binding site, to specifically recognize and bind to the human melanoma cells at the 
primary and metastatic progression stages and also to assess their selectivity to avoid 
binding the healthy melanocyte cells and eliminate them from their cytotoxic effects. 
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6.2 Material and Methods 
6.2.1 Cell Culture 
Two human melanoma cell lines at two different stages of cancer development (WM-115 
and WM 266-4) (ECACC, UK) were cultured in RPMI-1640 culture media (Sigma-
Aldrich, UK) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) 
glutamine at 37 ºC in a humidified atmosphere containing 5% carbon dioxide. 
Healthy human melanocyte cells (HEMn) (ECACC, UK) (Table 20) were cultured in 
melanocyte growth media (Sigma-Aldrich, UK) supplemented with bovine pituitary 
extract (0.004 ml/ml), basic fibroblast growth factor (1 ng/ml), insulin (5 μg/m), 
hydrocortisone (0.5 μg/ml) and phorbol myristate acetate (10 ng/ml) at 37ºC in a 
humidified atmosphere containing 5% carbon dioxide.  
All the cell lines were grown until 80% confluency achieved in about 72 to 96 hours 
followed by subculturing. The culture flask was decanted from the culture media and 0.5 
ml trypsin/EDTA (Sigma-Aldrich, UK) was added and incubated for about 5 minutes at 37 
ºC to detach the cell monolayer from the flask. The flask content was transferred into a 
universal tube and centrifuged at 500 x g for 5 minutes. The supernatant was discarded and 
the pellet was re-suspended in 5 ml of culture media. The split was carried out at 
recommended 1:3 ratio and transferred into 25 or 75 cm2 culture flasks according to the 
amount of cells needed for the further tests and the total volume of the media made up to 5 
or 15 ml respectively. 
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Table 20. Human cell lines used in cell culture experiments. 
Cell line Source Tumor Type  Passage No. 
HEMn   ECACC   Primary human epidermal melanocytes             - 
     isolated from neonatal foreskin 
WM-115   ECACC   Derived from the skin of 58 years old               85 
     homo sapiens female with primary 
     melanoma. 
WM 266-4   ECACC   Derived from the skin of the same 58               +3 
     years old homo sapiens female at the  
     metastatic level of melanoma. 
 
6.2.2 The apoptotic Effect of Lectin-Toxin Fusion Proteins on Cells  
Human melanoma cells (WM-115, WM 266-4) and the healthy melanocyte cells (HEMn) 
were cultured on 96-well plate with the optimum seeding density 5000 cells/well (~1.4 x 
104 cells/cm2) detected in section 4.2.5. After 24hours incubation at 37 ºC in humidified 
atmosphere containing 5% C02, the media was changed to the same RPMI-1640 but with 
lower amount of FBS (2%). The cells were then treated with 0.5µM from each of the 
fusion proteins and incubated another 24 and 48hours. The cell viability was measured 
through adding 20µl of the MTS solution and incubated at 37ºC for 3 hours. The 
absorbance of the mixture was then measured at 490 nm and the blank absorbance at 650 
nm using micro plate reader (Dynatech MR5000, USA). 
 
6.2.3 Cell Morphology Assessment 
The effect of Lectin-Toxin fusion proteins on cell morphology was assessed through 
treating human metastatic melanoma cells (WM 266-4) with different concentration of the 
fusions. The cancer cells were cultured in 25 cm2 flasks as described in section 4.2.5. 
When the cells reached 80% confluency the culture media was removed and the cells were 
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washed two times with 1X PBS. The cells were then detached from the flask using 
trypsin/EDTA and transferred into a universal tube followed by centrifugation. The cells 
were re-suspended in 3ml of appropriate culture media and the counted. The seeding 
density 5000 cells/well was used to plate the cells on the 96-well plate and the plate was 
incubated for 24 hours at 37oC in humidified atmosphere containing 5% C02. After the 
incubation time, the cells were treated with 0.1, 0.3 and 0.5µM fusion proteins overnight. 
Finally, the cells were screened and photographed under the microscope. 
 
6.2.4 Cell membrane Binding and Internalization of Lectin-Toxin Fusions 
The ability of the Lectin-Toxin fusion proteins to bind to the cell glycocalyx and cross the 
cell membrane was determined through Fluorescein isothiocyanate (FITC) staining. The 
subsequent morphological apoptotic signs caused by the incubation of the cells with the 
labelled proteins were also observed. 
 
6.2.4.1 FITC labelling of the Lectin-Toxin Fusions 
The FITC stain (Sigma-Aldrich, UK) was dissolved in 1X PBS with the concentration of 
0.5µg/µl. A fresh 1 M carbonate buffer pH 9.5 was prepared from 0.32 M sodium 
carbonate (Na2CO3) and 0.68 M sodium bicarbonate (NaHCO3). The conjugation reaction 
was carried out by mixing 200 µl of fusion protein (~1µg/µl), 25 µl carbonate buffer, 25 µl 
1X PBS and 50 µl FITC solution in light-protected eppendorf tube and incubated at room 
temperature for 2 hours with gentle agitation. The reaction mixture was then extensively 
dialyzed overnight at 4oC in dark to remove unbound FITC. The FITC labelled fusion 
proteins were stored at 4oC until further use. 
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6.2.4.2 Cell Preparation 
Human melanoma cells (WM-155 and WM 266-4) and the healthy human melanocyte 
cells (HEMn) were cultured in 25cm2 flasks as described in section 4.2.3. The cells were 
then plated on the 96-well plate with the seeding density of 5000 cells/well as described in 
section 4.2.5 and incubated for 24 hours at 37oC in humidified atmosphere containing 5% 
C02.  
 
6.2.4.3 Epifluorescence Imaging Microscopy 
Live confocal microscopy was conducted on two melanoma cell lines (WM-115 and WM 
266-4) and one healthy melanocyte cell line (HEMn) to investigate the binding and cell 
penetrating capacity of the Lectin-Toxin fusions and also to see the intracellular 
distribution of the internalized fusions. To plate the cells, a glass coverslip was placed in 6 
well plates and the cells were grown in the wells overnight. The cells were then treated 
with 0.5µM of FITC labelled fusion proteins for four hours followed by washing with ice-
cold PBS. The binding of the fusion proteins to the cell glycocalyx and their colocalization 
were screened under epifluorescence imaging microscopy equipped with 10X and 20X 
objectives (Nikon, UK). The FITC fluorophore was excited with blue light (488nm). 
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6.3 Results 
The binding of the recombinant MLB-Toxins, 1st Domain-Toxins and 2nd Domain-Toxins 
fusion proteins specifically to melanoma cancer cells and their utility in delivering 
cytotoxic peptides to the cells were assessed by treating two human melanoma cell lines 
(WM-115 and WM 266-4) and one healthy human melanocytes (HEMn) with the 
recombinant fusion proteins.  
 
6.3.1 Detection of Cell Variability by MTS Assay 
A colorimetric assay (MTS) was used to determine induced cell death in human melanoma 
and healthy melanocyte cells by the recombinant fusion proteins. 
 Significant increases were observed in the apoptosis of both melanoma cells (WM-115, 
WM 266-4) specifically metastatic cells (MW 266-4) when they were treated with 
(0.5µM) of the recombinant fusion proteins for 24 hours. However, all the fusion proteins 
showed negligible effects on the healthy human melanocyte cells (HEMn). 
Figure 111, 112, 113 show the effects of MLB-Melittin 1, MLB-Melittin 2, 1st Domain-
Melitin and 1st Domain-Mastoparan fusion proteins on the healthy human melanocytes 
(HEMn), human primary melanoma cells (WM-115) and human metastatic melanoma 
cells (WM 266-4) respectively. 
The treatment of the healthy melanocyte cells with the fusion proteins had almost no 
effects on the cells (Figure 111) whereas MLB-Melittin 1 and 1st Domain-Mastoparan 
showed a significant apoptotic effects on both primary and metastatic melanoma cells. 
However, MLB-Melittin 2 and 1st Domain-Melittin were seen to have no significant 
effects on the cancer cells as well (Figure 112, 113). 
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Figure 111. The MTS assay conducted on human healthy melanocytes cells (HEMn) after 24hours incubation time. First 
column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Melittin 1 fusion protein; Third 
column: Cells treated with 0.5μM of MLB-Melittin 2 fusion protein; Forth column: Cells treated with 0.5μM of 1st 
Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 1st Domain-Mastoparan fusion protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 112. The MTS assay conducted on human primary melanoma cells (WM-115) after 24hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Melittin 1 fusion protein; 
Third column: Cells treated with 0.5μM of MLB-Melittin 2 fusion protein; Forth column: Cells treated with 0.5μM of 1st 
Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 1st Domain-Mastoparan fusion protein. 
 
 
HEMn 
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Figure 113. The MTS assay conducted on human metastatic melanoma cells (WM 266-4) after 24hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Melittin 1 fusion protein; 
Third column: Cells treated with 0.5μM of MLB-Melittin 2 fusion protein; Forth column: Cells treated with 0.5μM of 1st 
Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 1st Domain-Mastoparan fusion protein. 
 
In figure 114, 115 and 116 the effect of MLB-Mastoparan 1, MLB-Mastoparan 2, 2nd 
Domain-Melitin and 2nd Domain-Mastoparan fusion proteins on the healthy human 
melanocytes (HEMn), human primary melanoma cells (WM-115) and human metastatic 
melanoma cells (WM 266-4) are shown respectively. 
The treatment of the healthy melanocyte cells with the fusion proteins showed almost no 
effects of the fusions on the cells (Figure 114) whereas MLB-Mastoparan 1 and 
2ndDomain-Mastoparan showed a significant apoptotic effects on metastatic melanoma 
cells but less effects on the primary cells. However, the effects of MLB-Mastoparan 2 and 
2nd Domain-Melittin were again seen insignificant on the cancer cells as well but higher 
than MLB-Melittin 2 and 1stDomain-Melittin (Figure 115, 116). 
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Figure 114. The MTS assay conducted on human healthy melanocytes cells (HEMn) after 24hours incubation time. First 
column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Mastoparan 1 fusion protein; 
Third column: Cells treated with 0.5μM of MLB-Mastoparan 2 fusion protein; Forth column: Cells treated with 0.5μM of 
2nd Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 2nd Domain-Mastoparan fusion protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 115. The MTS assay conducted on human primary melanoma cells (WM-115) after 24hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Mastoparan 1 fusion 
protein; Third column: Cells treated with 0.5μM of MLB-Mastoparan 2 fusion protein; Forth column: Cells treated with 
0.5μM of 2nd Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 2nd Domain-Mastoparan fusion 
protein. 
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Figure 116. The MTS assay conducted on human metastatic melanoma cells (WM 266-4) after 24hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Mastoparan 1 fusion 
protein; Third column: Cells treated with 0.5μM of MLB-Mastoparan 2 fusion protein; Forth column: Cells treated with 
0.5μM of 2nd Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 2nd Domain-Mastoparan 
fusion protein. 
 
Following the confirmation of the cytotoxic effect of the fusion protein on the melanoma 
cells especially on the metastatic cells (WM 266-4), a longer incubation time of the fusion 
proteins with the metastatic cells was tried in order to assess their cytotoxicity. For that, 
the cells were treated with the same concentration (0.5μM) of the fusion proteins but for 
48hours.  
In comparison with the 24hours incubation, a dramatic change was observed in the 
cytotoxic effect of the fusion proteins after 48hours incubation. The fusion proteins were 
seen more cytotoxic to the cells and significantly reduced their viability. 
Figure 117 shows the cytotoxic effect of MLB-Melittin 1, MLB-Melittin 2, 1st Domain-
Melitin and 1st Domain-Mastoparan fusion proteins on the metastatic melanoma cells (WM 
266-4) after 48hours incubation. It can clearly be seen that all the fusion proteins had more 
cytotoxic effect on the cells especially MLB-Melittin 2 and 1st Domain-Melittin which 
showed much higher activity than the 24hours incubation time. 
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Figure 117. The MTS assay conducted on human metastatic melanoma cells (WM 266-4) after 48hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Melittin 1 fusion protein; 
Third column: Cells treated with 0.5μM of MLB-Melittin 2 fusion protein; Forth column: Cells treated with 0.5μM of 1st 
Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 1st Domain-Mastoparan fusion protein. 
 
 
Figure 118 shows the cytotoxic effect of MLB-Mastoparan 1, MLB-Mastoparan 2, 2nd 
Domain-Melittin and 2nd Domain-Mastoparan fusion proteins on the metastatic melanoma 
cells (WM 266-4) after 48hours incubation. The longer incubation time was seen to 
dramatically increase the cytotoxic effect of the fusion proteins since longer exposure time 
of the cells to MLB-Mastoparan 1 and 2nd Domain-Mastoparan reduced their viability to 
almost half. 
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Figure 118. The MTS assay conducted on human metastatic melanoma cells (WM 266-4) after 48hours incubation time. 
First column: Untreated cells and control; Second column: Cells treated with 0.5μM of MLB-Mastoparan 1 fusion 
protein; Third column: Cells treated with 0.5μM of MLB-Mastoparan 2 fusion protein; Forth column: Cells treated with 
0.5μM of 2nd Domain-Melittin fusion protein; Fifth column: Cells treated with 0.5μM of 2nd Domain-Mastoparan 
fusion protein. 
 
 
6.3.2 Cell Morphology Assessment  
The interaction of melittin and mastoparan with the cell membrane and their ability to 
break it was assessed through screening the morphology of metastatic melanoma cells 
(WM266-4) under the microscope following treating them with various concentration of 
the Lectin-Toxin fusion proteins. The untreated cells were used as a control to distinguish 
the morphological changes happened during the treatment. The effect of the fusion 
proteins on the shape of the cells was clearly seen but different level of activity was shown 
by the proteins at different concentrations. The fusion proteins were seen to effectively 
interact with the cell membranes and lyse them. Figure 119-124 shows WM266-4 cells 
treated with three different concentrations (0.1, 0.3 and 0.5μM) of MLB-Melittin 1, 1st 
Domain-Melittin, 1st Domain-Mastoparan, MLB-Mastoparan 1, 2nd Domain-Melittin and 
2nd Domain-Mastoparan fusion protein respectively. The untreated cells in picture A was 
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used as control in which have clear shape and smooth cell membranes. In picture B, few 
number of deformed cells and chromatin shrinking can be seen and their number increased 
with the increase of the fusion protein concentration shown in picture C. In picture D, a 
large number of cells are deformed and a large amount of apoptotic bodies can be seen 
around the cells as a results of a higher ratio of cell membranes lysis caused by the higher 
concentration of the fusion proteins. Despite that all the fusion proteins showed effect on 
the morphology of the cells, MLB-Mastoparan 1 and 1st Domain-Mastoparan fusion 
proteins were seen to have the highest impact on the cells since the highest amount of 
apoptotic bodies was observed around the cells treated with these two fusion protein which 
is an indication that the fusion protein possesses a potent membrane lytic activity (Picture 
D of figure 121,122).  
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Figure 119. Human metastatic melanoma cells (WM 266-4) treated with MLB-Melittin 1 fusion protein. Picture A: 
Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red arrows 
show the deformed cells and the blue arrows show the apoptotic bodies. 
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Figure 120. Human metastatic melanoma cells (WM 266-4) treated with 1st Domain-Melittin fusion protein. Picture A: 
Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red arrows 
show the deformed cells and the blue arrows show the apoptotic bodies. 
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Figure 121. Human metastatic melanoma cells (WM 266-4) treated with 1st Domain-Mastoparan fusion protein. Picture 
A: Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red 
arrows show the deformed cells and the blue arrows show the apoptotic bodies. 
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Figure 122. Human metastatic melanoma cells (WM 266-4) treated with MLB-Mastoparan 1 fusion protein. Picture A: 
Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red arrows 
show the deformed cells and the blue arrows show the apoptotic bodies. 
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Figure 123. Human metastatic melanoma cells (WM 266-4) treated with 2nd Domain-Melittin fusion protein. Picture A: 
Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red arrows 
show the deformed cells and the blue arrows show the apoptotic bodies. 
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Figure 124. Human metastatic melanoma cells (WM 266-4) treated with 2nd Domain-Mastoparan fusion protein. Picture 
A: Untreated cells (control); Picture B, C, D: Cells treated with 0.1, 0.3, 0.5μM fusion protein respectively. The red 
arrows show the deformed cells and the blue arrows show the apoptotic bodies. 
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6.3.3 Epifluorescence Microscopy 
To visualise the binding and cell internalization of the recombinant fusion proteins, they 
were labelled with fluorescein isothiocyanate (FITC). Subsequent morphological 
assessment of cells was also used to determine the effect of the recombinant fusion 
proteins on the cells. One day prior to infecting the cells with the fusion proteins, the 
melanoma cells (MW-115 and MW 266-4) and healthy melanocyte cells (HEMn) were 
plated on 96-well plated with the cell density of 5000 cell/well as explained in section 
4.2.5. The cells were then treated with 0.5µM of each recombinant fusion protein and 
incubated for 4 hours. Cells were later screened under epifluorescence microscopy using 
blue light (488nm) to excite the FITC fluorophore (Figure 126-133). The typical shape of 
HEMn, WM-115 and WM 266-4 cells without any treatment is also shown in figure 125. 
From the microscopic images the attachment of the fusion proteins to the cell surfaces and 
crossing the cell membranes can clearly be seen. Furthermore, in comparison to the 
untreated cells a significantly higher proportion of cell death was observed in cells treated 
with fusion proteins. Such results were not observed in healthy cells. 
The fluorescent microscope imaging results also confirmed the results to the colorimetric 
assay (MTS) which was the observation of minor binding of the fusion proteins to the 
healthy melanocyte cells (HEMn) and minor cell agglutination. Also, the fusions proteins 
did not show cytotoxic effects to the healthy cells since the adhesion and growth 
morphology of the cells was not affected by their incubation with the fusion proteins as 
shown in the picture A of figure 126-133. On the other hand, picture B and C of figure 
126-133 show that all the fusion proteins effectively bound to the melanoma cells (WM-
115 and WM 266-45) and caused cell agglutination followed by cell internalization. 
However, different level of activity was observed between the fusion proteins and 1st 
Domain-Mastoparan fusion protein was again seen to have the strongest cell binding and 
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internalization to both WM-115 and WM 266-4 cells since the highest intensity of the 
fluorescence was detected around and inside the cells treated with this fusion protein as 
shown in picture B and C of figure 129. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 125. Typical shape of three human skin cells without any treatment. Picture A: Healthy human melanocyte cells 
(HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 266-
4). 
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Figure 126. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled MLB-Melittin 1 
fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human melanocyte 
cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 
266-4). 
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Figure 127. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled MLB-Melittin 2 
fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human melanocyte 
cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 
266-4). 
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Figure 128. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled 1st Domain-Melittin 
fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human melanocyte 
cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 
266-4). 
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Figure 129. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled 1st Domain-
Mastoparan fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human 
melanocyte cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human 
melanoma cells (WM 266-4). 
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Figure 130. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled MLB-Mastoparan 1 
fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human melanocyte 
cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 
266-4). 
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Figure 131. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled MLB-mastoparan 2 
fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human melanocyte 
cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human melanoma cells (WM 
266-4). 
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Figure 132. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled 2nd Domain-
Melittin fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human 
melanocyte cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human 
melanoma cells (WM 266-4). 
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Figure 133. Human healthy melanocyte and melanoma cells incubated with 0.5μM of FITC labelled 2nd Domain-
Mastoparan fusion protein overnight and screened under luminescence imaging microscopy. Picture A: Healthy human 
melanocyte cells (HEMn); Picture B: Primary human melanoma cells (WM-115); Picture C: Metastatic human 
melanoma cells (WM 266-4). 
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6.4 Discussion 
This study presents the application of the recombinant Lectin-Toxin conjugates in cell 
culture experiments to assess their binding and cytotoxic activity to different human 
healthy and cancer cell lines. 
In the previous chapters, the recombinant fusion protein produced from MLB fused to GFP 
were confirmed to have ability to bind to melanoma cells and cross their membrane and 
accordingly new recombinant fusion proteins were designed to use MLB as carrier vehicle 
to deliver cytotoxic peptides like melittin and mastoparan to melanoma cells and applied in 
this study.  
The first step of the cell experiments was the selection of cancer cells which was informed 
by previous knowledge on the availability of sialic acid on the cell surfaces. Hoja-
Łukowicz, Link-Lenczowski et al. (2013) carried out a study on two human melanoma cell 
lines known as WM793 and WM1205Lu which were at primary and metastatic 
progression stages respectively and showed that both lines have abundant sialic acid on 
their cell surface oligosaccharides. Furthermore, they observed that the two cell lines have 
two different sialic acid profiles on their L1CAM oligosaccharide. The primary melanoma 
cell line (WM793) was shown to have both α2-3 and α2-6 on their L1CAM, while, only 
α2-6 was observed on the metastatic melanoma cells (WM1205Lu). We believe that these 
two cell lines can be specifically targeted by the Lectin-Toxin conjugates since the sialic 
acid binding affinity of MLB fusions was confirmed in the previous chapters. Moreover, 
we suggested that a stronger binding of the fusion proteins to the metastatic cells (WM 
266-4) should be achieved compared to the binding to the primary cells (WM-115) 
because Müthing, Burg et al. (2002) have shown that the preferential affinity of MLB is to 
terminally α2-6 sialic acid.  
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The colorimetric assay (MTS) was carried out to assess the toxicity of the fusion proteins 
toward human healthy melanocyte (HEMn), human primary melanoma (WM-115) and 
human metastatic melanoma (WM 266-4) treated with the recombinant fusion proteins. All 
the fusion proteins showed minor or almost no effect on the healthy cells (HEMn) (Figure 
111, 114). This is an indication that in the treatment of HEMn, the designed delivery 
systems meet the most important criteria of selective delivery systems which is the 
elimination of healthy cells from their cytotoxic effects. On the other hand, differing levels 
of cytotoxicity of the fusion proteins were observed with the cancer cells. MLB-Melittin 1 
and MLB-Mastoparan 1 fusion constructs showed significant effects on both WM-115 and 
WM 266-4 melanoma cells, however, the lowest cytotoxic effect observed on both cell 
lines was obtained with the MLB-Melittin 2 and MLB-Mastoparan 2 fusions, these fusions 
do not have the Cat-B linker in their structure (Figure 112, 113, 115, 116). This confirms 
the importance of Cat-B in the activity of the recombinant fusion proteins in which helps 
the cytotoxic peptide to be quickly released from the lectin peptide and trigger their 
cytotoxicity because without the linker the toxic peptide remains attached to the lectin 
peptide in an inactive form and does not have any cytotoxic impact on the cells. The 1st 
Domain-Melittin fusion also showed limited effects on either melanoma cell lines 
(106.7%and 98.2%) (Figure 112, 113) although 2nd Domain-Melittin showed slightly 
higher effects (89.7%and 90.6%) (Figure 115, 116). However significant cytotoxicity was 
shown by 1st Domain-Mastoparan on both primary and metastatic melanoma cells (83.6% 
and 83.3%) (Figure 112, 113). Interestingly the effect of the 2nd Domain-Mastoparan 
fusion was shown to be higher (78.6%) on metastatic melanoma cells (WM 266-4) than on 
primary melanoma cells (WM-115) (95.1%) (Figure 115, 116), confirming that MLB 
specifically targets α2-6 sialic acids. 
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The treatment of WM 266-4 cells with the same concentration (0.5μM) of the fusions but 
for a longer incubation time (48hours) was seen to potentially increases the cytotoxic 
effect of all the fusion proteins especially those fusions containing melittin which showed 
lower cytotoxic effects in the 24hours incubation time (Figure 117, 118). This result agrees 
with a study conducted by Černe, Erman et al. (2013) and demonstrated that the cytotoxic 
effect of melittin is time dependent. 
Further cell morphological assessment was carried out to assess the effect of the 
recombinant fusion proteins on WM 266-4 metastatic melanoma cells, and again different 
levels of activity were shown by the fusion proteins. Deformed cells and cell membrane 
lysis was detected within the cells treated with all the recombinant fusion proteins (Figure 
119-124) but MLB-Mastoparan 1 and 1st Domain-Mastoparan fusion proteins were seen to 
have the highest impact on the cells as they caused more disruption of the cell membranes 
and produced more apoptotic bodies around the cells (Figure 121, 122), thus confirming 
the results with calorimetric assays. 
Fluorescein isothiocyanate reagent (FITC) was also used to label the fusion proteins so as 
to be able to visualise and track their localization during cell binding and internalization. 
The activity of the FITC labelled fusion proteins were tested with the healthy human 
melanocyte cells (HEMn) and both primary and metastatic human melanoma cells (WM-
115, WM 266-4) and the cells were screened by using florescence microscopy. The fusion 
proteins were seen to have a minor effect on the healthy cells (HEMn) (Picture A of figure 
125-133). However, the binding of the fusion conjugates to the surface of the cancer cells 
and cell agglutination which is a well-known activity of lectin family were clearly detected 
within the treated cells. Also we could observe abundant broken cell membranes as well as 
deformed cells being detected within the treated cell groups. This is believed to be due to 
their interaction with melittin and mastoparan well known to cause destabilization of the 
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membranes lipid bilayer and consequently causes membrane lysis as shown in picture B 
and C of figure 125-133. These results thus agree with Damianoglou, Rodger et al. (2010) 
and Park, Lee et al. (2000) who previously demonstrated the cellular toxicity of melittin 
and mastoparan. 
Due to the limited amount of highly purified fusion proteins, only one concentration of the 
proteins was able to be tested with the cancer cells in the time frame of this study. 
Therefore, to precisely understand the activity of the fusion proteins and their level of 
cytotoxicity toward cancer cells, different concentrations of the proteins should be tested 
so as to identify the half maximal inhibitory concentration (IC50) of the fusion proteins 
and also assess the dose response of the cells (Samant, Blair et al. 2013).  
In conclusion, the cytotoxic effect of Lectin-Toxin fusion constructs was tested with 
human healthy melanocyte and melanoma cell lines. The fusion proteins were confirmed 
to have almost no cytotoxic effect on the healthy human melanocytes (HEMn). However, 
some of the fusion proteins showed positive cytotoxicity on human primary (WM-115) 
and metastatic (WM 266-4) melanoma cells, particularly the fusions containing 
Mastoparan. 
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Chapter 7. Summary of Main Findings and Future Research 
 
7.1 Summary of Main Findings 
One of the greatest challenges in medicine is producing a drug to work only at the intended 
targeted site. Despite the fact that modern technology has widely improved the efficiency 
of the new generation of therapies, limited advances have been achieved in cancer 
therapies. Inefficient delivery and lack of specificity are two main factors that mainly 
affect the efficacy of the majority of the existent anti-cancer therapies such as 
chemotherapies because they limit the effective dose of the drugs reaches the target site 
and also expose the normal tissues to the large amount of the administrated doses. 
Therefore, substantial improvement is demanded in anti-cancer therapies especially in drug 
delivery and selectivity (Estanqueiro, Amaral et al. 2015, Xiao, Morris‐Natschke et al. 
2016). While promising anti-tumour effects have been detected in some drugs which have 
poor recognition capacity for cancer cells, recent studies about anti-tumour drugs have 
mainly focused on the discovery of appropriate carrier vehicles to specifically deliver these 
drugs to cancer cells. Although a diversity of drug delivery systems has been tried based 
on different carrier vehicles ranging from macro biomolecules to nanoparticles, the most 
significant advances have been achieved using anti-bodies to target caner tissues 
(Rodriguez-Ruiz, Maksimenko et al. 2015, Wei, Chen et al. 2015, Muralidhara, Baid et al. 
2016, Shojaei, Tabatabaeian et al. 2016). Despite this, some types of cancers like 
melanoma have remained without effective therapy (Rek, Krenn et al. 2009, Casi and Neri 
2012, Kurrikoff and Suhorut 2012). To date, the most effective drug for the advanced stage 
of melanoma is a combination of two drugs namely Nivolumab (Humanized IgG4 anti-
PD-1 monoclonal antibody) and Ipilimumab (Anti–cytotoxic T-lymphocyte–associated 
antigen 4 (CTLA-4) antibody) which has recently been approved for clinical use. The drug 
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acts to up-regulate antitumor immunity but the drug cannot be used with every melanoma 
patient because of the treatment-related adverse events resulting from the combination of 
the two drugs (Larkin, Chiarion-Sileni et al. 2015).   
Thus, the aim of the research in this thesis was to identify a novel bioactive peptide to 
deliver effective anti-cancer agents specifically to cancer cells, especially melanoma cells. 
Initially a range of novel fusion proteins were designed to potentially deliver cytotoxic 
peptides to cancer cells through targeting the overexpressed sialic acid residues on their 
surfaces using biochemical, molecular biology and cell culture methodologies. The 
binding chain (MLB) of Mistletoe lectin (Viscum album) isoform one (MLI) was thus 
chosen to be studied as a carbohydrate binding peptide and to be used as a carrier molecule 
in the fusion proteins. 
The whole isoform one (MLI) of mistletoe lectin which is comprised of two chains known 
as toxic chain (MLA) and binding chain (MLB) was amplified and cloned so as to be used 
later in designing different fusion constructs. Despite a few mismatched bases between the 
cloned sequences and the reference sequences from NCBI GeneBank server, a high quality 
sequences of both chains were produced so as to be used in the further experiments. 
In order to assess the sialic acid binding ability of MLB and identify an optimum 
orientation to fuse MLB to other peptides without causing major protein-protein 
interaction that affect the glycan binding ability of MLB, the coding sequence of a muted 
version of green florescent protein known as GFPuv was fused with MLB. Also, the 
coding sequence of the binding chain of elderberry (Sambucus nigra) lectin (SNA-B) 
which is a sialic acid binding lectin and snow drop (Galanthus nivalis) lectin (GNA) which 
is a mannose binding lectin were used as a positive and negative control respectively. The 
lectin sequences were fused to the GFP sequence in both N- and C- terminal orientations 
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and their expression level in the fusion constructs were determined according to the 
expression level of GFP since the correctly expressed GFP can be excited and visualized 
under standard UV light. 
The results presented in chapter 2 showed that the expression of both cloning strategies (N- 
and C- terminal) of MLB+GFP and SNA-B+GFP was successfully carried out and the 
emission of GFP in E. coli colonies containing the fusion constructs were clearly 
visualized under standard UV light. The SDS PAGE analysis also clearly showed the 
predicted size bands of all the fusion constructs (Figure 49). However, attempts to express 
GNA+GFP fusion constructs failed potentially due to the toxicity of GNA which caused 
the formation of inclusion bodies and also slowed down the proliferation of the E. coli 
cells. 
The affinity purification conducted to purify the expressed Lectin+GFP fusion proteins 
shown in chapter 3 demonstrated that the binding chain of both lectins (MLB, SNA-B) 
preserved their sialic acid binding ability as they successfully bound to the sialic acid 
residues of fetuin. This was the first experimental attempt to confirm the sialic acid 
binding affinity of MLB alone without MLA since the previous attempt carried out by 
Müthing, Meisen et al. (2004) was to assess the sialic acid binding of the whole mistletoe 
lectin (MLA+MLB) and Wu, Chin et al. (1992) that showed that mistletoe lectin is a 
galactose binding lectin. The in vitro cell culture experiments also confirmed that MLB 
and SNA-B can potentially bind to the sialic acid on the surface of melanoma cells (WM 
266-4) and cross their membranes (Figure 56, 57). 
Due to the confirmation of the binding ability of MLB to cancer cell in chapter 3, we 
decided to use MLB as a carrier vehicle to produce a selective drug delivery system (SDS) 
to deliver melittin (MLT) and mastoparan (MP) cytotoxic peptides specifically to 
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melanoma cells. Therefore, the coding sequence of MLB was further analysed (Section 
5.2.1) using bioinformatics analysis and consequently two separate putative sugar binding 
domains were identified in the sequence (Figure 68). The sequence of MLB, melittin and 
mastoparan were later optimized to E. coli tRNA pools so as to optimize their nucleic acid 
consistency which was previously proven that improve the expression of recombinant 
fusion constructs in bacteria. Then, a range of fusion constructs was designed from fusing 
the coding sequence of MLB and its two sugar binding domains to the coding sequence of 
MLT and MP through Cat-B biodegradable linker which hypothetically helps to keep the 
cytotoxic peptides in an inactive form and attached to the carrier peptides until they reach 
the intended site. Finally, the fusion constructs were successfully expressed in E. coli and 
purified. In this study we identified a potential method to effectively express and purify an 
active and soluble form of MLB fused to melittin and mastoparan peptides which were 
previously shown by Buhrman, Rayahin et al. (2013) and Peng, Hong et al. (2012) to be 
insoluble when they are expressed in E. coli. our study also yielded eight active fusion 
proteins to be used in the further cell culture experiments.  
Finally, the cell culture experiments were undertaken in chapter 6 to assess the binding and 
cytotoxic activity of the fusion proteins produced in chapter 5. Two melanoma cell lines 
(WM-115 and WM 266-4) at primary and metastasis progression stages respectively were 
selected to be targeted by the fusion proteins because they were previously studied by 
Hoja-Łukowicz, Link-Lenczowski et al. (2013) who demonstrated that they have sialic 
acid branches on their surfaces. A healthy melanocyte cell line (HEMn) was also used as a 
control to assess the ability of the fusion proteins to eliminate the healthy cells from their 
cytotoxic effects.  
The colorimetric assay (MTS) was also carried out to assess the cytotoxic effect of the 
fusion proteins on the viability of the melanoma cells (WM-115, WM 266-4) and the 
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healthy melanocyte cells (HEMn) and confirmed the results of the morphological 
assessments in which showed that majority of the fusion proteins especially MLB-Melittin 
1, MLB-Mastoparan 1, 1st Domain-Mastoparan and 2nd Domain-Mastoparan have 
significant impact on the viability of the melanoma cells, specifically on the metastatic 
cells which have abundant α2-6 sialic acid on their surface oligosaccharides (Hoja-
Łukowicz, Link-Lenczowski et al. 2013) (Figure 112, 113, 115, 116, 117, 118). This 
impact on the metastatic cells thus confirmed that MLB played a crucial role in delivering 
the cytotoxic peptides specifically to the melanoma cells since the primary affinity of 
mistletoe lectin to terminally α2-6 sialic acid was previously confirmed by Müthing, Burg 
et al. (2002). In contrast, the fusion proteins were seen to have almost no effect on the 
healthy melanocyte cells (HEMn) which again confirmed the specificity of the fusion 
proteins toward melanoma cells (Figure 111, 114). 
The morphological study revealed that all the fusion proteins containing the Cat-B linker 
had effects on the morphology of the cancer cells. However, two of the fusion proteins 1st 
Domain-Mastoparan and MLB-Mastoparan 1 were seen to have the highest impact on the 
cells morphology because more apoptotic bodies were detected with the cells treated with 
these two fusion proteins (Figure 121, 122). This is an indication that the binding peptide 
(MLB) successfully delivered the toxic peptides to the cancer cells and also the toxic 
peptides preserved their cytotoxic effect in the fusion protein especially mastoparan which 
caused more cell membranes breakdown. 
On the other hand, the labelling of the fusion proteins with fluorescein isothiocyanate 
reagent (FITC) facilitated visualising and tracking the cell binding and internalization of 
the fusion proteins and confirmed the lytic ability of the fusion proteins such as those 
detected in the treatment of the primary (WM-115) and metastatic (WM 266-4) melanoma 
cells with the Lectin-Toxin fusion proteins which clearly showed that the cell membranes 
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were lysed by the activity of some of the fusion proteins as shown in picture B and C of  
figure 125-133. 
The ability of MLB to specifically and potentially bind to the sialic acid residues on the 
surface of cancer cells and its ability to cross their membranes confirmed in the previous 
chapters supports the idea of using MLB and other potent peptides to specifically deliver 
anti-cancer agents to cancer cells which subsequently reduce the side effect of the drugs on 
the healthy tissues and increase the effective amount of drug reaches the target side.  
In summary, this thesis has made multiple contributions to knowledge: firstly, the 
confirmation of sialic acid binding affinity of the binding chain (MLB) of mistletoe lectin 
alone without the cytotoxic chain (MLA); secondly, confirming the ability of MLB to 
specifically bind to the sialic acid residues on the surface of cancer cells and also the 
ability to cross the cell membranes; thirdly, we have confirmed that the overexpressed 
sialic acid on the surface of melanoma cells (WM-115 and WM 266-4) can be used as a 
specific biomarker to specifically target the cells by sialic acid binding molecules. Finally, 
the production of a range of fusion proteins with the ability to specifically target melanoma 
cells through targeting their cell surface overexpressed sialic acid residues through the 
binding ability of MLB to sialic acid and inhibit the cells proliferation through the lytic 
ability of melittin and mastoparan.  
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7.2 Future Research 
7.2.1 Protein Structure 
This work, although providing preliminary knowledge about the structure and properties of 
the binding chain of mistletoe lectin (MLB), should lead to further attempts to analyse the 
coding sequence of the peptide and its two putative sugar binding chains in order to 
identify the core amino acids responsible for their sialic acid binding activity. 
Consequently, shorter coding sequences could be achieved for the sugar binding peptides 
which facilitates their movement in the biological systems like cell membrane and 
increases their application in further drug delivery systems (Bechara and Sagan 2013).  
7.2.2 Dose Response 
Due to time limitations a single concentration of fusion proteins was used in the cell line 
tests. In order to demonstrate the full therapeutic potential of these fusions a dose-response 
curve should be generated as per standard drug design protocols (Samant, Blair et al. 
2013), this would allow calculation of the minimum amount of therapeutic agent required 
for a biological effect. Furthermore, a wider range of cancer cell types should be tested as 
well as moving into tests with solid tissue biopsies (Coulstock, Sosabowski et al. 2013). 
Flow cytometry should also be conducted on the treated cells in order to accurately 
quantify the effects of the fusion protein (Sica, Maiuri et al. 2016). Finally, many lectins 
are known to provoke immune reactions in humans (Hajto, Horváth et al. 2016), the MLB 
peptide should at a minimum be screened against the database of known human allergens 
(Gendel and Jenkins 2006). 
Ultimately the MLB chain may be linked to a variety of cytotoxic peptides or other 
cytotoxic conjugates and utilised as a cell specific delivery tool. 
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7.2.3 Generating Peptide-siRNA Conjugate 
In this work, lectin fusion constructs were generated from mistletoe B-chain (glycan 
binding portion) using only a cathepsin B biodegradable cleavage site to link the targeting 
‘carrier’ peptide (MLB) and a selected cytotoxic peptide.   
For future work we propose to synthesise a different linker sequence with the necessary 
modifications for click chemistry in order to generate a peptide-siRNA conjugate.  In order 
to utilise siRNA as drugs, one potential alternative to the use of liposomal transfection 
agents is the covalent conjugation of a cell binding and cell-penetrating peptide (CPP), 
with the intention of imparting on the siRNA an enhanced ability to enter mammalian cells 
and reach the appropriate RNA target (Turner et al., 2007). 
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Clustal W2 alignment to identify novel C-type lectins 
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The full sequence of pGFPuv expression vector 
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Appendix 3 
 
The sequencing results of N- and C- terminally fused MLB, SNA, and GNA to GFP in 
pGFPuv expression vector  
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MLB N-terminally cloned in pGFPuv Expression Vector 
NNNNNNNNNNNNNNGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGAT
GGATATCTGCAGAATTCAGGACAGCGGAGCTCGCTGCAGCTGCAGATGATGTTACCTGCAGTGC
TTCGGGACCTACGGTGCGGATTGTGGGTCGAAATGGCATGTGCGTGGACGTCCGAGATGACGAT
TTCCACGATGGAAATCAGATACAGTTGTGGCCCTCCAAGTCCAACAATGATCCGAATCAGTTGTG
GACGATCAAAAGGGATGGAACCATTCGATCCAATGGCAGCTGCTTGACCACGTATGGCTATACT
GCTGGCGTCTATGTGATGATCTTCGACTGTAATACTGCTGTGCGGGAGGCCACTATTTGGCAGAT
ATGGGGCAATGGGACCGTCATCAATCCAAGATCCAATCTGGTTTTGGCAGCATCATCTGGAATCA
AAGGCACTACGCTTACGGTGCAAACACTGGATTACACGTTGGGACAGGGCTGGCTTGCCGGTAA
TGATACCGCCCCACGCGAGGTGACCATATATGGTTTCAGGGACCTTTGCATGGAATCAAATGGAG
GGAGTGCGTGGGTGGAGACGTGCGTGAGTAGCCAACAGAACCAAAGATGGGCTTTGTACGGGG
ATGGTTCTATACGCCCCAAACAAAACCAAGACCAATGCCTCACCTGTGGGAGAGACTCCGTTTCA
ACAGTAATCAATATAGTTAGCTGCAGCGCTGGATCGTCTGGGCAGCGATGGGTGTTTACCAATGA
AGGGGCCATTTTGAATTTAAAGAATGGGTTGGCCATGGATGTGGCGCAAGCAATCCAAAGCTCC
GCCGAATAATTATCTATCCTGCCACAGGAAAACCAATCAAATGTGGCTTCCCGTGCCAGCTGCAT
AAGAATTCTCATGCTCTGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTAC
CAAGCTTGATGCATAGCTTGAGTATTCTACGCGTCACCTAATAGCTTGGCGTAATCATGGTCATAG
CTTGTTTCCTGTGTGAAATTGTTATCCGCTCAC 
 
 
MLB C-terminally cloned in pGFPuv Expression Vector 
 
GNNNNNNNNNNATAGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGAT
GGATATCTGCAGAATTCAGGACAGCGTCTAGAAAAAGATGATGTTACCTGCAGTGCTTCGGGAC
CTACGGTGCGGATTGTGGGTCGAAATGGCATGTGCGTGGACGTCCGAGATGACGATTTCCACGA
TGGAAATCAGATACAGTTGTGGCCCTCCAAGTCCAACAATGATCCGAATCAGTTGTGGACGATCA
AAAGGGATGGAACCATTCGATCCAATGGCAGCTGCTTGACCACGTATGGCTATACTGCTGGCGTC
TATGTGATGATCTTCGACTGTAATACTGCTGTGCGGGAGGCCACTATTTGGCAGATATGGGGCAA
TGGGACCGTCATCAATCCAAGATCCAATCTGGTTTTGGCAGCATCATCTGGAATCAAAGGCACTA
CGCTTACGGTGCAAACACTGGATTACACGTTGGGACAGGGCTGGCTTGCCGGTAATGATACCGC
CCCACGCGAGGTGACCATATATGGTTTCAGGGACCTTTGCATGGAATCAAATGGAGGGAGTGCG
TGGGTGGAGACGTGCGTGAGTAGCCAACAGAACCAAAGATGGGCTTTGTACGGGGATGGTTCT
ATACGCCCCAAACAAAACCAAGACCAATGCCTCACCTGTGGGAGAGACTCCGTTTCAACAGTAAT
CAATATAGTTAGCTGCAGCGCTGGATCGTCTGGGCAGCGATGGGTGTTTACCAATGAAGGGGCC
ATTTTGAATTTAAAGAATGGGTTGGCCATGGATGTGGCGCAAGCAAATCCAAAGCTCCGCCGAAT
AATTATCTATCCTGCCACAGGAAAACCAAATCAAATGTGGCTTCCCGTGCCAGGTACCTCATGCCC
TGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGCATAG
CTTGAGTATTCTAACGCGTCACCTAAATAGCTTGNGTAATCATGGTCATAGCTGTTTCCTGTGTGA
AATTGTATCCGCTCACATT 
 
 
 
 
 275 
 
SNA N-terminally cloned in pGFPuv Expression Vector 
GGNNNNNNNCCTNTNGGGNGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGAT
GGATATCTGCAGAATTCAGGACAGCGGAGCTCGCTGCAGCTGCAGGGGGCGAGTACGAAAAAG
TATGTTCGGTGGTAGAGGTAACAAGGCGCATCAGTGGTTGGGATGGATTGTGTGTGGACGTGA
GGTATGGGCACTACATCGATGGGAATCCCGTCCAGCTGCGGCCGTGTGGAAATGAATGTAACCA
ACTATGGACGTTCCGCACTGATGGAACAATCCGGTGGTTGGGTAAATGCCTGACTGCCTCAAGCT
CTGTCATGATATACGATTGTAATACTGTTCCTCCAGAGGCCACTAAGTGGGTAGTATCTATTGACG
GCACCATCACCAATCCTCACTCAGGACTCGTCCTTACAGCTCCTCAAGCTGCAGAGGGAACCGCC
CTGTCTCTGGAGAACAATATCCATGCCGCTAGGCAAGGTTGGACTGTAGGAGATGTAGAGCCCC
TCGTTACTTTTATTGTGGGATATAAACAAATGTGCTTGAGGGAAAACGGTGAAAACAATTTTGTA
TGGTTGGAGGACTGCGTTCTCAACAGGGTGCAGCAAGAGTGGGCACTCTATGGCGACGGCACCA
TTCGAGTAAACAGTAATCGTAGCCTATGTGTGACCTCCGAAGACCACGAGCCCAGTGATCTTATC
GTCATTCTCAAGTGCGAAGGGTCGGGCAACCAGCGCTGGGTATTCAACACCAACGGTACCATCTC
AAACCCAAACGCTAAACTACTTATGGACGTTGCACAACGCGATGTCTCTCTTCGAAAAATCATTCT
CTATCGGCCCACTGGGAATCCTAACCAGCAATGGATAACTACCACCCATCCAGCTGCTGCATAAT
GAATTCTCATGCCCTGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCA
AGCTTGATGCATAGCTTGAGTATTCTAACGCGTCACCTAAATAGCTTGGNGTAATCATGGGTCAT
AGCTGTTTCCTGTGTGAAATTGTTATCCG 
 
 
SNA C-terminally cloned in pGFPuv Expression Vector 
 
GNNNNNANNCNTNTANGGCGATTGGAAGCTTGGGGGGCGAGTACGAAAAAGTATGTTCGGTG
GTAGAGGTAACAAGGCGCATCAGTGGTTGGGATGGATTGTGTGTGGACGTGAGGTATGGGCAC
TACATCGATGGGAATCCCGTCCAGCTGCGGCCGTGTGGAAATGAATGTAACCAACTATGGACGTT
CCGCACTGATGGAACAATCCGGTGGTTGGGTAAATGCCTGACTGCCTCAAGCTCTGTCATGATAT
ACGATTGTAATACTGTTCCTCCAGAGGCCACTAAGTGGGTAGTATCTATTGACGGCACCATCACC
AATCCTCACTCAGGACTCGTCCTTACAGCTCCTCAAGCTGCAGAGGGAACCGCCCTGTCTCTGGA
GAACAATATCCATGCCGCTAGGCAAGGTTGGACTGTAGGAGATGTAGAGCCCCTCGTTACTTTTA
TTGTGGGATATAAACAAATGTGCTTGAGGGAAAACGGTGAAAACAATTTTGTATGGTTGGAGGA
CTGCGTTCTCAACAGGGTGCAGCAAGAGTGGGCACTCTATGGCGACGGCACCATTCGAGTAAAC
AGTAATCGTAGCCTATGTGTGACCTCCGAAGACCACGAGCCCAGTGATCTTATCGTCATTCTCAA
GTGCGAAGGGTCGGGCAACCAGCGCTGGGTATTCAACACCAACGGTACCATCTCAAACCCAAAC
GCTAAACTACTTATGGACGTTGCACAACGCGATGTCTCTCTTCGAAAAATCATTCTCTATCGGCCC
ACTGGGAATCCTAACCAGCAATGGATAACTACCACCCATCCAGCTACTCTAGACNCCAGGGTTTT
CCCAGTCNNGACGTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTG
GGC 
 
 
 
 
 
 
 
 
 
 276 
 
GNA N-terminally cloned in pGFPuv Expression Vector 
 
ANNNNNNNNNNTNNNNGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTG
ATGGATATCTGCAGAAAACNGGGGAGCTCGCTGCAGCTAAGGCAAGTCTCCTCATTTTGGCCGC
CATCTTCCTTGGTGTCATCACACCATCTTGCCTGAGTGACAATATTTTGTACTCCGGTGAGACTCTC
TCTACAGGGGAATTTCTCAACTACGGAAGTTTCGTTTTTATCATGCAAGAGGACTGCAATCTGGTC
TTGTACGACGTGGACAAGCCAATCTGGGCAACAAACACAGGTGGTCTCTCCCGTAGCTGCTTCCT
CAGCATGCAGACTGATGGGAACCTCGTGGTGTACAACCCATCGAACAAACCGATTTGGGCAAGC
AACACTGGAGGCCAAAATGGGAATTACGTGTGCATCCTACAGAAGGATAGGAATGTTGTGATCT
ACGGAACTGATCGTTGGGCTACTGGAACTCACACCGGACTTGTTGGAATTCCCGCATCGCCACCC
TCAGAGAAATATCCTACTGCTGGAAAGATAAAGCTTGTGACGGCAAAGGCTGCATAACTACTAGT
GCCTGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGCA
TAGCTTGAGTATTCTAACGCGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGT
GTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCT
GGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCG
GGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTA
TTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCG
GTATCAGCTCACTCAAAGGCGGTAATACNGTTATCCACANAATCNNGGGATACGCNNNAAGAAC
ATGTGAGCCAAANG 
 
 
GNA C-terminally cloned in pGFPuv Expression Vector 
 
GNNNNNNNNCTNNTNGGGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGT
GATGGATATCTGCAGAAAACAGGACAGCGTCTAGAAGCTAAGGCAAGTCTCCTCATTTTGGCCG
CCATCTTCCTTGGTGTCATCACACCATCTTGCCTGAGTGACAATATTTTGTACTCCGGTGAGACTCT
CTCTACAGGGGAATTTCTCAACTACGGAAGTTTCGTTTTTATCATGCAAGAGGACTGCAATCTGGT
CTTGTACGACGTGGACAAGCCAATCTGGGCAACAAACACAGGTGGTCTCTCCCGTAGCTGCTTCC
TCAGCATGCAGACTGATGGGAACCTCGTGGTGTACAACCCATCGAACAAACCGATTTGGGCAAG
CAACACTGGAGGCCAAAATGGGAATTACGTGTGCATCCTACAGAAGGATAGGAATGTTGTGATC
TACGGAACTGATCGTTGGGCTACTGGAACTCACACCGGACTTGTTGGAATTCCCGCATCGCCACC
CTCAGAGAAATATCCTACTGCTGGAAAGATAAAGCTTGTGACGGCAAAGAAGGTACCTCATGCC
CTGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGCATA
GCTTGAGTATTCTAACGCGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGT
GAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGG
GGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGG
AAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATT
GGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGT
ATCAGCTCACTCAAANGCGGTAATACGGTTATCCNCAGAATCNNGGGGATAACGCAGNAAGAA
CATGTGAGCAAAGGCC 
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Appendix 4 
 
The sequencing results of Lectin-Toxin fusion constructs cloned into pGFPuv 
expression vector  
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MLB-Melittin 1 
 
GAGGTCGACTCTAGAGGATGATGTTACCTGTAGCGCAAGCGAACCGACCGTTCGTATTGTTGGTC
GTAATGGTATGTGTGTTGATGTGCGTGATGATGATTTTCATGATGGCAATCAGATTCAGCTGTGG
CCGAGCAAAAGCAATAATGATCCGAACCAGCTGTGGACCATTAAACGTGATGGCACCATTCGTA
GCAATGGTAGCTGTCTGACCACCTATGGTTATACCGCAGGCGTTTATGTTATGATCTTTGATTGTA
ATACCGCAGTTCGTGAAGCAACCATTTGGCAGATTTGGGGTAATGGTACAATTATCAATCCGCGT
AGCAATCTGGTTCTGGCAGCAAGCAGCGGTATTAAAGGCACCACCCTGACCGTTCAGACCCTGG
ATTATACCCTGGGTCAGGGTTGGCTGGCAGGTAATGATACCGCACCGCGTGAAGTTACCATTTAT
GGTTTTCGTGATCTGTGCATGGAAAGCAATGGTGGTAGCGTTTGGGTTGAAACCTGTGTTAGCA
GCCAGCAGAATCAGCGTTGGGCACTGTATGGTGATGGTAGCATTCGTCCGAAACAGAATCAGGA
TCAGTGTCTGACCTGTGGTCGTGATAGCGTTAGCACCGTTATTAACATTGTTAGCTGCAGCGCAG
GTAGCAGCGGTCAGCGCTGGGTTTTTACCAATGAAGGTGCAATTCTGAACCTGAAAAATGGTCTG
GCAATGGATGTTGCACAGGCAAATCCGAAACTGCGTCGTATTATCATTTATCCGGCAACCGGTAA
ACCGAATCAGATGTGGCTGCCGGTTCCGCCTCCGCCTCCTCCACCACCTCCGCCTGGTATTCCGGT
TAGCCTGCGTAGCAAAGGTATTGGTGCCGTTCTGAAAGTGCTGACCACCGGTCTGCCTGCACTGA
TTAGCTGGATTAAACGTAAACGTCAGCAGCATCACCACCATCCATTCATTATTGAATTTCCACCTG
GAGACCGCCGGTTCGCCTATCACAT 
 
 
MLB-Melittin 2 
 
NNNNNGNTTNNNANNGAAAGCGGGCAAGTGAGCGNANGCATTAANNNTGNANTTAGCTCNC
TCNTTAGGCNCCCCAGGCTTTACACTTTANGCTTCCGGCTCGTATGNTNNNGNGGAANTNNTGA
GCGGATAACATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGCCTGCAGG
TCGACTCTAGAGGATGATGTTACCTGCAGTGCTTCGGGACCTACGGTGCGGATTGTGGGTCGAA
ATGGCATGTGCGTGGACGTCCGAGATGACGATTTCCACGATGGAAATCAGATACAGTTGTGGCC
CTCCAAGTCCAACAATGATCCGAATCAGTTGTGGACGATCAAAAGGGATGGAACCATTCGATCCA
ATGGCAGCTGCTTGACCACGTATGGCTATACTGCTGGCGTCTATGTGATGATCTTCGACTGTAAT
ACTGCTGTGCGGGAGGCCACTATTTGGCAGATATGGGGCAATGGGACCGTCATCAATCCAAGAT
CCAATCTGGTTTTGGCAGCATCATCTGGAATCAAAGGCACTACGCTTACGGTGCAAACACTGGAT
TACACGTTGGGACAGGGCTGGCTTGCCGGTAATGATACCGCCCCACGCGAGGTGACCATATATG
GTTTCAGGGACCTTTGCATGGAATCAAATGGAGGGAGTGCGTGGGTGGAGACGTGCGTGAGTA
GCCAACAGAACCAAAGATGGGCTTTGTACGGGGATGGTTCTATACGCCCCAAACAAAACCAAGA
CCAATGCCTCACCTGTGGGAGAGACTCCGTTTCAACAGTAATCAATATAGTTAGCTGCAGCGCTG
GATCGTCTGGGCAGCGATGGGTGTTTACCAATGAAGGGGCCATTTTGAATTTAAAGAATGGGTT
GGCCATGGATGTGGCGCAAGCAAATCCAAAGCTCCGCCGAATAATTATCTATCCTGCCACAGGAA
AACCAAATCAAATGTGGCTTCCCGTGCCACGGGTACCGCCTCCTCCGCCACCTCCGCCTCCGCCTG
GTATTGGTGCAGTTCTGAAAGTTCTGACCACCGGTCTGCCTGCACTGATTAGCTGGATTAAACGT
AAACGTCAGCAGCATCATCACCATCATCATTAATGAATTCCAACTGAGCGCCGGTCGCTACCATTA
CCAACTTGTCTGGTGTCAAAAATAATAGGCCTACTAGTCGGCCGTACGGGCCNNNNNTCTCGCG
NGTTNNNNNNNN 
 
 
 
 
 
 
 279 
 
1st Domain-Melittin 
 
ATGACCATGATTACGCCAAGCTTGGATGTGCGTGATGATGATTTTCATGATGGCAATCAGATTCA
GCTGTGGCCGAGCAAAAGCAATAATGATCCGAACCAGCTGTGGACCATTAAACGTGATGGCACC
ATTCGTAGCAATGGTAGCTGTCTGACCACCTATGGTTATACCGCAGGCGTTTATGTTATGATCTTT
GATTGTAATACCGCAGTTCGTGAAGCAACCATTTGGCAGATTTGGGGTAATGGTACAATTATCAA
TCCGCGTAGCAATCTGGTTCTGGCAGCAAGCAGCGGTATTAAAGGCACCACCCTGACCGTTCAAA
CCCTGGATTATACCCTGGGTCAGCCTCCTCCGCCACCTCCGCCTCCGCCTGGTATTCCGGTTAGCC
TGCGTAGCAAAGGTATTGGTGCAGTTCTGAAAGTGCTGACCACCGGTCTGCCTGCACTGATTAGC
TGGATTAAACGTAAACGTCAGCAGCATCATCACCATCATCATTAATGAATTCCAACTGAGCGCCG
GTCGCTACCATTACCAACTTGTCTGGTGTCAAAAATAATAGGCCTACTAGTCGGCCGTACGGGCC
CTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGG
TCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGT
TGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCAT
ATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGGCCTTAAGGG
CCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGG
CACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGG 
 
 
1st Domain-Mastoparan 
 
GAGGTCGACTCTAGAGGATGTGCGTGATGATGATTTTCATGATGGCAATCAGATTCAGCTGTGGC
CGAGCAAAAGCAATAATGATCCGAACCAGCTGTGGACCATTAAACGTGATGGCACCATTCGTAG
CAATGGTAGCTGTCTGACCACCTATGGTTATACCGCAGGCGTTTATGTTATGATCTTTGATTGTAA
TACCGCAGTTCGTGAAGCAACCATTTGGCAGATTTGGGGTAATGGTACAATTATCAATCCGCGTA
GCAATCTGGTTCTGGCAGCAAGCAGCGGTATTAAAGGCACCACCCTGACCGTTCAAACCCTGGAT
TATACCCTGGGTCAGCCTCCTCCGCCACCTCCGCCTCCGCCTGGTATTCCGGTTAGCCTGCGTAGC
AAAATTAACCTGAAAGCACTGGCAGCCCTGGCGAAAAAAATCCTGCATCATCACCATCATCATTA
ATGAATTCCAACTGAGCGCCGGTCGCTACCATTACCAACTTGTCTGGTGTCAAAAATAATAGGCC
TACTAGTCGGCCGTACGGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGAC
ACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCG
TCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCA
GATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATAC
CGCATCAGGCGGCCTTAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTT
CTAAATA 
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MLB-Mastoparan 1 
 
GGAAAAAAACACCTCTGGTGAGGTCGACTCTAGAGGATGATGTTACCTGTAGCGCAAGCGAACC
GACCGTTCGTATTGTTGGTCGTAATGGTATGTGTGTTGATGTGCGTGATGATGATTTTCATGATG
GCAATCAGATTCAGCTGTGGCCGAGCAAAAGCAATAATGATCCGAACCAGCTGTGGACCATTAA
ACGTGATGGCACCATTCGTAGCAATGGTAGCTGTCTGACCACCTATGGTTATACCGCAGGCGTTT
ATGTTATGATCTTTGATTGTAATACCGCAGTTCGTGAAGCAACCATTTGGCAGATTTGGGGTAAT
GGTACAATTATCAATCCGCGTAGCAATCTGGTTCTGGCAGCAAGCAGCGGTATTAAAGGCACCAC
CCTGACCGTTCAGACCCTGGATTATACCCTGGGTCAGGGTTGGCTGGCAGGTAATGATACCGCAC
CGCGTGAAGTTACCATTTATGGTTTTCGTGATCTGTGCATGGAAAGCAATGGTGGTAGCGTTTGG
GTTGAAACCTGTGTTAGCAGCCAGCAGAATCAGCGTTGGGCACTGTATGGTGATGGTAGCATTC
GTCCGAAACAGAATCAGGATCAGTGTCTGACCTGTGGTCGTGATAGCGTTAGCACCGTTATTAAC
ATTGTTAGCTGCAGCGCAGGTAGCAGCGGTCAGCGCTGGGTTTTTACCAATGAAGGTGCAATTCT
GAACCTGAAAAATGGTCTGGCAATGGATGTTGCACAGGCAAATCCGAAACTGCGTCGTATTATCA
TTTATCCGGCAACCGGTAAACCGAATCAGATGTGGCTGCCGGTTCCGCCTCCGCCTCCTCCACCAC
CTCCGCCTGGTATTCCGGTTAGCCTGCGTAGCAAAATTAACCTGAAAGCACTGGCAGCCCTGGCG
AAAAAAATCCTGCATCACATCATCATATGATCACCTGAACGGCGTTCGCTACATTACCACTTGTCT
GCGTCCAAAAATAATAGTCCTACTAGTCGGCCGTAG 
 
 
MLB-Mastoparan 2 
 
GATTCNTNAATGCAGNTGGCANGNCNNTTNNCCGACTGGAAAGCGGGCAGTGAGCGCAACGC
AATTTAATGTGAGTTAGCTCACTCNTTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTA
TGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCC
AAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATGATGTTACCTGCAGTGCTTCGGGACCTACGG
TGCGGATTGTGGGTCGAAATGGCATGTGCGTGGACGTCCGAGATGACGATTTCCACGATGGAAA
TCAGATACAGTTGTGGCCCTCCAAGTCCAACAATGATCCGAATCAGTTGTGGACGATCAAAAGGG
ATGGAACCATTCGATCCAATGGCAGCTGCTTGACCACGTATGGCTATACTGCTGGCGTCTATGTG
ATGATCTTCGACTGTAATACTGCTGTGCGGGAGGCCACTATTTGGCAGATATGGGGCAATGGGA
CCGTCATCAATCCAAGATCCAATCTGGTTTTGGCAGCATCATCTGGAATCAAAGGCACTACGCTTA
CGGTGCAAACACTGGATTACACGTTGGGACAGGGCTGGCTTGCCGGTAATGATACCGCCCCACG
CGAGGTGACCATATATGGTTTCAGGGACCTTTGCATGGAATCAAATGGAGGGAGTGCGTGGGTG
GAGACGTGCGTGAGTAGCCAACAGAACCAAAGATGGGCTTTGTACGGGGATGGTTCTATACGCC
CCAAACAAAACCAAGACCAATGCCTCACCTGTGGGAGAGACTCCGTTTCAACAGTAATCAATATA
GTTAGCTGCAGCGCTGGATCGTCTGGGCAGCGATGGGTGTTTACCAATGAAGGGGCCATTTTGA
ATTTAAAGAATGGGTTGGCCATGGATGTGGCGCAAGCAAATCCAAAGCTCCGCCGAATAATTATC
TATCCTGCCACAGGAAAACCAAATCAAATGTGGCTTCCCGTGCCACGGGTACCGCCTCCTCCGCC
ACCTCCGCCTCCGCCTATTAACCTGAAAGCACTGGCAGCCCTGGCGAAAAAAATCCTGCATCATC
ATCACCATCATTAATGAATTCCAACTGAGCGCCGGTCGCTACCATTACCAACTTGTCTGGTGTCAA
AAATAATAGGCCTACTAGTCGGCCGTACGGGCCNNTNGTCTCGCGNGNNNNNNNNNNNNN 
 
 
 
 
 
 
 
 281 
 
2nd Domain-Melittin 
 
CTGATACCCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAA
GAGCNCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGA
CAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATT
AGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAA
CAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGAAAGCAATGGTGGTAGC
GTTTGGGTTGAAACCTGTGTTAGCAGCCAGCAGAATCAGCGTTGGGCACTGTATGGTGATGGTA
GCATTCGTCCGAAACAGAATCAGGATCAGTGTCTGACCTGTGGTCGTGATAGCGTTAGCACCGTT
ATTAACATTGTTAGCTGTAGCGCAGGTAGCAGCGGTCAGCGCTGGGTTTTTACCAATGAAGGTGC
AATTCTGAATCTGAAAAATGGTCTGGCAATGGATGTTGCACAGGCAAATCCGAAACTGCGTCGTA
TTATCATTTATCCGGCAACCGGTAAACCGAATCAGCCTCCTCCGCCACCTCCGCCTCCGCCTGGTA
TTCCGGTTAGCCTGCGTAGCAAAGGTATTGGTGCCGTTCTGAAAGTTCTGACCACCGGTCTGCCT
GCACTGATTAGCTGGATTAAACGTAAACGTCAGCAGCATCATCACCACCATCATTAATGAATTCCA
ACTGAGCGCCGGTCGCTACCATTACCAANTTGTCTGGTGTCAAAAATAATAGGCCTACTAGTCGG
CCGTACGGGCCCTTTCNTCNCGCGNGTTNNNGNNNNNNN 
 
 
2nd Domain-Mastoparan 
 
GAGGTCGACTCTAGAGGAAAGCAATGGTGGTAGCGTTTGGGTTGAAACCTGTGTTAGCAGCCAG
CAGAATCAGCGTTGGGCACTGTATGGTGATGGTAGCATTCGTCCGAAACAGAATCAGGATCAGT
GTCTGACCTGTGGTCGTGATAGCGTTAGCACCGTTATTAACATTGTTAGCTGTAGCGCAGGTAGC
AGCGGTCAGCGCTGGGTTTTTACCAATGAAGGTGCAATTCTGAATCTGAAAAATGGTCTGGCAAT
GGATGTTGCACAGGCAAATCCGAAACTGCGTCGTATTATCATTTATCCGGCAACCGGTAAACCGA
ATCAGCCTCCTCCGCCACCTCCGCCTCCGCCTGGTATTCCGGTTAGCCTGCGTAGCAAAATTAACC
TGAAAGCACTGGCAGCCCTGGCGAAAAAAATCCTGCATCATCATCACCATCATTAATGAATTCCA
ACTGAGCGCCGGTCGCTACCATTACCAACTTGTCTGGTGTCAAAAATAATAGGCCTACTAGTCGG
CCGTACGGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCT
CCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTG
AGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGC
GGCCTTAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAG
ACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTATTTTTCTAAATACATT
CA 
 
